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Abstract
The work presented in this thesis concentrates on the functional consequences of 
acétylation upon the retinoblastoma tumour suppressor protein (pRh), the activity of which 
is frequently, if  not universally, de-regulated in tumour cells. This study has shown that the 
acétylation of pRb at lysine (K) residues 873/874 reduces the interaction of E2F-1 with the 
carboxyl terminal (C-temiinal) region of pRb. In turn this acétylation event promotes the 
association of the C-tei*minal region of pRb with its amino terminal (N-terminal) domain 
(residues 1-378). A further aspect of this study suggests that acétylation may result in a 
change of pRb localization from the nucleus to the cytoplasm. Moreover it is also shown 
that the N-terminal of pRb is acetylated in vitro and in cells. These results suggest a model 
whereby the acétylation o f pRb at E2F-1 target genes results in a reduced interaction 
between the C-teiiuinal of pRb and E2F-1. Another ramification of the model implies that 
the N-terminal region of pRb interacts with the C-terminal region in response to DNA 
damage induced acétylation of pRh. This interaction may influence the bipartite nuclear 
localization signal (NLS) within the C-terminal domain, thus providing a possible 
mechanism for retaining pRb localised to the cytoplasm. These results highlight a new 
mechanism through which pRb may mediate tumour suppressor activity, and in addition 
define a previously undescribed pathway through which acétylation can influence growth 
control.
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PREFACE:
It is apparent that many transcription factors have multiple roles, often in different 
cellular processes. In particular, some transcription factors appear to have roles in two 
opposing processes. In order to coordinate cellular processes, protein function is regulated 
by post-translational modification. This thesis is concerned with the later. Post- 
translational modification can affect a protein in different ways. Modification of amino 
acid residues alters the chemical reactivity and the physical characteristics of the amino 
acid residue. This can affect the secondary or tertiary structure of the protein, or simply 
affect the local binding surface around the site of the modification. Many proteins interact 
with each other via specific peptide consensus sequences. Post-translational modification 
of a protein can therefore alter its affinity for binding partners.
As an analogy, changes in our hormone levels (triggered by shock) can transiently 
effect changes in our mood and physiology. Similarly post-translational modification can 
affect protein function in response to external factors in the cells microenvironment. 
Proteins can change their partners, their location, and their function as a result of 
posttranslational modifications. Upstream signalling pathways directly transmit stimuli 
emanating from the cell membrane to effect changes in post-translational modification and 
hence gene expression in the nucleus [8].
The transcription factors pRb, E2F-1 and p53 all have multiple functions that are 
tightly regulated by post-translational modification. These proteins play key roles in 
processes such as tumour suppression, control of proliferation, apoptosis, differentiation, 
foetal development and DNA repair. I f  a cell loses its ability to control the post­
translational modification of these proteins, the resulting change in cellular physiology can 
augment the process of tumour formation and progression. Conversely, certain drugs that
XVI
control post-translational modification are now being utilized to treat cancers, in particular 
HD AC inliibitors [271].
My studies have centred on post-translational modification of proteins involved in 
controlling the cell cycle, particularly concentrating on the affect of acétylation on the 
retinohlastoma tumour suppressor protein (pRb), and the effect on the E2F-1 transcription 
factor. This study has uncovered some new insights into the functional consequence of pRb 
acétylation in response to DNA damage. Damage responsive acétylation of pRb appears to 
affect the interaction between the carboxyl terminal region of pRb and E2F-1. It is possible 
that damage-responsive acétylation of pRb releases E2F-1 to activate specific genes that 
promote apoptosis.
The N-terminal domain o f pRb is the single largest domain o f the protein, spamiing 
the first 378 amino acids. Until recently, this domain was thought to be involved in 
processes not related to the role o f pRb tumour suppression and control of proliferation. 
My study suggests that tlie N-terminal region of pRb may play an important regulatory role 
by facilitating various changes in the conformation of pRb bought about by acétylation. 
Overall, this study has illuminated new levels of control in pRb, and defined previously 
umecognized pathways influenced by acétylation.
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In t r o d u c t io n
T h e  P a t h  t o  N e o p l a s ia
A cell becomes cancerous due to a combination of factors; excessive proliferation 
(the loss of cell cycle control), an ability to survive (loss of apoptotic control), and an 
ability to modify its environment (its supply of blood and nutrients). The development of 
neoplasia (cancer) is therefore a multistage process, each step characterised by distinct 
genetic changes (mutations). Many of the oncogenes mutated in the initiation and 
promotion of healthy cells to cancerous cells are involved in controlling progression 
through the cell cycle (Figure la).
T h e  c e l l  c y c l e
The cell cycle is divided into four phases (Growth phase 1 (G l) —> Synthetic (S)- 
phase—> Growth phase 2 (0 2 )—> Mitosis (M)-phase) [1]. There are two basic events in cell
division; generation of a single copy of its genetic material (S-phase), and the partition of 
the cellular components between two identical daughter cells (M-phase). The two other 
phases of the cycle, G l and 02 , represent gap periods during which cells prepare 
themselves for the successful completion of the S- and M- phases. Cells may also enter a 
quiescent state (GO) in response to specific anti-mitogenic signals, or to the absence of 
proper mitogenic signalling (Figure lb) [2].
C o n t r o l l in g  p r o g r e s s io n  t h r o u g h  t h e  c y c l e
In order to ensure controlled progression through the cell cycle, cells have 
developed a series of checkpoints that prevent them from entering into a new cell cycle 
phase until they have successfully completed the previous one [3].
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Figure 1; The cancer cell cycle 
a) The pathway to neoplasia
111 order to transform and become malignant, pre-cancerous cells develop 
progressive mutations in genes whose protein products regulate celluiai' processes 
(such as proliferation and apoptosis). As mutations accumulate (Steps A to B to C), 
premalignant cells develop into a small tumour mass. Further mutation enables the 
premalignant cells to bypass all controls on proliferation and apoptosis (Steps C to 
D) and hence they become malignant. Malignant cells replicate and dominate the 
tumour mass (Steps D to E). Malignant cells mutate further still and become 
capable of existing without local survival factors. Mutation occurs in genes that 
control cell/cell adhesion, and malignant cells detach from the tumour mass (Steps 
E to F). Metastasis of the tumour occurs through the blood and lymphatic systems, 
and migrating tumours may find their way into other organs where they develop 
further (Step G).
b) Depicts the cell cycle
There are 4 phases of the cell cycle, G l (Growth phase) in which cells grow 
and prepare for S-phase, S-phase (DNA synthesis) in which DNA is duplicated, G2 
(Growth phase 2) in which the cell prepares for mitosis, and M-phase (Mitosis 
phase) in which cells divide their nuclear and cytoplasmic content to create 2 
daughter cells.
Quiescent cells and newly divided ceils must pass certain checkpoints to progress through 
the cycle. These checkpoints function to make sure that cells reach their homeostatic size, 
otherwise cells would decrease in size with each round of division [2]. A cell’s passage 
through checkpoints can be influenced by any incurred DNA damage, the availability of 
nutrients, or the intensity of mitogenic information that cells receive at any given time.
After mitosis, cells undergo a period of mitogen dependence, before deciding 
whether or not to enter the cell cycle. A transition then occurs when cells are no longer 
dependent on mitogenic signals. The transition between the two states was coined the 
‘Restriction Point’ by Arthur Pardee in 1974 (Figure lb) [4]. The restriction point (R) 
represents the point of no return that commits cells to a new round of cell division. The 
molecular events that allow cells to pass through the (R) have not been thoroughly 
elucidated. It has been shown that members of the retinoblastoma (Rb) family of proteins 
play key roles. Indeed ablation of this gene family eliminates (R) [5].
MITOGENIC STIMULATION DURING THE Gl/S PHASE TRANSITION OF 
THE CELL CYCLE
Extra-cellular ligands trigger various processes such as proliferation and 
differentiation through receptor activation. Differentiation is triggered by neurotrophic 
factors, such as nerve growth factor (NGF). On the other hand, proliferation is triggered by 
mitogenic factors, such as epidermal growth factors (EGF). Other anti-mitogenic factors 
such as TGFp are released in response to contact inhibition [6]. Cellular stress such as 
those generated by inflammatory cytokines mediates inflammation response, apoptosis, and 
developmental pathways (Figure 2a).
Upon ligand binding, cell surface receptors activate their particular cell signalling 
cascade. These cascades eventually signal through to the nucleus and affect changes in
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Figure 2: Mitogenic growth factor signalling pathways affect the cell cycle
a) Table showing various mammalian MAPK signalling pathways.
A variety of signalling pathways respond to various extracellular signals. 
Mitogen activated protein kinase (MAPK) pathways are shown here as an example. 
Growth factors such as EOF activate Ras signalling through Raf. Other MAPK 
kinase pathways respond to inflammatory signals and serum stress.
b) Ras and PI3K signalling pathways both regulate the activity of cyclin/Cdk 
complexes.
The Ras/Raf and phosphoinositide 3-kinase (PI3K) signalling pathways 
both converge to regulate cyclin/Cdk activity. The type of regulation is dependent 
on the level of mitogenic signalling. High levels of Ras activation lead to increases 
in p21^^' expression, a protein which inhibits cyclin/Cdk activation. Moderate 
levels of Ras signalling lead to decreased expression of p27^ '^^  ^ thereby activating 
cyclin/Cdk heterodimers. Ras can also activate the PI3K pathway which eventually 
lead to the inhibition of p i a n d  the corresponding activation of cyclin 
D /C dk4/6.
c) Cyclin/Cdk complexes are regulated by multiple mechanisms
Cdk enzymes are not active unless bound to their cognate cyclin. Activation 
of cyclin/Cdk complexes requires increased cyclin transcription, and the inhibition
of CKTs. Cdks themselves are activated by phosphorylation and de-phosphorylation 
events. Cdks aie activated by phosphorylation of T 161 by Cdk-activating kinase 
(CAK), and by the de-phosphorylation of Y15 by CDC25A phosphatase.
gene expression. There are numerous signalling cascades, which feed through and effect 
the cell cycle (both positively and negatively). I describe here the mitogen activated protein 
kinase (MAPK) signalling pathway as one example (Figure 2a and 2b).
The basic arrangement of the MAPK kinase cascade begins with receptor activation 
of a G-protein (that recruits the upstream kinase to the cell membrane upon receptor 
stimulation by the ligand). The G-protein works upstream of a core module consisting of 
three kinases; a MAPK kinase kinase (MAPKKK) that phosphorylates and activates a 
MAPK kinase (MAPKK), which in turn activates MAPK [7, 8]. There are presently four 
known MAPK signalling pathways observed in maimnals (Figure 2a).
These include the extra-cellular signal-regulated kinase I and 2 (ERKl/2) cascade, 
which preferentially regulates cell growth and differentiation, as well as the c-Jun N- 
terminal kinase (JNK) and p38 MAPK cascades (which function mainly in stress responses 
like inflammation and apoptosis) [9-11].
The effect of Ras/Raf/MEK/ERK pathway on the cell cycle
The G 1/S phase transition requires cyclin dependent kinases (Cdks) to facilitate the 
expression of genes involved in DNA synthesis and proliferation. Cdks are inactive 
without their cyclin binding partners (see below). Researchers studying the mitogenic 
stimulation of macrophages by colony-stimulating factor 1 first cloned cyclin D l. In this 
macrophage model, colony-stimulating factor 1 is required for continuous expression of 
cyclin D l [12]. Mitogens stimulate the induction of cyclin D l expression via signalling 
cascades. These involve tyrosine kinase receptors and G-proteins known to transmit signals 
through the Ras/Raf/MAPK/ERK pathway (Figure 2b) [13]. Activated Ras or Raf are 
known to induce cyclin D l expression (Figure 2b and 2c) [14-16]. Furthermore, 
stimulation of cells in response to growth factors or Ras signalling requires cyclin 
D/Cdk4/6 [17-20].
Studies carried out using NIH3T3 cells show that mitogenic stimulation causes a 
sustained activation of MAPK, lasting until cells begin progressing through the G 1/S phase 
boundary. The activation of Cdk2 and hence DNA synthesis was inhibited by treating 
NIH3T3 cells with a MEK inhibitor (PD98059). The MEK inhibitor also ablated Cdk2 
Thr-161 activating phosphorylation, indicating a role for the Ras/Raf/MEK/ERK pathway 
in the regulation of Cdk activating kinase (CAK) (Figure 2c) [21, 22]. Raf despatches 
signals into different down-stream pathways that promote proliferation, cellular 
differentiation and inhibit cell cycle arrest/apoptosis. A recent report has also implicated 
Raf-1 as a pRb kinase contributing to pRb inactivation [23]. Mitogen stimulation induces 
the binding of pRb to Raf-1, and pRb inactivation was dependent on Raf-1 binding.
CYCLIN DEPENDENT KINASES (Cdks) 
Cdks are promoters of the cell cycle
Cdks phosphorylate serine/threonine (S/T) residues of key proteins controlling the 
cell cycle, thus driving forward the cell cycle. Cdks aie a group of S/T kinases that form 
active heterodimeric complexes upon binding cyclin regulatory subunits. Cdk3 is involved 
in driving cells through quiescence into G1 (Figure 3). Cdk4 and Cdk6 are involved in 
driving cells through early G1 phase, whereas Cdk2 is required to complete G1 and initiate 
S-phase (Figure 3). Cdks are only active when bound in complex with cyclins [24]. Cdk3 
form complexes with C type cyclins. Cdk4/6 form complexes with D type cyclins (D1-D3). 
Cdk2 is activated by forming complexes with cyclin El and E2 during G 1/S transition, and 
by cyclins A1 and A2 during S-phase [25].
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Cdk regulation
Cdks are not active unless they are bound to their cognate cyclin. Also, Cdks need 
to be phosphorylated on T residues (T172 in Cdk4 and T160 in Cdk2) located in their T 
loop for proper catalytic activity (Figure 2c) [24, 26, 27]. This phosphorylation is canied 
out by the cyclin K/Cdk7 complex (CAK). This S/T kinase is also involved in transcription 
and DNA repair [27].
Cdk activity can also be regulated during G2/M transition. This is achieved by 
phosphorylation of a (T) residue and the de-phosphorylation of the adjacent tyrosine (Y) 
residue (T14/Y15) in Cdkl. W eei/M ytl phosphorylates T14 and T15 (Figure 2c). This 
allows cyclin B to complex with Cdkl. Cyclin B is then phosphorylated on T161. The 
complex is activated hy the de-phosphorylation of Y15 by CDC25A [24, 26]. Regulation of 
CDC25A is critical for the G1 response to DNA damage. Mammalian cells respond to UV 
or ionizing radiation by rapid ubiquitin/proteasome-mediated degradation of CDC25A 
[28].
Cdks ai'e also regulated by inhibitors coined Cdk inhibitors (CKIs), and were 
initially proposed to accumulate in response to a cells need to cease dividing. There are two 
types of CKIs; the complex inhibitors (INKs) and the kinase inhibitors (Cipl, Kip). The 
four members of the ENK4 family are pl6^ '^ '^^‘\  p^giNK4c p|g[NK4ci jn k 4
family members exert their inhibitory activity by binding to the Cdk4 and Cdk6 kinases, 
preventing their association with D type cyclins (Figure 2b) [29]. The kinase inhibitors of 
the Cipl/Kip family bind and inhibit Cdk kinases and cyclins. The Cip/Kip family is 
composed of three members; p 2 l ‘^ ‘^^ ‘, p27^'^\ and p57’^ ‘^"“. The Cip/Kip family block 
kinase activity by interfering with both substrate recognition and ATP binding [30]. The 
Cip/Kip family preferentially inhibit Cdk 1/2. Cipl/Kip inhibition of cyclin D/Cdk4/6 
complexes is relatively inefficient [30].
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Figure 3: The phosphorylation of pRb by Cdks through the cell cycle 
a) The structural and functional protein domains of pRb.
pRb contains five protease resistant sub domains (N, R, A, Spacer ‘S’, and B 
domains). There is a sixth sub domain which is sensitive to proteases coined the‘C terminal 
domain’. The A, B, and C sub domains correspond to functional domains that have been 
mapped genetically. Beneath the pRb schematic are listed some identified functional 
properties of pRb. The line shown next to the listed properties indicates the extent of the 
protein that is sufficient for function. The A, S and B sub domains comprise the small 
pocket, and are sufficient for viral oncoprotein binding and for interaction with pRb 
binding partners that utilize an LXCXE amino acid motif. The A, S, B and C sub domains 
comprise the large pocket and are sufficient for most pRb-binding partners. The amino 
terminal domain is required for normal tumour suppression and embryonic development.
b) Phosphorylation events through the cell cycle.
Exit from cell cycle arrest initiates when pRb is phosphorylated by cyclin C/Cdk3. 
Mitogenic stimulation results in the sequential phosphorylation of pRb by cyclin D/Cdk4/6 
which induces conformational change in pRb, thus allowing cyclin E/Cdk2 to further 
phosphorylate pRb. This promotes the gradual release of E2F-1 from pRb. Once inhibition 
of E2F-1 is lifted, cells can progress through S-phase. When S-phase is completed, further 
phosphoiylation of E2F-1 by cyclin A/Cdk2 causes E2F-1 to leave its promoter. A further 
pRb kinase that is not under the control of cyclins has been shown to be active during late 
G2/M phase. During mitosis, cyclin B/Cdk2 is activated. At the end of mitosis, pRb is de- 
phosphorylated by Protein Phosphatase 1 (PPl).
The Cip/Kip family act to promote the complex formation between cyclin D and Cdk 4/6. 
The Cip/Kip family also stimulate the nuclear import of cyclin D/Cdk4/6 and increase the 
half life (ti/2) of cyclin D [24].
In contrast to their affects on cycin D/Cdk4/6, Cip 1/Kip inliibitors block 
phosphorylation by cyclin E/Cdlc2, and promote cyclin E/Cdk2 ubiquitination and 
degradation. Increases in protein levels of cyclin D (following mitogenic stimulation) may 
increase cyclin E/Cdk2 activity via Cdk inhibitor exchange. On the formation of cyclin 
D/Cdk4/6 dimer, Cipl from cyclin E/Cdk2 may dissociate and complex with cyclin 
D/Cdk4/6 [24]. Increases in INK4 protein levels (following differentiation or other signals 
promoting cell cycle withdrawal) may decrease both cyclin E/Cdk2 and cyclin D/Cdk4/6 
by Cdk inhibitor exchange [24].
RETINOBLASTOMA PROTEIN 
The pRb/E2F pathway
Approximately seventeen years ago, the retinoblastoma tumour suppressor gene 
(Rb) was molecularly cloned [31]. Later on, Knudson’s two-hit hypothesis [32] was 
validated by demonstration that mutational inactivation of both alleles of Rb induces 
cancer of the retina. Patients with one allele o f Rb have a high chance of developing 
sporadic retinoblastoma by loss-of-heterozygosity [33]. pRb controls cell growth and 
proliferation, and will facilitate cell cycle anost upon DNA damage to allow repair to take 
place.
Mutation or deregulation of pRb has been observed in nearly every type of human cancer 
examined [2]. The protein sequence is well conserved across five disparate species (bird, 
human, rodent, fish and amphibian) (Figure 4a). Deregulation of pRb is so frequent in 
cancer, that some have argued it is a prerequisite for all human cancers [25]. Although pRb 
can physically interact with well over one hundred different cellular proteins [34], the most 
studied interaction is that of the pRb large pocket with the E2F-1 protein.
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Figure 4: The conservation of amino acids betvreen the pocket protein family
members 
a) The N, A, B and C domains are depicted schematically.
The arrows above the map highlight the position o f phosphorylation sites 
that are present in the 5 indicated vertebrate species. Below the schematic are 
barcodes depicting multiple protein sequence alignments of pRb homologues 
from chicken, human, mouse, trout, and newt.
The barcode for each species consists of a series of vertical lines 
representing each amino acid within the linear sequence of the relevant protein. 
The shading of the vertical lines is proportional to the sequence 
identity/similarity at the given position. An amino acid that is identical at a 
particular position in the alignment is shaded black. Dissimilar amino acids are 
shaded white. Patches of dark shading indicates regions of conservation, while 
lightly shaded patches indicate non-conserved regions.
b) Sequence similarity between pRb, p i07 and pl30.
A schematic of human pocket proteins is shown indicating the 4 major 
domains (N, A, B, and C). Multiple sequence alignment is depicted as in (a) 
above. The schematic of pRb depicts the four major domains (N, A, B and C 
domains). Arrows above the schematic represent mis-sense mutations 
identified in the Rb gene. Black arrows indicate fully penetrating inactivating 
mutations. Grey arrows indicate mutations in tumours from patients with low
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penetrating retinoblastoma families. A i t o w s  below the map indicate in-frame 
deletion mutants identified in Rb. The arrows represent less than or equal to 5 
amino acid deletions. The bars indicate the extent of larger in-frame deletions. 
As ahove, lightly shaded arrows and bars indicate mutations identified in 
partially penetrant retinoblastoma families.
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The Rb tumour suppressor protein (pRb) binds to the E2F-1 transcription factor 
preventing it from interacting with the cells transcription machinery. In the absence of 
pRb, F2F-1 (along with its binding partner DP-1) mediates the tran-activation of F2F-1 
target genes that facilitate the G 1/S transition and S-phase. E2F target genes encode 
proteins involved in DNA replication (for example DNA polymerase a , thymidine kinase 
(TK), dihydrofolate reductase (DHFR) and cdc6), and chromosomal replication 
(replication origin-binding protein HsOrcl and MCM 5). When cells are not proliferating, 
E2F DNA binding sites contribute to transcriptional repression. In vivo footprinting 
experiments obtained on Cdc2 and B-myb promoters demonstrated E2F DNA binding site 
occupation during GO and early G l, when F2F is in transcriptional repressive complexes 
with the pocket proteins [35, 36].
The family of pocket proteins
p i 07 and p / 3d are genes which encode proteins with similar structure to pRb [37]. 
Comparison of the amino acid sequences of pRb, pl07, and p i 30 indicates substantial 
amino acid similarity (Figure 4b). Overall, pRb shares approximately 21 % sequence 
homology with p l07  and pl30. However, it is clear that p l07  and pl30  (47 % identity) are 
more closely related to each other than either one is to pRb. Most o f the conserved 
sequences lie within the small pocket region (residues 379-792) sharing 30-40 % identity. 
Viral oncoproteins. Simian virus 40 large T antigen (SV40 FT), adenovirus early gene A 
(ad FI A) and ‘high risk’ Human papillomavirus E7 (HPVs E7) all target the pocket 
domain. Viral oncoprotein binding to the pocket domain displaces cellular proteins which 
interact with the pocket, thereby de-activating the pocket proteins (PP) through preventing 
them from interacting with E2F-1 [38] [39-41]. The N- and C-tenninal domains of pRb are 
not well conseiwed (10-20 % identity). Key sub domains within the N-terminal domain are 
also shared with a high degree o f sequence homology between pocket proteins. For
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example, the spacer region of pRb lacks a cyclin/Cdk binding motif shared by p i 07 and 
p i 30 and is considerably shorter.
It is likely that the pocket regions of pRb, p i07 and p i 30 have similar function. 
The main functional differences between the pocket proteins are likely to relate to 
differences in their N-terminal and C-terminal domains. Despite being closely related, only 
pRb  is frequently mutated in tumour cells (Figure 4c). p i 07 and p i 30 are not frequently 
mutated in naturally occumng tumour cells. Indeed, mutation of p i 07 has only been 
detected in a B cell lymphoma cell line [42] and possibly human myelogenous leukemias 
[43]. While still relatively uncommon, mutation or alteration of p i 30 expression is 
detected more frequently in cancer than mutation or alteration of p i 07 expression. 
Potentially inactivating mutations of plSO  have been discovered in lung cancer [44, 45] 
and Burkitt’s lymphoma [46]. Levels of pl30 are lower in tumours of higher stage and 
grade in lung, endometrial, oral squamous cell carcinoma, and uveal melanoma [47-50]. It 
is clear that Rb is more frequently mutated in human cancer than p l0 7  or p i  30.
The unique tumour suppressor function of pRb is reinforced in mouse models 
containing inactivating mutations of the various pocket proteins. Mice lacking either p i  07 
or p i 30 are viable, whereas mice lacking Rb are not [51, 52]. Inactivating both p i 07 and 
p i 30 causes severe defects in bone development, resulting in death shortly after birth. This 
suggests that these two genes are either redundant or can functionally compensate for one 
another in a way that Rb cannot. It seems that pRb has a different function to p l07/p l 30 in 
foetal development.
pRb is laiown to be required for cells to enter permanent cell cycle arrest prior to
differentiation [53]. Murine cells lacking Rb are compromised in their ability to
differentiate into adipocytes, whereas cells lacking in p l0 7  or p i 07/p i30 actually
differentiate into adipocytes more efficiently [54, 55]. Importantly, neither p i 07 null nor
p i 30 null mice are tumour prone. Although tumour phenotypes cannot be assessed in
double pl0T ^'/p l30 ’^ ’ knockout mice, p lO T '/ pl30^^' and p l07^’'lpl30''~ genotypes are
19
viable and have been examined. Unlike mice, these genotypes do not exhibit a 
tumour prone phenotype [52]. Hence sporadic loss of the remaining p l0 7  or p J 30 wild- 
type allele does not initiate tumourigenesis. Interestingly, Rb^^' mice do not suffer from 
retinoblastoma, but instead develop tumours of pituitary and thyroid origin. This difference 
may be attributable to the physiology of humans as compared to mice.
E2F proteins
pRb, p i 07 and p i 30 have their own preference for binding to different E2F family 
members [56]. The E2F family presently consists of eight members (E2F-1 to 8) [57]. E2F- 
1, 2 and 3 are activating E2F family members and prefer to bind pRb (Figure 5a). In 
contrast, E2F-4 and 5 are repressive E2F and prefer to bind pl07/p l30  (Figure 5a and 5b). 
In general, pl30/E2F complexes are mainly found in quiescent or differentiated cells, 
whereas pl07/E2F complexes predominate in S-phase cells. pRb/E2F complexes form 
during Gl and G l/S  phase transition, but also exist in quiescent or differentiated cells [58]. 
E2F-6 also acts as a transcriptional repressor, but through a distinct, pocket protein 
independent manner. E2F-6 mediates repression by direct binding to polycomb group 
proteins or via the formation of a large multimeric complex containing Mga and Max 
proteins [59].
E2F-7 recognises and binds E2F sites utilizing two distinct DNA binding domains, 
and does not require a DP-subunit to effectively bind to DNA. E2F-7 has no transcriptional 
activation domain and no pRb binding domain [60, 61]. The most recently discovered E2F, 
E2F-8 is veiy similar in stmcture and sequence to E2F-7, with its two distinct DNA 
binding domains.
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Figure 5; Pocket proteins and their E2F partners can activate or repress 
transcription
a) Promoter occupancy of E2F target genes
The E2F family of transcription factors is divided into activator and 
repressor E2Fs. Repressor E2F (E2F-4 to 6) occupy E2E promoters in GO and 
early G l, and recruit chromatin remodeling factors directly (E2F6) or 
indirectly through p i07 and p i 30 (E2F-4, 5). As cells enter into late G l phase, 
the repressor E2F complexes are replaced by activator E2Fs (E2F-1 to 3). Two 
types of E2F-regulated promoters were uncovered, based on whether activator 
E2F remained at the promoter throughout late G l and S-phase {cyclin A, cdc6), 
or whether they were only detected transiently during late G l {b-myb). These 
binding differences correlate with other studies identifying promoters 
essentially regulated by transcriptional activation, and those regulated mainly 
tlirough repression. pRb was not localized on most E2F-regulated promoters, 
despite the fact that it forms in vivo complexes with ‘E2F-1 to 4 ’ (dashed 
lines).
b) Proposed transcriptional program of the E2F/pocket protein pathway
The E2F/pRb pathway acts down-stream of several important signaling 
cascades that trigger cell cycle arrest. Cellular senescence and the transforming 
growth factor p pathway induce cell cycle inhibitors such as p27* '^‘’*
and plS*^^* ,^ which inactivate cyclin D/cdk4 and trigger pocket protein-
dependent cell cycle arrest. Alternatively, the MAPK pathway induces cyclin
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D expression and leads to E2F tiunscriptional activation. DNA damage can 
induce two types of response depending on the context and intensity o f DNA 
damage: a cell cycle arrest requiring pRb, or a pro-apoptotic response mediated 
through ATM and E2F-1. Recent microarray studies suggest that the network 
of E2F-regulated genes is vastly broader than previously suspected. For many 
of these new targets however, it remains to be shown if their regulation by E2F 
is important for the biological processes in which they participate. E2F 
functions beyond the G l/S  transition of the cell cycle to regulate DNA 
replication, DNA repair and DNA damage checkpoint genes. It also controls 
the transcription of genes that function during mitosis, in mitotic checkpoints, 
and in apoptosis. Finally, E2F induces genes that are involved in differentiation 
and development. ATM, ataxiatelangiectasia protein; MCM, mini chromosome 
maintenance protein; PcG, Polycomb group protein.
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E2F-8 expression is induced at the G l/S  phase transition, and does not require DP 
subunits to bind and repress E2F promoters. Over-expression of E2F-8 in diploid human 
fibroblasts reduces expression of E2F-target genes and inhibits cell growth consistent with 
a role for repressing E2F transcriptional activity [62, 63].
pRb/E2F complexes
Genes that encode proteins involved in regulation of DNA synthesis and 
proliferation need to be tightly regulated. The cell needs to switch on these genes during 
the G 1/S-phase transition, and switch them off again when S-phase is complete. As 
mentioned above, E2F-1 to 3 bind promoters and are able to activate transcription, whilst 
E2F-4 to 8 repress transcription (Figure 5a) [64]. The pocket proteins bind both activating 
and repressing E2Fs, and by doing so inhibit any activation mediated by the E2F 
[65]. This is loiown as non-active (or static) repression (reviewed in [66]), This repression 
is lifted by Cdk phosphorylation (Figure 3). Pocket proteins that are bound to E2F are also 
able to bind other proteins via the small pocket. It has been shown that pRb/E2F 
complexes can fonn repressor complexes at promoters tliat actively repress transcription 
(Figure 6) [67-69]. Histone deacetylases such as HDACl can bind pRb
and recruit repressor complexes that serve to deacetylate histones. This process is 
labelled active repression [66]. On the other hand, histone acetyl-transferases can acetylate 
histones and activate transcription. This process is dynamic activation, which is distinct 
from pocket protein phosphorylation by Cdks (reviewed in [66]). An E2F controlled gene 
whose expression is silent but requires activation must remove the repressing E2F/pocket 
protein complex and replace it with an activating E2F/Pocket protein complex (Figure 6).
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Figure 6: The re-localization of E2F/DP complexes during DNA damage
Double stranded DNA damage is relayed through to the E2F/DP 
heterodimer tlirough the ATM/Chk2 pathway. In response to DNA damage, 
activating E2F (E2F-1) present at TK/DHFR promoters re-localizes to the p73 
promoter. There, they swap places with repressive E2F (E2F-4), which 
relocates to the TK/DHFR promoter. This changing place of E2F/DF 
complexes affects the transcriptional activity at the promoters. E2F-1/DP-1 
complexes facilitate an increase in acétylation of histone H4 by recruiting HAT 
enzymes, which facilitate the unwinding of condensed chromatin leading to an 
increase in transcription. E2F-4/DP complexes recmit HD AC enzymes that 
result in a decrease in acetyl histone H4 and a corresponding drop in 
transcription resulting from chromatin condensation.
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pRb/E2F complexes are found during Gl and G l/S  phase transition, pl07/E2F 
complexes predominate during S-phase, and pl30/E2F complexes are mainly found in 
quiescent differentiated cells. Using chromatin immunoprécipitation assays (ChIP), it was 
found that repression on E2F-responsive promoters was associated with the recruitment of 
E2F-4 and p i 30, and coincided with low level of histone acétylation [70]. In late G l phase, 
the E2F-4/pl30 complex is replaced by E2F-1 and E2F-3, together with enlianced level of 
acétylation of histones H3 and H4 (Figure 5a). These studies indicate that distinct E2F 
heterodimers recruit enzymes to deacetylate or acetylate core histones, therefore repressing 
or activating E2F-responsive genes [71].
Double stranded DNA damage such as that induced by irradiation (IR) or DNA 
damage inducing chemicals (such as etoposide or doxombicin) cause the recruitment of 
DNA damage homologous recomhination and repair (HRR) response proteins such as 
TIP60. TIP60 is able to acetylate ATM kinase, thus activating the ATM DNA damage 
response pathway [72]. One of the down-stream targets of ATM kinase is Chk2. ATM 
activates Chk2 kinase by phosphorylating it. ATM and Chk2 phosphoi-ylate E2F-1 at S31 
and S364 respectively [73, 74]. The result is an increase in protein stability of E2F-1. Its 
phospho form undergoes an intra-cellular localization change.
Using ChIP assays, studies showed that E2F-4 (present on the p73 E2F promoter) 
and E2F-1 (present on the TK and DHFR responsive E2F promoter) swap promoter in 
response to doxorubicin induced DNA damage [75]. This swap induced a coiTcsponding 
drop in histone H4 acétylation at the TK/DHFR gene, and a corresponding increase in 
histone H4 acétylation at the p73 gene (Figure 6). Phospho-E2F-l can be seen to re- 
iocalise into distinct nuclear speckles after cells were treated with etoposide to induce 
DNA damage [74]. It seems likely that those genes whose functions oppose each other 
(such as TK and p73) might swap their E2F/pocket protein complexes upon a change in 
conditions such as DNA damage (as in this case) or cell cycle progression from G l-S 
phase (as in the first example).
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Organization of pRb
Domains A and B of pRb are highly consei*ved, and they interact with each other 
along an extended inter-domain interface to form the central “pocket” [41], which is 
cmcial to the tumour suppressor function of pRb [76]. The pocket is disrupted by most 
naturally occurring geim-line mutations in hereditary retinoblastoma patients [77], and by 
most tumour-derived mutations [78]. Viral oncoproteins and a number of endogenous pRb 
binding proteins contain and LXCXE motif that allows them to bind pRb [38, 41, 79, 80]. 
The LXCXE sequence motif is found in certain cellular pRb binding proteins, such as the 
D-type cyclins, but not in the E2F transcription factors, which share a distinct eighteen 
residue pRb binding motif [81, 82].
An LXCXE peptide binds a highly conserved groove on the B-box portion of the 
pocket [41]. Flowever, domain A is required for domain B to assume active conformation, 
thus explaining the conservation of both domains [40, 41]. A number of endogenous 
proteins that interact with pRb also contain an LXCXE like sequence, including HDACl 
and HDAC2, and the ATPase BRGl, from the SWI/SNF nucleosome remodelling complex 
[83]. In contrast to experiments in vitro^ transfection assays in cultured cells have 
suggested that interaction with HDAC is required for the inhibition of E2F-1 by pRb [83, 
84]. Other studies have shown a partial requirement for HDAC activity in the pRb- 
mediated inliibition of E2F activity [85, 86]. E2F-1 has been shown to interact with the 
HAT p300/CBP and P/CAF [87]. It is possible that pRb-mediated recruitment of HDAC to 
E2F acts to offset this HAT activity.
It has been shown that E2F-1 can be acetylated, which increases the binding of the 
E2F/DP complex to DNA [88]. The recruitment of HDAC to E2F via pRb may inhibit E2F 
activity by deacetylation of the protein, further decreasing its binding to DNA. Binding of 
pRb and other PP complex to E2F does not simply inliibit E2F activity. The resulting
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pRb/E2F complex binds to promoters and actively represses transcription by blocking the 
activity of surrounding enhancers on the promoter [67-69, 83, 89-95].
Phosphorylation control of pRb
Mitogenic and growth factor signalling pathways activate Cdks in a sequential 
manner (Figure 2b and 3). It was thought that pRb represses E2F-1 via its pocket 
interaction with the E2F-1 activation domain (Figure 7), and that this interaction was 
sufficient. Recent reports have shown that the C-tenninal domain of pRb binds E2F-1, and 
that this interaction is similar in strength to the pRb pocket interaction with the trans- 
activation domain of E2F-1 [96-98]. Models suggested that phosphorylation of the C- 
teiminal domain of pRb allowed for further phosphorylation of S/T residues in the A/B 
pocket and spacer domains thereby reducing affinity of pRb small pocket for the E2F-1 
^mw-activation.
Thus it was demonstrated that cyclin D/Cdk4/6 sequentially phosphoi-ylates pRb 
causing its partial dissociation with E2F, and facilitating cyclin E/Cdk2 interaction with 
pRb [98]. Cyclin E/Cdk2 then further phosphorylates pRb completely freeing E2F-1 from 
pRb and allowing the host transcription machinery to bind to E2F/DP-1 [98]. There are 
sixteen consensus phosphorylation sites for Cdk phosphoiylation across pRb (Figure 8). 
Studies have characterized the residues across pRb which phosphorylated, by cyclin/Cdk 
complexes (Figure 8) [99-102] also reviewed in [103, 104]. Sequential phosphorylation of 
pRb not only removes E2F-1 binding, but also controls the binding o f proteins like HDACs 
(containing the LXCXE binding motif) to the B domain [40, 41, 105] also reviewed in [66, 
104]. Reports have indicated that phosphorylation of pRb alters its intra-nuclear 
localization thereby preventing pRb from inliibiting E2F-1 ^raws'-activation [106, 107].
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Figure 7: Schematic representation of E2F-1 showing domains and binding
proteins
The E2F-1 protein is made up of 437 amino acids. The schematic depicts 
the main domains so far characterized. Relevant domains include; the DNA 
binding and DP-1 binding domains (that are required for stable binding to 
DNA), the marked box domain (MB) required for interactions with the C- 
terminal domain of pRb, and the /ra«5-activation domain (required for binding 
the small pocket region of pRb, and for promoting transcription).
Below the main schematic; relevant post-translational modifications, 
characterized domains, and other binding proteins are displayed. Post- 
translational modifications; yellow circle with A = Acetylated K residues 
(K117/K120/K125) which are acetylated in response to induced double strand 
DNA damage, white circle with P = Serine residues phosphorylated during the 
G1 to S phase transition, black circle with P = Serine residue phosphorylated 
during the G2 to M phase transition by cyclin A/Cdk2 causing the release of 
E2F-1 from the DNA. S31 and S364 marked by a red line on the schematic are 
represented because these residues are phosphoi-ylated by ATM kinase and 
Clik2 kinase respectively in response to etoposide induced DNA damage.
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The role of the pRb in tumour suppression
Mutation of the Rb allele predisposes patients to develop other tumours, such as 
osteosarcomas and fibrosarcomas. Almost two-thirds of the secondaiy tumours arising in 
patients with retinoblastoma are mesenchymal in origin. The Rb gene was cloned and 
shown to contain twenty seven exons, spanning across 180kb on chromosome 13 [31, 108]. 
Mutations to the Rb gene may result in premature tennination of protein translation. A 
huge variety of mutations have been obseiwed in tumours derived from patients over the 
last twenty years (http://rbl-lsdb.d-lohmanii.de) . It is important to note that inactivation of 
pRb can occur indirectly by inactivation of proteins that inliibit Cdk phosphorylation, or 
the amplification of proteins that lead to the stimulation o f Cdk activation and 
phosphoiylation.
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Figure 8: Schematic representation of pRb depicting its domains and binding
partners
The pRb tumour suppressor protein (shown mapped) is a 928 amino acid 
phospho-protein. The map shows regions in the protein that have been 
implicated in specific protein interactions. A/P rich region, CC-coiled coil 
protein motif, NES-nuclear export motif, CK-casein kinase II phosphorylation 
recognition site, LZ-leucine zipper motif, HLH putative motif, NLS m otif (pRb 
contains a mono partite NLS spanning the A/B pocket, a bipartite NLS in the 
C-terminal domain (residues 860-877), and the DEAD box (residues 883-887). 
Filled circles at sites o f known phosphoiylation and open circles at possible 
sites o f phosphorylation denote the S/T phosphorylation sites. The A and B 
domains o f pRb are connected by a Spacer region (S).
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THE N-TERMINAL REGION OF pRb 
Factors that interact with the N-terminal region of pRh 
Hsc73
Heat shock cognate protein Hsc73 and Hsp75 are related proteins have been 
reported to co-immunoprecipitate with pRb. It was hypothesised that they are required to 
fold pRb into an active conformation. Hsp75 binds to the C-terminal domain o f pRb. 
However, Hsc 73 (heat shock cognate protein) was shown to bind to the N-terminal/ 
domain/A domain o f pRb using an in vitro kinase assay, and this binding was not affected 
by the addition o f E l A (which binds the pRb small pocket domain). A GST fusion protein 
containing amino acids 1-515 of pRb was the smallest fragment that retained binding 
activity (Inoue et al., 1995). It was reported that Hsc 73 preferentially associates with 
hypophosphorylated pRb and that Hsc 73 might act as a molecular stabilizer o f 
hypophosphoiylated pRb [109].
Microchromosome maintenance protein-7 (MCM7)
MCM7 is a DNA replication factor required for DNA synthesis. A two-hybrid
screen was used to probe for proteins that interact with the first 400 amino acids o f  pRb,
yielding MCM7 [110]. GST pull downs using GST-MCM7 as bait were found to bind N-
terminal domain fusion proteins of pRb, p i 07 and p i 30 as well as full length pRb in vitro.
Studies showed that small deletions in the N-terminal domain had no effect on MCM7
binding, suggesting that MCM7 interacts with a large surface o f the N-tenninal domain o f
pRb. This is indeed likely, as the N-teim inal domains o f p i 07 and p i 30 only share 12 %
homology with the amino acid sequence o f N-terminal domain o f pRb [111]. Endogenous
MCM7 was shown to interact with pRb in co-immunoprécipitation experiments in
myeloblastic leukemia (ML-1) cells. The function o f the interaction between N-terminal
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domain o f pRb and MCM7 was illuminated by experiments using the Xenopus cell free 
DNA replication system. Studies demonstrated that human N-terminal domain pRb (which 
binds Xenopus MCM7) was able to ablate DNA replication. This effect could be reversed 
by the addition o f the C-terminal domain o f MCM7 (which binds the N-terminal domain o f 
pRb) [110]. These data suggest that pRb might function to suppress pre-replication 
initiation at origins of replication through interactions with MCM proteins, including 
MCM7. This model has been bolstered by the finding that pRb co-localizes with MCM 
proteins in perinucleolar foci in G1 and early S-phase [112].
The human insulin receptor (JilR) promoter
The vast majority o f literature on pRb concentrates on its repressive inliibitory 
functions in relation to the cell cycle and tumour suppression. In a study by Wen-jun Shen 
e/ «/ [113], pRb was shown to activate the transcription o f the human insulin receptor {MR) 
thus increasing the cells sensitivity to insulin, pRb regulates cellular proliferation and cell 
cycle control by activating several cellular genes, through a conseiwed cis-activating 
element termed the retinoblastoma control element (RCE). As well as pRb, Spl activates 
transcription through binding the RCE m otif [114-119].
Using the human hepatoma cell line (HepG2), Shen et a l demonstrated that pRb 
stimulated the expression of the MR gene through RCE sites in the MR promoter, pRb N- 
temiinal domain deletion mutants showed dramatically reduced ability to activate the hIR 
promoter, whilst deletion mutants that ablate the binding o f viral oncoproteins (such as 
E l A) increased promoter activity. In addition, over-expression o f Spl was shown to 
augment MR promoter activity, suggesting that Spl can also augment the hIR promoter. 
This is significant because hyperphosphorylated pRb can out compete Spl for binding to 
its inliibitor Spl-I, leaving Spl to activate hIR [113].
Three regions in the N-tenninal domain o f pRb were shown to be important for
stimulation o f the MR promoter (amino acids 37-89, 89-140, and 343-389), although the
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actual residues in the N-temiinal domain that are required for binding to the hIR promoter 
have not been determined. It is also interesting that the spacer region o f pRb is required for 
hIR  promoter stimulation. Therefore perhaps protease sensitive linking regions such as the 
spacer between the A and B domains in pRb (that are not required for E2F and viral 
oncoprotein binding) seiwe some function in regulating the ability o f pRb to elicit hIR 
promoter activation.
This study suggested a model where pRb not only releases E2F-1 upon its 
phosphorylation by Cdks, but also then actively promotes the expression o f genes that 
facilitate growth and proliferation. It is possible that functional A and B domains o f pRb 
are not involved in regulating the pRb activation o f the hIR promoter. Instead, post- 
translational modification (such as phosphoiylation) of the spacer region might be 
required. The spacer region is phosphorylated by Cdks during G l/S  phases o f the cell 
cycle. Phosphoiylation o f pRb may facilitate the interaction o f pRb with Spl-I and/or 
promote the recruitment and binding o f pRb to the hIR promoter. The N-tenninal domain 
has three regions of protein sequence containing kinase recognition sites [76, 120] and has 
been proposed to be important for hyperphosphorylation o f pRb [120], A requirement for 
pRb hyperphosphorylation in order to mediated hIR promoter stimulation is consistent 
with the observation that pRb N-terminal domain deletion mutants fail to stimulate the hIR 
promoter [113].
Nuclear Death Domain Protein p84N5
p84N5 (p84) was isolated as a pRb binding protein in a two-hybrid screen using 
GST-pRb (1-300) as bait [121], Over-expression of p84 leads to increased apoptosis. 
Incidently, over-expression o f the N-terminal domain o f pRb led to increased apoptosis in 
M V l-L u cells [122], p84 contains a death domain consensus sequence in its C-terminal 
domain that shows sequence similarity to death domains in the tumour necrosis factor
receptor 1 (TN FRl), TNFRSFlA-associated via death domain (TRADD) and Fas/Apol.
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Mutations in the conserved death domain region o f p84 ablate its ability to induce 
apoptosis. GST-p84 fusion proteins have been shown to bind preferentially to 
hypophosphorylated pRb in cell lysates. Whereas p84 is present throughout the cell cycle, 
p84 could only be co-precipitated with pRb from G1 phase Monlcey kidney BSC-1 (C V -l) 
cell extracts [123]. p84 is a component o f the nuclear matrix and immunostaining 
experiments suggest that a high proportion o f p84 is co-localized with centers of RNA 
processing. pRb is also known to localize to the nucleolus, and can interact with nuclear- 
associated proteins and Mdm2 [124, 125]. Enrichment o f pRb in the nucleolus could 
represent a means of attenuating RNA polymerase I/III transcription [126]. Over­
expression of cyclin E (forcing pRb hyperphosphorylation) in SA 0S2 cells causes the 
removal o f pRb from the nucleolus. This effect is dependent on the phosphorylation o f the 
pRb large pocket domain. Localization o f pRb to the nucleolus requires the N-terminal 
domain [106], It seems therefore that pRb inhibits p 84-induced apoptosis during G1 phase. 
p84 association to pRb is lost after Cdk phosphorylation o f pRb and its subsequent 
expulsion from the nucleolus [123],
pRb interacts with SR C /pl60 and NG FIB facilitating the //wis-activation of pro­
opiomelanocortin (POMC)
pRb can actively enhance the activity o f some nuclear receptor transcription factors 
(such as Glucocorticoid receptor nuclear (GR)) by the recmitment o f activator complexes 
such as Brm/GRGl subunits o f the SWI/SNF complex [127]. In the pituitary gland, cells 
express the pro-opiomelanocortin (POMC) and HNF-4 genes during enterocyte 
differentiation. Enterocyte differentiation is triggered through the action o f  the 
hypothalamic hormone ‘corticotrophin-releasing horm one’ (CRH) that binds to receptors 
in the cell membrane. Signal cascades are activated by CRH/receptor interaction. The 
down-stream consequence leads to ligand activation o f nuclear receptors (NR) in the 
nuclear membrane.
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Mutant mice heterozygous for the Rb gene {Rb^^') develop tumours of pituitary 
POMC expressing cells [52]. Humans do not develop pituitary tumours as a direct result o f 
Rb inactivation. Comparing adenomas to poorly differentiated carcinomas, loss o f  Rb 
expression was linked to pituitary corticotroph tumour progression in humans [128]. 
Batsche et al investigated whether pRb regulates the tianscription of the POMC gene 
[129].
A subset o f three N R (Nur factors) are targeted by pRb including; Nur77, Nur- 
related factor (N u itI )  and neuron-derived orphan receptor 1 (NOR-1) [130-132]. Nur77 
and NOR-1 are implicated in the control o f thymocyte apoptosis, while N urrl plays an 
essential role in the development o f the midbrain dopaminergic neurons (reviewed in 
[132]). Nur factors contribute to basal and CRH-induced POMC transcription. The 
pituitary POMC promoter target o f Nur homodimer action is the Nur response element 
(NurRE) [130, 132].
The N-terminal activation domain (AF-1) recmits co-activators o f the steroid 
receptor co-activator SRC/p 160 family [133]. The C-tenninal activation domain (AF-2) 
contains a ligand-binding domain (LBD), the direct target o f CRH signalling. The AF-1 
and AF-2 domains require co-activators such as SRCs to mediate their transcriptional 
effects. SRCs have HAT activity and are able to recmit CBP/p300 to enhance transcription 
[134].
Batsche et al [129] demonstrate that pRb acts as a potentiator o f SRC/p 160 co­
activator function and that this action is mediated by direct interactions between pRb, Nurr 
77 and SRCs. Their data demonstrated strong activation of the POMC promoter upon over­
expression o f pRb in AtT-20 eorticotropin-secreting cells (AtT-20 cells), and that this 
effect was NurRE dependent. Interestingly, the N-tenninal domain o f pRb was required for 
the enhancement o f NGFI-B/SRC activity. Co-transfection o f the POMC promoter with a 
truncated pRb mutant (containing amino acids 379-928) exhibited markedly decreased 
POMC expression [129].
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Studies into the structural domains of the N-terminal region of pRb
Two major studies on pRb domain stmcture presently exist. The initial study used 
tiyptic digest to reveal protease resistant domains [135]. Later studies utilised caspases to 
reveal caspase resistant domains that roughly mirrored protease resistant domains [136]. 
Digestion o f pllO*^^ (fiill length pRb) occurred in a stepwise fashion with transient 
fragments giving way to more stable proteolysis-resistant fragments, p i 10*^ '’ yielded four 
protease-resistant fragments designated R (lOlcDa), N (30kDa), A (24KDa) and B 
(19.5KDa). The C-terminal domain o f pRb is the least well defined. It is predicted that the 
C-terminal domain o f pRb is highly flexible containing many turns and is therefore highly 
protease susceptible [136]. Sequence analysis o f the N-terniini o f the recovered peptides 
revealed the exact location o f these domains in pRb. The N-terminal domain o f pRb was 
further digested and found to consist o f 2 protease resistant sub-domains, N (1-263) and R 
(263-378).
This study was followed by the observation that pRb is cleaved by caspases into 
two fragments (p48 and p68) corresponding to N-terminal domain o f pRb (1-378) and the 
large pocket (379-928) [136]. This cleavage is likely facilitated by caspases on one o f four 
Aspartic acid (D) residues in the N-terminal domain o f pRb (D 349, 363, 394, and 421). 
Over-expression o f Bcl-2 (which blocks caspase activation) prevented the cleavage. This 
cleavage happens shortly before apoptosis, and results in p48 re-localising to the 
cytoplasm, and p68 releasing E2F-1.
Oncogenic mutations in the N-terminal domain of pRb
The HA-N-pRb construct (1-376) is coded for by exons 1 to 12 in the Rb gene.
Mutations that have been found in the N-terminal domain o f the Rb  gene (http://rbl-lsdb.d-
lohmann.de) include point mutations, small deletions and insertions, large deletions, and
small deletion/insertion complex mutations. Most mutations of the Rb  gene in human
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cancers lead to either splicing errors or premature tennination o f translation. Presently 
there are only six in-frame mutations identified in the sequence coding for the N-terminal 
domain of pRb in the Rb gene, and no in-frame deletion mutants [111]. That said, a 
deletion at 638 bp of the Rb gene leads to the altering o f a splice donor site, causing the in­
frame deletion o f exon 4 [137]. Exon 4 covers amino acids 127-166. This mutant protein 
retains partial or complete large pocket activity in a number o f in vitro assays o f pRb 
function [138, 139].
At a general level, one might expect cancer-derived mutations affecting the N- 
tenninal domain to correlate with highly conseiwed regions, or in regions important for the 
structural conformation o f the protein. Among distantly related vertebrate species, pRb 
orthologues share 33 % amino acid identity over the entire length of the protein. The 
highest degree o f stmctural similarity is in the A and B domains, but the N-teiminal 
domain has identical amino acids at about 20 % o f the positions. W ithin the N-terminal 
domain, the level o f similarity varies considerably. Several sub-regions within the N- 
terminal domain (amino acid positions 195-235, 270-289, and 317-343 o f human pRb) all 
exhibit greater than 50 % amino acid identity among the 5 disparate vertebrate species. 
W ithin these sub domains, there are stretches o f amino acids that exhibit nearly complete 
similarity [111]. It is notable also that the N-terminal domain o f pRb is unique and shares 
only 12 % homology to the N-terminal domains in p l0 7  an d p l3 0  [111].
The affect o f the N-terminal domain of pRb in relation to the tumour suppressor 
function of full length pRb.
Over the last two decades, the published literature on pRb has concentrated on the 
characterisation o f the small and large pockets (379-792 and 379-928) respectively. This is 
not suiprising considering that research on pRb tends to concentrate on its tumour
suppression functions. Further, the N-terminal domain o f pRb was thought to be
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dispensable for pRb-mediated tumour suppression, and an N-terminal truncated pRb 
protein exerts more potent cell growth suppression than wild-type pRb [140]. The authors 
proposed that tmncated pRb proteins could be produced by alternative translation from the 
second in-frame AUG codon o f the Rb mRNA [140]. Alternative splicing at exon 2 has 
more recently been found in normal human placenta, various tumour cells, and rat tissues 
[141]. The resultant Rb transcript should be translated exclusively into a truncated Rb 
protein lacking the N-terminal 112 amino acid residues [141]. Viable N-terminal domain 
truncated pRb proteins have also been shown to accumulate in growth-arrested or 
differentiated human leukaemia cell lines after addition o f retinoic acid, phorbol 12- 
myristate 13-acetate, or a-interferon [142-144].
In 1997, a study brought into serious question the assumption that the N-tenninal 
region is dispensable for tumour suppression [145]. Although the entire deletion o f the N- 
terminal domain leaves a truncated protein that growth suppresses more efficiently than 
wild-type pRb, mutation of specific regions in the N-terminal domain does compromise 
pRb-mediated tumour suppression. Studies were carried out in transgenic mice expressing 
human pRb with different deletions in the N-terminal domain (RbAN). None o f the 
deletions compromised Cdk2 consensus phosphorylation sites. The mutant mice were 
compared with mice expressing identically regulated wild-type pRb. Expression o f both 
pRb and RbAN caused developmental growth retardation, but the wild-type protein was 
more potent. In contrast to wild-type pRb, the RbAN proteins were unable to rescue Rb'''' 
mice completely from embryonic lethality. Embryos survived until gestational day 18.5 but 
displayed defects in the terminal differentiation o f eiythrocytes, neurons, and skeletal 
muscle. Thus, the N-terminal domain is important for complete tumour suppression, as the 
RbAN  transgenes failed to prevent pituitaiy melanotroph tumours in Rb^^'micQ, This study 
strongly suggests that the N-terminal domain o f pRb is required for embryonic and post­
natal development, tumour suppression, and the functional integrity o f the entire Rb 
protein.
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The N-terminal domain of pRb can be phosphorylated
There are presently two publications reporting the phosphorylation o f the N- 
temiinal domain o f pRb. The first showed that pRb 1-378 is phosphorylated during G2/M 
phases by a novel pRb/histone HI kinase (RbK) [100] and the second found that pRb is 
phosphoiylated by cyclin D/Cdk4/6 and cyclin (A/E)/Cdk2 and that several residues in the 
N-tenninal domain o f pRb are phosphorylated during G l/S  transition [146].
RbK was discovered during GST-pull down experiments using GST-pRb (1-378) 
bound to glutathione-agarose beads and used as affinity reagents in an in vitro protein- 
binding assay followed by an in vitro kinase assay. It was further discovered that part o f 
the N-terminal domain of pRb (amino acids 89-202 [100]) associated with RbK in 
metaphase-arrested cells, and that RbK enzymatic activity peaks during G2/M phases o f 
synchronised human Caucasian, lung carcinoma cells (A549) and M Ll cells.
In 1992, a study reported that a variety of subtle N-terminal domain Rb mutations 
abrogate pRb-mediated growth suppression and block pRb phosphorylation in vivo despite 
the retention o f E2F-binding activity within the pRb pocket[120]. The N-temiinal domain 
consists o f three regions that contain kinase recognition sites [76, 120] and have been 
proposed to be important for phosphoiylation o f pRb [120]. There are two clusters o f 
phosphorylation sites within the N-terminal domain o f pRb (S230/S250/T252 and 
T356/T373), efficiently phosphorylated by Cdks [146]. These sites may be crucial to pRb 
function because they are conserved in rodents, fish, birds, and amphibians. Since 
phosphoiylation can alter binding to pRb, phosphorylation can alter the spectrum o f pRb 
protein complexes formed.
THE P53 TUM OUR SUPPRESSOR PROTEIN
The p53 tumour suppressor is a DNA binding transcription factor often found
mutated in cancer. In response to DNA damage and conditions that require growth aiTest
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(such as cell density) p53 is activated [147]. Through inducing p53 regulates
the G l/S  DNA damage checkpoint, where the cells arrest prior to S phase to allow DNA 
repair to be perfomned. Central to this process is Mdm2 (human Hdm2), an E3 ligase that 
targets both p53 and itself for ubiquitination. This function o f Mdm2 has been shown to 
play a role in allowing export of p53 from the nucleus to the cytoplasm and degradation o f 
p53 by the proteosome [148]. Mdm2 is a transcriptional target o f p53, creating a negative 
feedback loop where p53 activates expression o f Mdm2. This keeps p53 levels low during 
normal growth and development. Activation o f the p53 response to cellular stress such as 
DNA damage, oncogene activation, telomere erosion and hypoxia is mediated, at least in 
part, by inhibition o f Mdm2 and rapid stabilisation o f the p53 protein [148].
Several oncogenes can induce stabilisation o f p53 by enlisting the activity o f ARE, 
a protein that functions by binding directly to Mdra2, inhibiting the ubiquitination o f p53 
and allowing accumulation o f p53 in the nucleus [148]. ARE expression can be directly 
activated by the transcription factors DM Pl and E2F-1. In normal cells, a proliferative 
signal that activates the Ras/Raf/MEK/MAPK pathway will result in the activation o f the 
transcription factors E2F, Ets and AP-1. Stabilization of E2F-1 leads to activation o f ARE, 
which leads to activation o f p53 and apoptosis. Ets and AP-1 bind to the Mdm2 promoter 
and stimulate its production. These increased levels of Mdm2 balance the increase in ARE 
[149].
P300 AND CROSS-TALK IN THE CELL CYCLE
The p300/CBP family o f proteins includes p300, CBP, p270 and potentially other
proteins [150]. Evidence indicates that p300/CBP genes are altered in various human
tumours [151-155], which is consistent with studies on Cbp^'^' mice that suggest CBP
possesses tumour suppressor activity in the haematopoietic system [156]. Thus p300/CBP
proteins may be regarded as having some o f the hallmarks expected o f a classical tumour
suppressor protein. The p300/CBP family are involved in processes including proliferation,
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differentiation and apoptosis (reviewed by [157-159]. p300/CBPfunction as transcriptional 
co-activators and are involved in multiple, signal-dependent transcriptional events [160].
Viral oncoproteins (such as E l A and SV40 large T antigen) specifically target 
p300/CBP family proteins (Figure 9) [161-165]; reviewed by [166, 167]. p300/CBP 
interaction with viral oncoproteins causes a loss o f cellular growth control [168, 169], 
enliances DNA synthesis [170] and blocks cellular differentiation [164, 171-173], 
reviewed by [159]. It is thought that p300/CBP proteins regulate transcription by directly 
remodelling chromatin through the acétylation o f histories, facilitating the decondensation 
o f chromatin, which allows the transcription machinery to access promoters [174-177]. 
p300/CBP family proteins are endowed with histone acetyl-transferase (HAT) activity 
[178] [179]. They are able to facilitate the transfer of an acetyl group to the é-amino group 
o f a K residue. The acétylation level o f chromatin has been established as the key 
mechanism in regulating transcription, reviewed by [180].
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Chapter 1
Figure 9: Schematic representation of the p300 protein depicting its domains and
binding partners
The full length p300 contains all o f the following defined domains; Nuclear 
receptor binding domain (NR), 3 cysteine-histidine domains (C /H I) (C/H2) 
(C/H3), CREB binding domain (KJX), the CRD domain, the Bromo-domain, 
the IBiD, and the N-tenninal phosphopeptide-binding domains with homology 
to IBiD (IHD). The N-terminal and C-terminal domains are rra;75-activation 
domains that bind a variety o f transcription factors to facilitate gene 
expression. The acetyl-transferase region (residues 1135 to 1673) recognises its 
substrates through the bromo-domain.
Underneath the schematic, known transcription factors that bind p300 are 
shown in relation to the region o f p300 they bind.
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The identification of p300/CBP
p300 and CBP were identified as proteins that bind to the adenoviral E l A and the 
cAMP-response-element-binding protein (CREB), respectively [181]. p300/CBP  genes are 
conserved in a variety of multicellular organisms. p300  is present in chromosome 22 
(22ql3) [163] and CBP resides in chromosome 16 (16pl3.3) [182]. Curiously, the 22ql3  
region shares significant homology to 16pl3.3, which is also implicated in Rubinstein- 
Taybi syndrome (RTS; [151]. Apart from p300/CBP, these two regions may contain eight 
other pairs of paralogous genes [183].
p300 and CBP share several conseiwed regions, which constitute most o f the known 
functional domains in the proteins (Figure 9) [161]. The main conserved regions include 
the bromo-domain (conserved through out mammalian HATs), three cysteine-histidine rich 
(CH)-rich domains (CEtl, CH2 and CH3), and a KIX domain. The CH I, CH3 and the KTX 
domains are likely to be important in mediating protein-protein interactions, and a number 
o f cellular and viral proteins bind to these regions (Figure 9). Crystallographic studies 
show that the bromo-domain recognises acetylated residues [184]. p270 shares some 
common antigenic determinants with p300, and has been reported to be a component o f 
mammalian SWI/SNF complexes (involved in chromatin remodelling) [185].
p300/CBP have many overlapping functions but also a number o f unique functions. 
Most sequence specific transcription factors can be activated by p300/CBP in transfection- 
based assays. ICnockout mice have been utilised to study the unique and connected 
functions o f p300/CBP, Mice were generated that exliibited p300'^~ or Cbp'^' genotypes. 
Both show similar embryonic lethal phenotypes [186]. Examination revealed defects in 
growth and neural tube closure [186]. Further more, some p30O^^' mice and Cbp^^' mice 
suffer early lethality [186]. It is thought to be important for the protein levels o f p300 and 
CBP to be maintained above a threshold (hence explaining p300^^‘ or Cbp^^~ lethality) 
[186].
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CBP and p300 also have unique functions. Patients suffering from the haplo- 
insufficient RTS are heterozygous for a mutation in the Cbp allele [151], and Cbp^’~ mice 
also show skeletal abnonnalities similar to sufferers o f RTS [1^1]. p 300'^' fibroblasts have 
specific defects in retinoic-acid dependent transcription but retain nomial CREB activity 
[186].
p300/CBP and the cell cycle
E l A mutants that cannot bind to p300 exhibit defective cellular transformation 
[39]. This suggests that p300 and CBP are important in cell cycle regulation, reviewed by 
[167]. Studies o f p300  and Cbp knockout mice have provided direct evidence that 
p300/CBP proteins are important for cell cycle regulation and differentiation [186]. 
Consistent with this idea is the obseiwation that in cell-based assays p300/CBP can 
cooperate with members o f the MyoD family o f muscle-differentiatiou regulating 
transcription factors in modulating the expression o f down-stream myogenic factors, 
including myogenin and MEF2, and promote cell cycle withdrawal in myoblasts induced 
to differentiate [172].
The p300/CBP-P/CAF protein complex can arrest cell cycle progression [169]. Cell 
cycle arrest is required for cells to begin differentiation, and acétylation o f pRb by P/CAF 
is required for C2C12 cells to arrest and undergo myogenic differentiation [53]. M utation 
in the FIAT domain o f P/CAF impairs MyoD-dependent /raw.s-activation [188]. It is 
interesting that the over-expression o f E l A (which antagonises P/CAF binding to 
p300/CBP), drives cells into S-phase [169]. In Caenorhabditis elegans (C. elegans), 
inactivating the Cbp-1 gene blocks most aspects of differentiation. Evidence that 
acétylation by p300/CB P/P/C AF promotes differentiation was obseiwed indirectly by the 
obsei*vation that components o f the FIDAC complexes which antagonize HAT activity, 
rescues some o f the Cbp-1 phenotype [189], providing evidence that p300/CBP/P/CAF
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HAT activity is required for differentiation, at least in C. elegans, to counteract the role o f 
HDACs.
Cell growth and proliferation are influenced by p300/CBP activity [170]. It was 
obseiwed that p300'^' mouse embryonic fibroblasts MEFs grow more slowly compared to 
wild-type cells and have a phenotype reminiscent o f senescence. The binding o f E l A to 
p300 comelates with E 1 A-induced DNA synthesis [170], so the ElA -p300 complex might 
play an active role in stimulating cellular growth and proliferation.
There are other ways in which p300/CBP promotes cell growth and proliferation. 
p300 forms a ternary complex with p53 and Mdm2. Mdm2 mutants that fail to bind p300 
are unable to degrade p53, hence p300 is required to degrade p53 [190]. In E2F-5, a Cdk- 
phosphoiylation consensus site in the transcription activation domain is phosphoiylated by 
cyclin E/Cdk2 as cells approach S-phase [191]. This phosphoiylation was shown to 
augment interaction o f p300 with E2F thereby enliancing the transcription of E2F genes 
[191].
p300/CBP proteins are also involved in mediating apoptosis. p300 can interact with 
the hypoxia-inducible factor (H IF la) [192], which binds to and stabilizes p53 during 
hypoxia [193]. The HIFla-p300/CBP-p53 pathway is thought to play an important role in 
regulating apoptosis under hypoxic conditions and may prevent tumour development. In  
vitro studies in mammalian cell-based assays have provided evidence that p300/CBP is 
involved in apoptosis [194]. Cells lacking p300 but not CBP have impaired ionising 
radiation (IR) sensitivity [195], and functional sequestration o f p300/CBP activity by E l A, 
or a dominant negative version o f p300, reduces p53-dependent apoptosis [194]. In vivo 
p300 also interacts in complex with JMY (junction-mediating and regulatoiy protein), and 
p53 in response to stress [196]. This complex up-regulates a variety o f target genes 
including bax, which may account for its pro-apoptotic ability [196].
p300 is also involved in controlling cell adhesion [197]. The nuclear proto­
oncoprotein SYT can associate with p300 and this association occurs predominantly in
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contact inliibited cells [198]. SYT is an SH2/SH3 domain containing protein that becomes 
mutated in synovial sarcomas and certain other cancers. SYT mutant cells are believed to 
exhibit deficient cell adhesion control [197]. The mechanisms by which the p300-SYT 
interaction affects cell adhesion remains unclear.
Transcriptional regulation by p300/CBP
The initiation o f transcription by RNA polymerase II requires sequence-specific 
promoter/enliancer-binding transcription factors as well as the basal transcription 
machineiy. Unless transcription factors can directly interact with the basal transcription 
machineiy, other proteins must act as bridges that connect them to the basal machinery. 
p300/CBP is known to interact both with a wide variety of transcription factors and with 
components o f the basal transcriptional machinery, including TBP, TFIIB, TFIIE and 
TFIIF [196].
Therefore, in one model, p300/CBP provides such a bridge. Since p300/CBP 
proteins are involved in numerous signal transduction pathways, Kamei and colleagues 
have proposed that a coordinated re-distribution of p300/CBP activity among different 
classes of factor in a signal-dependent maimer imparts specificity in transcriptional 
regulation [199]. For example, the engagement of p300/CBP by various hormone receptors 
inhibits AP-1 transcription [199], and over-expression o f E2F-1 can hinder p53 trans- 
activation in a p300/CBP-dependent manner [200].
p300/CBP has been frequently found in complex with other HATs, including
P/CAF [201], SRC-1 [202] and P/CIP/ACTR/AIB1 [203]. p300/CBP proteins might
nucleate the assembly o f diverse cofactor proteins into multi-component co-activator
complexes [202]. p300/CBP may flmction as a scaffolding protein that binds a variety o f
transcription co factors thereby facilitating protein-protein and protein-DNA interactions
that make up the transcription machinery. Studies o f the human interferon j3 (IFN(3)
enhancer have shown that the surface o f p3 00/CBP provides a scaffold for different
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components o f the transcription apparatus [204]. The recmitment o f p300/CBP, together 
with transcription factors such as ATF2/JUN, p50/p65 o f NF-kB and interferon regulatoiy 
factor 1, alongside architectural proteins including high mobility group (HMG) proteins, 
may be important for cooperativity and transcriptional activation [205].
p300/CBP FIAT activity acts upon transcription factors, and the basal 
transcriptional apparatus, to influence transcription. Many transcription factors are 
acetylated by p300/CBP such as p53 [206], E2F-1, E2F-2 and E2F-3[88, 207], Myb [208], 
MyoD [188], GATA-1 [176], EKLF [209], HNF-4 [210] and NF-Y [211] (Figure 10). In 
almost all cases, acétylation enhances their DNA-binding activity. Acétylation at the p53 
C-terminal domain may cause a conformational change that relieves the inliibitory effect o f 
this region towards p53 DNA-binding, leading to increased DNA-binding activity [206].
It is also possible that acétylation creates a surface that facilitates protein-DNA 
recognition; this idea is consistent with the observation that many transcription factors 
have enlianced DNA-binding activity upon acétylation. Protein acétylation can also 
regulate protein-protein interaction; acétylation of Drosophila TCF inhibits its binding to 
Armadillo, thereby leading to down-regulation of transcription [212]. The viral 
oncoprotein E l A is also acetylated, and acétylation of ÏC239 in E l A regulates its binding 
to CtBP (C-terminal binding protein), which is capable of interacting with various 
transcription repressors [213]. The pRb is acetylated in a fashion that influences 
subsequent phosphorylation o f pRb, and E l A can stimulate pRb acétylation [214]. pRb is 
also acetylated dming early stages o f differentiation by P/CAF [53]. Components o f  the 
basal transcription apparatus (for example, TFIIE and TFIIF, and TAF(I)68), can also be 
acetylated [175]. Acétylation o f these factors enhances DNA-binding activity and 
consequently stimulates gene activity [215]. Many more transcription factors are known to 
be acetylated and with various functional outcomes (listed in Figure 10).
Acétylation o f multiple sites in the core histone tails is associated with
transcriptional activity. An important question is whether the p300/CBP HAT activity
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targets nucleosomal histones directly and regulates transcription by chromatin remodelling. 
Although p300/CBP can acetylate all four core histone in vitro [179, 216], it is not clear 
whether histones are the bona fid e  targets o f p300/CBP HAT activity in vivo and, if  so, 
which K residues in the histone tails are specifically modified by p300/CBP HAT. 
Biochemical and genetic experiments have demonstrated the importance o f histone tails as 
key targets o f acétylation, which has a significant impact in regulating transcription [177] 
reviewed by [217]. Specifically, by mutating the N-terminal tail of histone H4, Durrin et al 
showed that conditionally active genes, such as G all or Pho5, become less inducible 
[218]. Furtheimore, mutation of certain K residues in the H3 and H4 tails may bypass the 
need for GCN5 (a key yeast HAT) for transcriptional activation [177]. Acétylation may be 
responsible for transcriptional repression, because deletion or K  substitution in the histone 
H3 tails leads to higher basal levels o f G all m à P h o S  transcription in budding yeast [219].
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Figure 10
Protein References
p53 Gu and Reeder, 1997
SRY Thevenet et al., 2004
Acétylation increases DNA STATS Yuan et al,, 2005
binding affinity GATAI Boyes et al., 1998
GATA2 Hayakawa et al., 2004
E2F-1 Martinez-Balbas et al., 2000; Marzio et al., 2000
Acétylation decreases DNA 
binding affinity
YY-I Yao et al., 2001
HMG-Al Munshi et al., 1998
HMG-N2 Luhrs et al., 2002
p65 Kiernan et al., 2003
p53 Gu and Roeder, 1997; Luo et al., 2004
HMG-Al Munshi et al., 2001
STAT3 Wang et al., 2005; Yuan et al., 2005
AR Fu et al., 2000; Gaughan et al., 2002
Acétylation increases ERa (basal) Wang et al., 2001
transcriptional activation GATAI Boyes et al., 1998
GATA2 Hayakawa et al., 2004
GATAS Yamagata et al., 2000
EKLF Zhang and Bieker, 1998
MyoD Sartorelli et al., 1999; Polesskaya et al., 2000
E2F-1 Martinez-Balbas et al., 2000; Marzio et al., 2000
Acétylation decreases 
transcriptional activation
ERa (ligand dependent) Wang et a l, 2001
HIFla Jeong et a l, 2002
p53 Ito et a l, 2002
Acétylation increases protein 
stability
c-MYC Patel et a l, 2004
AR Gaughan et a l, 2005
ERa Kawai et a l, 2003
E2F-1 Martinez-Balbas et a l, 2000
Smad? Gronroos et a l, 2002
Acétylation decreases protein 
stability HIFla
Jeong et a l, 2002
Acétylation promotes protein 
protein interaction
STATS Wang et a l, 2005; Yuan et a l, 2005
AR Fu et a l, 2002
EKLF Zhang et a l, 2001
Importin a Bannister et a l, 2000
Acétylation disrupts protein 
protein interaction
NF-KB Chen et a l, 2001
Ku70 Cohen et a l, 2004
Hsp90 Kovacs et a l, 2005
5 4
Chapter 1
Figure 10: The ramifications of acétylation of non histone cellular proteins
This table lists the non-histone proteins presently known to undergo 
acétylation. Shown here is a summary o f transcription factors and other non-histone 
proteins are acetylated. In each case the purported function o f acétylation is listed 
in the left column.
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Biochemical analysis indicated that the removal o f H2A/H2B from nucleosomal 
arrays enhances gene activity, at least in part by decreasing the level o f chromatin folding 
[220, 221]. More recently, a functional interaction between p300/CBP and a family o f 
proteins involved in nucleosome assembly, the nucleosome assembly proteins (NAP), has 
been documented [222]. NAP is involved in the assembly o f regularly spaced nucleosomal 
arrays [223]. Ito et al demonstrated that acétylation o f histoires by p300 helps the transfer 
o f H2A-H2B dimers from nucleosomes to NAP-1 [222], such a mechanism might directly 
couple acétylation of nucleosomes to nucleosome remodelling in transcriptional regulation.
HATs might then play roles in both transcription activation and inactivation [205]. 
Hypo-acétylation generally (but not always) correlates with transcriptional repression, and 
hyper-acetylation correlates with transcriptional activation, reviewed by [180]. 
Mechanistically, acétylation o f K residues within the histone tails may have several 
outcomes: (1) it may promote transcription factor access to DNA in chromatin [224], 
possibly by neutralising the positive charge associated with the K 8-amino group (reviewed 
by [225]); (2) it may weaken inter-nucleosomal interactions and de-stabilise higher-order 
chromatin structure [220, 221]; and (3) it may promote the procèssivity o f RNA 
polymerase through nucleosome arrays [226].
Li et al elegantly demonstrated the requirement o f p300 HAT activity in 
stimulating transcription from the thyroid hormone receptor bA {tr ba) promoter and hsp70 
promoter. Importantly, these studies suggested that p300 facilitates transcription from a 
disrupted chromatin template but is not itself involved in disrupting chromatin structure 
and instead stabilises a remodelled chromatin state [211, 227].
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Objectives
pRb was first discovered to be acetylated by Chan et al [214]. pRb acetylated at 
residues K873/874 was shown to prevent in vitro phosphorylation o f pRb by 
cyclinE/Cdk2. Thus, acétylation o f K873/874 was predicted to induce cell cycle aiTest at 
the G l/S  phase boundary. Flow cytometiy studies confimied that the pRb mutant 
derivative pRb (379-928) 873/874 QQ, caused an increase in the percentage o f cells in G l- 
phase as a proportion of the total asynchronous cell population [214].
Further to this, acétylation o f pRb was observed to be induced by differentiation in 
‘human leukemic monocyte lymphoma cell line’ (U937 cells) [214]. This has been 
followed by a recent study that confirms pRb acétylation at residues K873/874 is required 
for the initial stages o f differentiation in C2C12 cells [53]. Using a specific antibody raised 
against acetylated K873/874, acétylation o f pRb was shown to be induced by etoposide 
treatment in a variety of cell lines [97]. Consequently, a corresponding change in the intra­
nuclear localization o f acetylated pRb was obseiwed in response to DNA damage [74, 97]. 
One o f the aims of this study is to trace some o f the down-stream functional consequences 
of K873/874 acétylation, in relation to the control o f E2F-1.
Analogous studies on E2F-1 and p53 revealed they are acetylated in response to 
DNA damage [75, 228]. Similar studies found that E2F-1 is phosphorylated and stabilized 
by ATM kinase and Chk2 kinase in response to DNA damage [73, 229], and that phospho- 
E2F-1 (phosphorylated at S364) also undergoes a nuclear redistribution in response to 
DNA damage. Exogenous expression o f E2F-1 is known to induce apoptosis by trans- 
activation of apoptotic genes such as p73  and apaf-1 [75]. As pRb is acetylated in response 
to DNA damage, it follows that the acétylation of pRb might be involved in regulating 
E2F-1-dependent apoptosis. A further objective of this study was to address how the 
acétylation o f pRb might influence E2F-1 activity, and to test whether acétylation o f pRb 
at residues K873/874 could facilitate nuclear redistribution in response to DNA damage.
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pRb was shown to be in vitro acetylated by p300 in four out o f its six domains; 
only the spacer and the N-terminal demain remained left to study [214]. An additional aim 
o f this study was to address whether the N-terminal demain o f pRb is acetylated both in 
vitro and in vivo, and under what control. A key question concerned whether or not the N- 
temiinal domain of pRb can impact on the well-characterized properties o f pRb (for 
instance, its interaction with E2F-1) through interacting with the C-terminal domain.
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CHAPTER 2
M A TERIA LS AND M ETH O D S
PLA SM ID S
pGEX2T-Rb (379-928) has been described in Bandar a et. al. 1991 [230]. pGEX2T 
763-928, and pcDNA3-9E10 Rb (1-928) were kind gifts from Robert White and Sybille 
Mittnacht. pSG5L-HARb 1-928 was kindly provided by Bill Sellers. pGEX2T GST-Rb 10- 
330 was provided by Paul Robins [231]. Flag-p300 1134-2414, and FIis-p300 1195-1673 
have been described previously [214]. Flag-p300 (FL) baculovirus was also provided by 
Nakatani [216]. pFIA-B2F-l and pCMV-Pgal plasmids have been described in Lee et. a l  
[232]. pE2F-l and pDP-1 have been described in Bandara et. al. [233]. The mammalian 
expression vector for Mdm2 has been described [234].
pGEXKG-Rb 1-376 and pcDNA3HA-Rb 1-376 were PGR cloned from pSG5L~ 
ElARb 1-928 using the Advantage® -G C 2 PGR kit (Glontech) as per supplied protocol.
Plasmids 5’-Primer 3’-Primer
pGEXKG-Rb 
1-376 and 
pCDNASHA- 
Rb 1-376
TAATTACCATGGCCTACCCCTACGACGTG TTCTAGCTCGAGTGACCTAACTGGAGTGTGTG
The ‘Quick change multi site-directed mutagenesis k it’ (Stratagene) was utilised to
generate pGEX2T-Rb 763-928 K:873Q/X874Q pGEX2T-Rb 763-928 K 873R/K 874R from
pGEX2T-Rb 763-928. The 2HA-pcDNA3-Rb 763-928, 2HA-pcDNA3-Rb 763- 
g 2 g K 873Q/K874Q  ^ and 2HA-pcDNA3-Rb 763-928 k 813r / k s 74r  subcloned from pGEX2T
763-928, pGEX2T 763-928*^*’^^^ **^ '“  ^ and the pGEX2T 763-928'^^^^'"'^^™ bacterial 
expression vectors respectively by restriction digest using Bam  H I, and EcoKl restriction
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enzymes (Promega). The resulting vectors were sequenced by Lark technologies using the 
universal pGEX reverse primer to confirm the mutant’s identity. pSG5L-HARb 1- 
92gK873Q/K874Q pSG5L-HARb 1-928 '^ 873R/K874R subcloned by restriction digest
from pcDNA3 9E10 Myc-Rb 1-928.
SITE-DIRECTED MUTAGENESIS
pGEX2T-C-pRb 763-928 point mutants were generated using Quick change site- 
directed mutagenesis kit (Stratagene). Primer pairs encoding Rb K873/874 to Q (QQ) or R 
(RR) were generated (using specifically designed software on the Stratagene website 
http://labtools.stratagene.com/QC) . The primer properties match those listed in the manual; 
ie 25 to 45 bases in length, with a melting temperature (TM) o f > 78 °C, and with the 
desired mutation in the middle of the primer, with 10-15 bases o f the coinect sequence on 
both sides. Primers were manufactured by Sigma-Genosys. Briefly; these primers were 
annealed to the circular double-stranded template (pGEX2T-C-pRb 763-928) and extended 
by PGR reaction in a thennal cycler with PfuTurbo® DNA polymerase to produce two 
nicked circular strands. The parent template DNA was then digested using D pnl (which 
only recognises methylated template DNA). The mutated product was then transfonned 
into XL 1-Blue super competent cells. These cells repair nicks in the mutated DNA strands. 
The resulting cells were grown on Terrific Broth (TB) (Sigma-Aldrich)/agar plates 
containing ampicillin at 50 pg/ml final concentration (Sigma-Aldrich). Colonies were 
cultured overnight in TB/amp growth media and the DNA was harvested using the mini 
prep kit (Qiagen). The resulting DNA was sequenced using the universal pGEX reverse 
primer to confirm the mutations and the accuracy o f the PGR product (Lark technologies).
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Plasmids Primer pair
873/874RR
Sense 5'-ccctcctaaaccactgagaaga ctacgctttgatattgaag-3' 
aSense 5'-cttcaatatcaaagcgtagtcttct cagtggtttaggaggg-3'
873/874QQ
Sense 5'-caaccctcctaaaccactgcagcaa ctacgctttgatattgaag-3' 
aSense 3'-cttcaatatcaaagcgtagttgctg cagtggtttaggagggttg-3'
TISSUE CULTURE AND TRANSFECTION
The C33A, U 20S, HEK 293, and HeLa cells were cultured in Dulbecco modified 
Eagle medium (GIBCO) supplemented with 10 % foetal calf semm (ECS) and 0.1 % 
penicillin/streptomycin (GIBCO) at 37 °C in 5 % CO2 . These human cancer cell lines were 
purchased from the European Tissue Culture Collection (ECACC). High Five (HI5) and 
SF9 insect cells were utilised for the protein expression and baculovirus amplification 
respectively. Insect cells were maintained in T C I00 medium (GIBCO) supplemented with 
5 % FCS and 0.1 % gentamycin (GIBCO) at 26 °C. HI5 and SF9 cells were purchased 
from Cancer Research UK (CRUK). Detection o f acetyl-N-pRb was aided by treating cells 
with 10 pM TSA, which was purchased finm Sigma Aldrich. Transfections were cainied 
out using both Effectene transfection reagent (Qiagen) and Genejuice transfection reagent 
(Novagen) according to m anufacturer’s guidelines. pCM V-p galactosidase (p-gal) 0.5 pg 
was included in all transfections to compare transfection efficiency between samples. The 
amount of DNA in each transfection in an experiment was equalised by the addition of the 
appropriate amount o f empty vector DNA.
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IM MUNOBLOTTING AND IMMUNOPRECIPITATION  
Primary Antibodies
The ‘Acetylated-Lysine Polyclonal Antibody’ (Anti-Ac-K poly) and the 
‘Acetylated-Lysine Monoclonal Antibody’ (Anti-Ac-K mono) were both purchased from 
Cell Signalling. Anti-HA monoclonal antibody aH A II (ascites form) was purchased from 
Covance, and the anti-HA polyclonal antibody aH A -Y  11 was purchased from Santa Cruz. 
The monoclonal E2F-1 antibody KH95 along with the E2F-1 polyclonal antibody C20 
were purchased from Santa Cruz. The pRb antibodies IF8 (monoclonal) and C l5 
(polyclonal) were purchased from Santa Cruz. The pRb antibody G3-245 mouse 
monoclonal antibody was purchased from BD biosciences. Anti-D P-1 polyclonal antibody 
K20 was purchased from Santa Cmz. The anti-Mdm2/Hdm2 monoclonal antibody SMP14 
was purchased from Santa Cruz. The anti-Flag antibody (M2) was purchased from Sigma. 
The anti-GST antibody B 14 was purchased from Santa Cruz.
Secondary antibodies
The following secondary antibodies were used for immunoblotting at 1 in 5000 
dilution from manufacture’s stock: Goat anti-mouse antibody and goat anti-rabbit antibody 
were purchased from Dako.
The following fluorescent secondary antibodies were used during immunostaining 
at 1 in 400 dilution from manufacture’s stock: The ‘Alexa Fluor ® 488 (green) goat anti­
mouse antibody (2 mg/ml)’, the ‘Alexa Fluor ® 594 (Red) goat anti-mouse antibody (2 
mg/m l)’, and the ‘Alexa Fluor © 595 (Red) donkey anti-rabbit antibody (2 mg/m l)’ were 
purchased from Invitrogen.
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Preparing ceil lysate with IPH buffer
Cells were incubated for 48 h post-transfection. The cells were then washed twice 
in ice-cold PBS purchased from Sigma (supplemented with protease inhibitor cocktail 
((Calibiochem) at 1 in 1000 dilution). Cells were harvested by scraping cells into 1 ml o f 
fresh ice-cold PBS. Cell pellets were collected by centrifugation at 1200 rpm in a Sorvall 
bench top centrifuge. Pellets underwent lysis by rotation on a wheel at 4 °C in IPH buffer 
(50 mM Tris pH 8.0, 150 mM NaCl, 5 mM EDTA, 1 mM PMSF, protease inliibitor 
cocktail ((Calibiochem) at 1 in 1000 dilution), 10 pM TSA (Sigma)), supplemented with 
0.5 % NP-40. Cells undeiwent lysis for 45 min before being centrifuged at 13000 rpm for 
20 min (in a Sorvall bench top micro centrifuge) to separate the required supernatant from 
the waste cell debris. Supernatant was kept on ice whilst the protein concentration was 
determined using the Bradford assay (Biorad).
Preparation of separate nuclear and cytoplasmic extracts.
Separate nuclear and cytoplasmic extract was prepared using a slightly modified
version o f the Dignam method [235]. After transfection, cells were incubated for 48 h. The
cells were washed twice in ice-cold PBS (containing protease inhibitor cocktail
(Calibiochem) at 1 in 1000 dilution). Cells were scraped into 1 ml o f ice-cold hypotonic
buffer (20 mM HEPES pH 7, 10 mM KCL, 1 mM M gCb, 0.5 mM DTT, 0.1 % Triton X-
100, 20 % Glycerol, 2 mM PMSF, 10 pM  TSA) supplemented with protease inhibitor
cocktail ((Calibiochem) at 1 in 1000 dilution). Cells were disrupted using 15 strokes of a
Dounce Homogeniser. Following this, samples were centrifuged at 3000 ipm  for 5 min.
The supernatant was removed and stored as the cytoplasmic fraction. The remaining pellet
was re suspended in 2/3-pellet volume o f extraction buffer (hypotonic buffer supplemented
with 420 mM NaCl). Nuclear lysis was achieved by incubating samples (under rotation) at
4 °C for 20 min. The nuclear extract was separated from the nuclear matrix by centrifuging
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samples for 10 min at 13,000 rpm. Cytoplasmic and nuclear extract was kept on ice whilst 
the protein concentration was determined using the Bradford assay (BioRad). Extract was 
used right away or else stored at -80 °C.
Immunoprécipitation
In order to ensure equal loading o f exogenous protein for each IP, the transfection 
efficiency o f each sample was determined by measuring the relative expression o f (3- 
galactosidase ((3-gal). To measure the p-gal activity, 20 pi o f cell extract was mixed with 
20 pi o f 2x (3-gal buffer (200 niM Na phosphate buffer pH 7.3, 2 mM M gCb, 100 mM P- 
mercaptoethanol (Sigma), 1.33 mg/ml o-nitrophenyl-beta-d-galactopyranoside (ONPG) 
(Sigma)). The reaction mixtures were incubated at 37 °C until a yellow colour developed. 
The reactions were stopped by the addition o f 960 pi o f 0.5 M Na2C 0 3  to each sample, and 
the relative absorbances were measured at 420 nm.
In some experiments it was necessaiy to measure the difference in binding affinity 
of various mutants o f the C-tenninal domain o f pRb for E2F-1. In order to ensure the equal 
loading o f mutant proteins, 100 pg o f input for each transfected mutant were first run on a 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. 
Immunoblotting facilitated visualisation o f relative protein levels. Relative protein levels 
were ascertained by measuring the band intensity o f the exogenous protein in each sample 
using densitometric analysis software (Image J).
Protein-G-agarose was incubated with 3 pi o f primary antibody (2.5 pg/pl) for 2-4 
h at 4 °C. The resulting beads were washed 6 times with IPH buffer (supplemented with 
0.5 % NP-40) to remove excess antibody. Each protein extract sample was first pre­
incubated for 1 h at 4 °C with antibody free Protein-G-agarose in order to remove that 
bound non-specifically to the agarose beads. Pre-cleared extract was incubated with 
antibody bound Protein-G-agarose for 2-5 h at 4 °C rotating on a wheel. After incubation,
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the beads were extensively washed (approximately 6 to 10 times) with IPH buffer 
(supplemented with 0.5 % NP-40). Proteins bound to the beads were eluted with 3X SDS 
loading buffer (150 mM Tris pH 6.8, 6 % SDS, 0.3 % Bromophenyl Blue, 30 % glycerol, 
and 2 mM p~mercaptoethanol) and visualised by immunoblotting using the appropriate 
antibodies.
All other immunoprécipitations described were carried out in the same manner as 
above, with slight modifications o f the NP-40 concentrations.
STRIPPING AND RE-PROBING OF BLOTS
In order to re-probe blots, bound antibodies were removed by immersing the 
blotting membrane in 15 ml o f stripping buffer (0.2 M Glycine, 1 % SDS, HCL to pH 2.5) 
for 45 min at room temperature. The stripped memhrane was rinsed with dHiO over and 
over for a period o f about 5 min. Removal o f any residual stripping buffer was ensured by 
3 (5 min) washes in PBS (supplemented with 0.1 % Triton-X-lOO). The membrane was 
then re-blocked in 5 % milk (Marvel) diluted in PBS (Sigma) for 30 min before re­
applying the primary antibody.
IMMUNOSTAINING
The following immunostaining protocol is a modified version previously published
by Gonzales et al [236]. Cells were transfected and fixed 48 h after transfection. Cells were
washed twice in ice-cold PBS to remove growth media. Cells were then fixed in PBS
(supplemented with 3.7 % formaldehyde) for 15 min. Residual fonnaldehyde was removed
by washing the cells 3 times (5 min washes) with PBS. Cells were permeabilized by
immersion in PBS (supplemented with 0.5 % Triton-X-100) for 5 min at room
temperature. Cells were treated with PBS (supplemented with 10 % FCS) for 30 min at
room temperature. The blocking solution was aspirated and the cells were treated with 100
pi o f primary antibody solution (antibody added to PBS at the appropriate dilution) for 1 h
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at room temperature. During primary antibody incubation, cells were stored in a humid 
box. Following this, the primary antibody solution was aspirated. The cells are washed 4 
times (4 min washes) in PBS (supplemented with 0.025 % Tween 20). Cells were then 
treated with 100 pi of the appropriate Alexa Fluor® secondary antibody (diluted 1 in 400 
in PBS) for 30 min in a covered humid box. The cells were washed 4 times (4 min washes) 
in PBS (supplemented with 0.025 % Tween 20). The cover slips were drained and 
mounted in Vectashield mounting medium with DAPI (Vector Labs H-1200) on a glass 
microscope slide. The slides were sealed with nail varnish. The cells were viewed on an 
Olympus BX60 fluorescent microscope. Images were taken using the Hamamatsu Digital 
CCD camera, and digitally manipulated using the Open lab computer software.
PROTEIN PREPARATION  
Expression and Purification of Glutathione-S-Transferase-tagged fusion proteins.
Glutathione-S-Transferase fusion protein expression and purification were 
performed as described in the company protocol (Amersham, formerly Phannacia). Fresh 
overnight starter cultures (50 ml) o f BL21 (DE3) pLys (Invitrogen) were transformed with 
the appropriate pGEX-recombinants diluted 1 in 10 in TB media (supplemented with 0.8 
% glycerol and ampicillin (100 pg/ml)). The bacterial cultures were incubated for 16 h at 
37 °C with shaking (225 rpm).
Cells were diluted 1 in 50 in the same growth media, and sub-cultured in the same 
conditions until the bacterial culture density (measured by a spectrophotometer) reached an 
absorbance o f approximately 0.5-0.6 at 600 nm. Upon reaching this cell density, the 
culture was supplemented with 50 pM  isopropyl-(3-D-thiogalactopyranoside (IPTG, 
Sigma). The culture was subsequently incubated at 15 °C for 15 h to allow for the 
induction o f protein expression before harvesting the cells.
Bacterial pellets were collected from the cultures by centrifugation at 13,000 rpm
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for 10 min at 4 °C. The bacterial pellet was then re-suspended in 30 ml (or equal pellet 
volume) o f PBS (supplemented with 200 pM PMSF, protease inhibitor cocktail 
(Calibiochem) at 1 in 1000 dilution and 1 % Triton-X-100 (Sigma)). Lysis o f the re­
suspended culture was achieved by passing the culture drop-wise through a pressure 
gradient o f 995 psi (three times) in a French press machine. The soluble and insoluble 
fractions were separated by centrifugation at 13000 rpm for 30 min at 4 °C. The soluble 
supernatant was transfeiTed to 50 ml falcon tubes. Glutathione-Sepharose beads (200 pi o f 
beads per 100 ml bacterial culture) was added to the soluble fraction and incubated under 
rotation at 4 °C for 1 h. The glutathione-Sepharose beads were washed three times with 20 
ml o f ice-cold PBS supplemented with 1 % Triton, and once with cold PBS prior to the 
addition o f soluble lysate.
GST beads were separated from the lysate by passing the mixture through a 5 ml 
polypropylene column (Qiagen). The beads were washed twice (30 min per wash) in 5 ml 
PBS (supplemented with 200 pM  PMSF, protease inhibitor cocktail ((Calibiochem) at 1 in 
1000 dilution) and 1 % Triton-X-100). The beads were washed for a further 40 min in PBS 
without Triton-X-100. Protein impurities were removed by a further 20 min wash step 
using PBS (supplemented with 200 pM PMSF, protease inhibitor cocktail (Calibiochem) at 
1 in 1000 dilution and 10 pM reduced glutathione (Sigma)). Protein preparations produced 
for in vitro pull down assays were stored at -20 '^C at this stage. For experiments requiring 
eluted protein, GST-tagged proteins were batch eluted by incubating the GST beads for 30 
min in elution buffer (50 mM Tris-FtCL (pH 8), 10 mM reduced glutathione, 120 mM 
NaCl) rotating at 4 °C. The ratio o f bead volume to elution buffer volume ratio for elution 
was 1:1. All fusion proteins were subsequently dialysed into BClOO exchange buffer (20 
mM Tris-HCL (pH 8), 0.5 mM EDTA, 100 mM KCl, 20 % glycerol, 0.5 niM DTT, 0.5 
niM PMSF and protease inhibitor cocktail (Calibiochem) at 1 in 1000 dilution). Dialysis 
was facilitated by injecting eluted protein into 500 pi capacity dialysis slides (Pierce Slide-
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A-Lyser® 0.5 ml dialysis cassettes) and immersing the cassettes into ice-cold BClOO 
exchange buffer. Cassettes were left rotating in buffer for approximately 3 h. All aliquots 
o f protein were run through SDS-PAGE gels and visualised by Coomassie staining. Protein 
aliquots were stored at -80  °C.
Expression and purification of His-tagged fusion proteins
The procedure for His-tagged fusion protein expression was similar to that 
described for GST-fusion protein expression. Fresh overnight starter cultures (50 ml) of 
BL21 (DE3) pLys (Invitrogen) transformed with the appropriate pET28-recombinants 
were diluted 1 in 10 in TB media (supplemented with 0.8 % glycerol, containing 
kanamycin (10 pg/ml)) and incubated for 16 h at 37 °C with shaking (225 ipm). The 
bacterial culture was sub cultured, induced, pelleted and lysed using exactly the same 
procedures as those outlined in the GST-fusion protein expression protocol above. The 
buffers used to prepare His-tagged proteins were different. Pelleted bacteria were 
resuspended in Lysis buffer (10 mM Tris pH 7.9, 10 % glycerol, 0.5 M NaCl, 0.1 % NP- 
40, 0.5 mM PMSF, and protease inhibitor cocktail (Calibiochem) at 1 in 1000 dilution).
The soluble fraction o f the lysate was supplemented with 1 mM Imidazole. At this 
stage, Ni-NBT agarose beads (Qiagen) were washed 3 times in lysis buffer. The Ni-NBT 
agarose beads (200 pi o f beads/100 ml culture) were added to the extract and incubated 
under rotation at 4 °C for 1 h. Ni-NBT beads were separated from the lysate by passing the 
mixture through a 5 ml polypropylene column (Qiagen). The beads were washed 3 times in 
5 ml volumes o f BClOO (supplemented with 20 mM Imidazole) each wash lasting 30 min 
under rotation at 4 °C. The beads were then washed for 20 min in BClOO (supplemented 
with 40 mM Imidazole). Elutions o f the bound His-tagged proteins were facilitated by the 
addition o f a volume o f BClOO (supplemented with 2 M Imidazole) equal to the Ni-NBT 
bead volume. The polypropylene column containing the beads and elution buffer were
rotated at 4 °C for 1 h. Protein samples were dialysed in BClOO as described for GST
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protein preparation, so removing the Imidazole.
Amplification of Flag-p300 FL baculovirus
SF9 insect cells were used to amplify the Flag-p300 baculovirus. SF9 cells were 
grown in 150 ml tissue culture flasks. The first step was to initially infect the cells with 
vims. The media was aspirated and 200 pi o f virus along with 2 ml o f semm free T C I00 
(GIBCO) were added to the flask. The flasks were covered from the light and left rocking 
for 1 h at room temperature. After initial infection, the flask was supplemented with 23 ml 
o f T C I00 (supplemented with 5 % FCS and 0.1 % gentamycin (GIBCO)). The SF9 cells 
were left until most o f the cells had burst (between 10 to 14 days). The virus and media 
was aliquoted into sterile screw capped vials and stored at -80 °C (wrapped in tin foil to 
keep out the light).
Expression and purification of Flag-p300 FL baculovirus
The first step was to determine the optimal amount o f vims and the optimal cell 
density for baculovims expression in High Five (HI5) cells. HI5 cells were grown on 6 
well tissue culture plates. The 6 well plates were infected at different levels of cell density 
(40 %, 50 %, 70 %, 80 %, and 90 % confluence). Each plate was then divided so each well 
was infected with increasing volumes o f virus (10 pi, 20 pi, 50 pi, 100 pi, 150 pi and 200 
pi). Infection procedure was identical to that described above. The HI5 cells were 
harvested 48 h post-transfection in 500 pi ice-cold PBS. The cells were pelleted by 
centrifugation at 1,500 rpm for 5 min. The supernatant was removed, and replaced with 
100 p i o f 3X SDS loading buffer. Cells were mixed and briefly sonicated for 10 sec before 
heat denaturing the proteins at 100 °C for 5 min. The samples were run on an SDS-PAGE 
gel and visualised by immunoblotting. Anti-Flag antibody was used to detect p300 levels. 
The virus concentration that gave the best expression was scaled up for infection of a T150
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tissue culture flask.
Large-scale expression of Flag-p300 FL required 9 flasks o f FII5 cells (T150 tissue 
culture flasks). Optimum cell density was determined to be approximately 70 % 
confluence. The growth media in the flasks was aspirated and the appropriate volume o f 
virus was added with 2 ml o f sem m  free media. The flasks were covered to keep out light 
and left rocking at room temperature for 1 h. After the infection period, the flasks were 
topped up with 23 ml o f TClOO (supplemented with 5 % FCS, 0.1 % gentamycin). Cells 
were incubated at 26 °C for 48 h. Cells were removed by agitation. The cells and media 
were decanted into 50 ml falcon tubes and washed 3 times in ice-cold PBS (supplemented 
with 0.5 mM PMSF, and protease inhibitor cocktail (Calibiochem) at 1 in 1000 dilution). 
The cell pellets were combined so that they were shared between 2 falcon tubes. Cells 
were lysed by the addition of 5 ml lysis buffer (25 mM HEPES pH 7.8, 0.1 mM EDTA, 0.4 
M KCL, 0.1 % NP-40, 5 mM p-mercaptoethanol, and protease inhibitor cocktail 
((Calibiochem) at 1 in 1000 dilution). Pellets were lysed using 15 strokes o f a dounce 
homogenize!' (kept cold in ice throughout). Soluble lysate was recovered by centrifugation 
at 13000 rpm for 15 min at 4 °C.
Precipitation o f Flag-p300 FL was accomplished by incubating the lysate with 1 ml 
o f resuspended ‘EZ view ™  Red ANTI-FLAG ® M2 Affinity G el’ (Sigma). These ‘Flag’ 
beads were washed 3 times with 10 ml lysis buffer prior to incubation with the lysate in 
order to remove the preservative. The incubation mixture was rotated for 1 h at 4 °C. After 
binding, the Flag beads were washed 2 times with 10 ml o f ice-cold wash buffer (50 mM 
Tris pH 8.6, 200 mM KCL, 2 mM p-mercaptoethanol) each wash rotating for 30 min at 4 
°C. The Flag beads were transferred to 5 ml polypropylene columns (Qiagen). Flag-p300 
FL was eluted into 300 pi fractions with elution buffer (50 mM diethanolamine, 1 M KCL, 
1 mM EDTA, 50 % ethyleneglycol). Fractions were eluted into chilled eppendorf tubes 
containing 20 pi o f 2 M NaH2P0 4  to adjust the pH to 7. All samples were dialysed into
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BClOO exchange buffer (supplemented with 0.5 mM PMSF and protease inhibitor cocktail 
((Calibiochem) at 1 in 1000 dilution) using the same dialysis slides mentioned in the GST 
fusion protein purification protocol. Small aliquots (10 pi) o f the fractions were run on an 
SDS-PAGE gel and visualised by immunoblotting. Anti-Flag antibody was used to detect 
p300 levels.
Protein concentration
If  the protein preparations required concentrating, dialysed protein was placed into 
‘Viva spin columns’ (Pierce). The columns contain an imier vessel with a porous 
membrane on one side, and an outer vessel that completely encloses the imier vessel. 
Protein samples were concentrated through centrifugation o f the columns at 13,000 rpm on 
a bench top Sorval micro centrifuge. Spin columns with a MWCO of 10,000 Daltons were 
used to concentrate the various GST-pRb proteins for use in acétylation assays.
IN  VITRO PROTEIN ACETYLATION ASSAY
Recombinant proteins (for use as substrate) were compared against known 
concentrations of BSA protein by visualisation on a Coomassie stained SDS-PAGE gel. 
Core histones purified from chicken eiythrocytes were purchased from Upstate for use as 
positive control in p300 acétylation assays.
Reactions were prepared with 2-4 pg o f substrate protein, 6 pi o f 5x HAT buffer 
(260 mM Tris pH 8, 25 % glycerol, 0.5 mM EDTA), 3 pi o f DTT (10 mM), 1 pi [^H] 
Acetyl-Coenzyme A (50 pCi/ml) purchased from Amersham, 0.2 pg o f HAT, and de­
ionised water to bring the reaction volume to 30 pi. Reactions were mixed briefly by 
vortex, and centrifuged briefly at 13,000 rpm. Reactions were incubated in a 30 °C water 
bath for 30-45 min, and then briefly centrifuged (at 13,000 rpm). Samples were mixed by 
pipetting, and carefully spotted onto 2 cm diameter phosphocellulose filter paper circles
(P81 grade chromatography paper purchased from Wliatman). The filters (spotted
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reactions) were then left to air dry for 15 min at room temperature. The filters were washed 
in 0.2 M sodium carbonate buffer (pH 9.2) 3 times (each wash lasting 5 min) at room 
temperature. The washed filters were briefly dipped into acetone and left to air dry for 1 h 
at room temperature. The dried filters were placed into scintillation vials containing 4 ml 
o f scintillation fluid. Scintillation vials were mixed by inversion. Incorporation o f  [^H] 
Acetyl-Coenzyme A was measured using a liquid scintillation counter.
IN  VITRO PULL DOWN ASSAYS
In each experiment GST-tagged proteins (for use as bait) had their concentrations 
compared by visualisation on a Coomassie stained SDS-PAGE gel. Relative concentrations 
were determined by densitometric analysis o f protein bands (using Image J software).
Cell extract (1 mg per pull down) was initially pre-cleared by incubation with 30 
pi of GST sepharose beads (Amersham) rotating at 4 °C for 1 h. Pre-cleared extract was 
incubated at 4 °C for 1 h with 2 pg o f GST tagged recombinant protein. Reaction volume 
was brought to 1 ml by addition o f IVT buffer (50 mM Tris pH 7.5, 150 mM NaCl, 5 pM 
EDTA, 0.5 % v/v NP-40, supplemented with 0.8 mM DTT, 200 pM PMSF, 400 pM 
Sodium Orthovanadate, and protease inhibitor cocktail (Calibiochem) at 1 in 1000 
dilution). Each reaction was then supplemented with 30 pi of GST beads and incubated for 
a further 3 h at 4 °C. Reactions were then washed 4 times (5 min per wash) with 700 pi o f 
IVT buffer (0.5 % NP-40) to remove non-specifically bound proteins. All centrifugation 
steps were carried out at 2000 ipm  for 2 min at 4 °C. Proteins bound to the beads were 
eluted with 40 pi o f 3X SDS loading buffer and analysed by SDS-PAGE, followed by 
immunoblotting.
Listed are specific conditions and variations o f the protocol for the different GST 
binding assays included in the thesis://? vitro translated (IVT) ^^S labelled pCMV E2F-1 
was used for a source o f target protein for the GST pRb (763-928) bait. Interaction was
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therefore assessed using autoradiography to identify E2F-1, and coomassie staining to 
identify GST pRb (763-928). On establishing that E2F-1 bound GST pRb (763-928), the 
E2F-1 source for subsequent pull downs was derived from HEK 293 nuclear extract. 
Interaction was assessed as described in the main protocol (above). Levels o f E2F-1 were 
detected by immunoblotting with anti-KH95 antibody (Santa Cruz). Levels o f recombinant 
C-terminal domain o f pRb were assessed by immunoblotting using anti C15 antibody 
(Santa Cruz), which binds to the C-temiinal domain o f pRb. Levels of recombinant GST- 
Gst Protein (used as a negative control) were detected using anti-GST B14 (Santa Cruz).
IVT Mdm2 was used as a source of target protein for accessing whether the pRb 
763-928 k '^^ 3Q/k874Q derivative was able to bind other target proteins. IVT buffer
used in the binding assay was supplemented with only 0.1 % NP-40. Mdm2 was detected 
by immunoblotting using anti-SMP14 antibody (Santa Cruz). Levels o f recombinant C- 
terminal domain pRb were assessed by immunoblotting using anti-C 15 antibody (Santa 
Cruz). Levels o f recombinant GST-Gst Protein (used as a negative control) were detected 
using anti-GST B14 (Santa Cruz). HA-pSG5L-Rb 1-928 or 2HA-NRb 1-376 were 
transfected into HEK 293 cells.
Cells were lysed in IPH buffer (0.5 % NP-40). Following the GST pull down, 
levels o f NRb and FL pRb were detected using mouse monoclonal HAII antibody 
(Covance). Levels o f recombinant C-terminal domain pRb were assessed by 
immunoblotting using anti-C 15 antibody (Santa Cruz). Levels o f recombinant GST-Gst 
Protein (used as a negative control) were detected using anti-GST B14 (Santa Cruz).
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CHAPTER 3
INTRODUCTION: THE N-TERM INAL DOMAIN OF pRb IS ACETYLATED
T h e  N - t e r m i n a l  d o m a i n  o f  p R b  i s  a c e t y l a t e d  i n  v i t r o .
Mutation or deregulation o f pRb has been obsei*ved in nearly every type o f human 
cancer examined [2], Deregulation o f pRb is so frequent in cancer that some have argued it 
is a prerequisite for all human cancer [25]. Although pRb can physically interact with well 
over 100 different cellular proteins [34], the most studied interaction is that o f the pRb 
large pocket with the E2F-1 protein. Point mutations occurring in the N-teiminal domain 
o f pRb have been identified from cancer patients (reviewed in [111]). It is likely that 
point mutations would occur in locations close to important regulatory regions within 
protein domains.
Proteins have been found to specifically interact with the N-terminal domain o f 
pRb. Proteins that interact with the N-terminal domain o f pRb may have their binding 
regulated through the post-translational modification o f  the N-terminal domain. If K 
acétylation o f the N-teim inal domain o f pRb affects its protein/protein interactions, one 
might expect potential acetylated K residues to be mutated in human tumours. In that 
regard, the only documented K residue undergoing point mutation in human tumours is 
K136. In the C-terminal domain, acétylation o f pRb at K873/874 reduces phosphorylation 
of pRb, possibly through preventing cyclin E/A from docking [214]. Also, pRb can be 
phosphorylated by RbK, a mitotic pRb kinase [100], and Cdk enzymes [146]. There may 
be additional phosphoiylation sites along the N-pRb that have not yet been defined.
I set out to address whether N-pRb is acetylated. For this study, I configured a 
robust in vitro acétylation assay that allowed an investigation into the acétylation of N-
pRb. The assay demonstrated that GST-pRb 1-376 is acetylated by Flag-p300 FL but not
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by the HAT domain constructs His-p300 1195-2414 and Flag-p300 1135-2414. These 
results indicate that the N-terminal domain of pRb is acetylated.
T h e  N - t e r m i n a l  d o m a i n  o f  pRb is  a c e t y l a t e d  in  H E K  293 c e l l s
The acétylation o f the C-terminal domain in pRb has been shown to be damage 
responsive [97], and induced during differentiation o f C2C12 cells [53]. This suggests that 
the N-terminal domain has a function in tumour suppression. Other transcription factors 
are acetylated. Presently, two other reports have described the DNA damage induced 
acétylation of the cell cycle transcription factors E2F-1 and p53 [75, 228]. These studies 
both report that treating cells with doxorubicin (for E2F-1) and IR (for p53) results in the 
induction o f acétylation. Studies on E2F-1 demonstrate that residues 117, 121, and 125 are 
acetylated in vivo in response to doxorubicin treatment [53]. This induction o f acétylation 
occurs between 8 h and 16 h post treatment (induction o f pRb acétylation by etoposide 
occurs between 4 h and 24 h post treatment [97]).
A similar study on DNA damage inducible Chkl/2  phosphoiylation o f p53 has 
more closely studied the link between Chk phosphorylation and DNA damage inducible 
acétylation [228]. Importantly, Chkl and Chk2 have roles in regulating p53 acétylation. 
Using siRNA to knockdown C hkl/2, it was observed that levels o f C-terminal domain p53 
phosphoiylation and acétylation o f K382 were reduced [228], leading to a reduced 
activation o f p21 and Bax  in response to DNA damage. Reduced expression o f Chk kinases 
leads to decreased DNA damage responsive acétylation o f p53, and a corresponding drop 
in apoptosis. Therefore, perhaps DNA damage could induce N-terminal domain pRb 
acétylation in cells. To test this idea I sought to study the in vivo acétylation and the intra­
cellular location of the N-terminal domain o f pRb.
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CHAPTER 3
RESULTS
T h e  N - t e r m i n a l  d o m a i n  o f  p R b  i s  a c e t y l a t e d  i n  v i t r o ,
His-p300 1195-1673 does not efficiently acetylate GST-pRb fusion proteins
Three recombinant p300 proteins were purified for in vitro acétylation assays 
(Figure 11). The catalytic domain o f p300 stretches across residues 1195-1673 (Figure 
12a), and was purified in BL21 cells (Figure 12b). This region contains the bromo-domain, 
two zinc binding domains and the cysteine-histidine domains C/H2 and CH3 (Figure 12a). 
His-p300 1195-1673 efficiently acetylates core histones, but does not maintain significant 
auto-acetylation. Increasing the concentration o f His-p300 1195-1673 caused a linear 
increase in the acétylation of core histones (Figure 12c and d). His-p300 1195-1673 was 
repeatedly unable to efficiently acetylate either GST-pRb 379-928 or GST-pRb 1-376 in 
vitro (Figure 12c and d).
Flag-p300 1135-2414 does not efficiently acetylate GST-N-pRb 1-376
The p300 acetyl-transferase domain was not sufficient to acetylate GST-N-pRb, but 
was able to acetylate core histones. As well as the acetyl-transferase domain, Flag-p300 
1135-2414 contains the p300 /‘ra/?5'-activation region (1673-2414). Domains in this region 
are depicted (Figure 13a). Flag-p300 1135-2414 was purified from High five insect cells 
infected with baculovirus-Flag-p300 1135-2414 (Figure 13b). The resulting purified 
protein was visualised by coomassie staining. Flag-p300 1135-2414 resolved at 
approximately 140 KDa (Figure 13b).
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Flag-p300 1135-2414 was used to acetylate either core histones or GST-N-pRb fusion 
proteins (Figure 13c). Flag-p300 1135-2414 was observed to have significant auto- 
acetylation (3.3 fold greater than Flis-p300 1195-1673, Figure 13d). Flag-p300 1135-2414 
acetylated core histones as efficiently as the His-p300 1195-1673. However, despite an 
increase in auto-acetylation, Flag-p300 1135-2414 was not able to efficiently acetylate 
GST-N-pRb fiision proteins (Figure 13d).
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Figure 11: p300 HAT constructs
a) Three p300 constructs were used in HAT assays: The Flag-p300 FL construct 
contains the following domains; Nuclear receptor binding domain (NR), 3 
cysteine-histidine domains (C /H l) (C/H2) (C/H3), CREB binding domain 
(KIX), Bromo-domain, IBiD, and N-terminal phosphopeptide-binding domain 
with homology to IBiD (IHD).
b) Flag p300 FL is able to acetylate GST-pRb (1-376), GST-pRb (10-330), GST- 
pRb (379-928), GST-pRb (763-928) and core histones (Upstate). Flag-p300 
(1135-2415) contains the HAT domain and the C-terminal domain trans- 
activation region o f  p300, and can acetylate the core histones efficiently, but 
not the GST-N-pRb proteins. His-p300 (1195-1673) contains the HAT o f p300, 
and can efficiently acetylate core histones but is unable to acetylate GST-N- 
pRb (1-376), GST-N-pRb (10-330), GST-pRb (379-928), or GST-C-pRb (763- 
928).
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Figure 12: His-p300 1195-1673 is sufficient to acetylate core histones but not
GST-pRb fusion proteins
a) Schematic showing the region o f purified His-p300. This region covers the 
catalytic domain of p300. Residues 1195-1673 contain the cysteine-histidine 
domain (C /H l), and a zinc finger domain shown in red. This derivative stops just 
short o f the C/H2 domain.
b) The His-p300 1195-2414 construet was expressed in BL21 cells as described in 
Materials and Methods. Fractions from the various stages o f purification were m n 
on a 10 % SDS PAGE gel and visualised by coomassie staining. His-p300 1195- 
1673 resolves at a molecular weight o f approximately 66 KDa (Lane 6).
Lanes Fraction
1 Un-induced BL21 cells Pre bacterial lysis2 Induced BL21 cells
3 Soluble fraction Post-bacterial lysis.4 Insoluble fraction
5 First wash fraction
6 Elute
c) The input levels o f the proteins used are shown visualised by coomassie staining. 
Lanes 3 to 6 show 3pg core histones (-10-22 KDa). Lanes 7 and 8 show 3pg of 
GST-pRb 379-928, and lanes 9 to 10 show 3 pg of GST-N-pRb 1-376.
d) In vitro acétylation reactions were incubated for 30 min and measured using a 
scintillation counter for incorporation o f acetyl co-enzyme A. Values on the bar
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graph represent an average o f three independent experiments. Each experiment was 
carried out using the same batch o f His-p300 1195-1673. Lanes 4 to 6 show a 
titration o f His-p300 (Lane 4, 0.4 pg, Lane 5, 1 pg, Lane 6, 2 pg).
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Figure 13: FIag-p300 1135-2414 is sufficient to acetylate core histones but not
GST-N-pRb fusion proteins
a) Schematic showing the region of purified Flag-p300. This region covers the 
catalytic domain o f p300 and also the neighbouring ^raw.s'-activation domain 
(see also Figure 2). The Flag-p300 1135-2414 constmct encodes all o f the 
following domains: the acetyl-transferase domain (2 cysteine-histidine domains 
(C/H2, C/H3), 3 zinc-finger domains), and a rrrzM^y-activation domain (the C- 
terminal glutamine rich region containing the IBiD domain).
b) Shows purified fractions o f FIag-p300 1135-2414 (2 pg) separated by 
electrophoresis and visualised by staining with coomassie blue. Flag-p300 
1135-2414 resolves at approximately 150 KDa. Lane 1 shows protein eluted in 
the wash buffer (W) prior to elution.
c) Core histones (10-17 KDa) acetylated by Flag-p300 1135-2414 were resolved 
on a 15 % SDS-PAGE gel (reactions 2 and 3). N-tenuinal domain pRb GST 
fusion proteins used in reactions 4 to 7 were resolved on a 10 % SDS-PAGE gel 
(protein position marked with asterix). Gels were visualised using coomassie 
staining.
d) In vitro acétylation o f substiates was assessed by measuring the incorporation 
of acetyl co-enzyme A. Values on the bar graph represent an average o f 
three independent experiments. Each experiment was earried out using the same 
fraction o f Flag-p300 1135-2414 (fraction 2 shown in Figure 13b).
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Flag“p300 FL can efficiently acetylate GST N-pRb fusion proteins in vitro
The region spanning the first 1135 residues o f p300 contains domains that are also 
important for the /raw.s'-activation capacity o f p300 (Figure 11). This region contains the 
nuclear hormone receptor-binding domain, a cysteine-histidine domain (C /H l) containing 
a zinc-binding domain, the IFiD domain (an N-terminal phosphopeptide-binding domain 
with homology to IBiD), the CREB binding domain (KIX), and the CRD domain (Figure 
14a). Purified Flag-p300 FL (Figure 14b) was used to acetylate GST-pRb fusion proteins 
(visualised in Figure 14c). Flag-p300 FL exhibited approximately 2-fold greater auto- 
acetylation than the equivalent concentration o f Flag-p300 1135-2414. Flag-p300 FL was 
repeatedly able to acetylate GST-pRb fusion proteins. The large pocket o f pRb (GST pRb 
379-928) and the C-terminal domain (GST-C-pRb 763-928) showed approximately twice 
the acétylation o f GST-N-pRb fusion proteins (Figure 14d).
The effects of varying substrate and HAT concentration on in vitro acétylation
The catalytic activity o f p300 is regulated by its auto-acetylation [237]. Hypo- 
acetylated p300 is less catalytically active than hyper-acetylated forms. The basal catalytic 
rate o f p300-mediated acétylation is stimulated by the acétylation o f key K residues in the 
activation loop o f p300 spanning residues 1520 through 1560 [237]. Optimizing in vitro 
acétylation assays involves a carefull balancing act. Adding greater amounts o f HAT to the 
acétylation reaction will cause a proportional increase in levels o f substrate or auto- 
acetylation. In vitro acétylation reactions are inhibited by too much salt in the reaction mix. 
The auto-acetylation o f various titrations o f Flag-p300 FL was measured to assess the 
optimal amount of Flag-p300 required.
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Figure 14:Flag-p300 FL acetylates the N-terminal domain of pRb
a) Schematic showing Flag-p300 FL (see also Figure 9).
b) Purified Flag-p300 FL (0.3 pg and 0.5 pg) was run on a 6 % SDS-PAGE gel, 
and immunoblotted with anti Flag antibody. Flag-p300 FL resolves at 265 KDa.
c) Reactions contained 4 pg of substrate protein (Lane 1 Core histones, lane 2 
GST-pRb 37 9-928, Lane 3 GST-pRb 763-928, Lane 4 GST-pRb 10-330, Lane 5 
GST-pRb 1-376, and Lane 6 GST protein) for acétylation by 1 pg o f Flag-p300 
FL (50 ng/pl). Substrates for the six reactions are shown resolved on a 12.5 % 
SDS-PAGE gel stained with coomassie.
d) The bar graph shows the acétylation o f proteins visualised in a). GST protein 
was not acetylated. Each bar in the graph plots the average o f three independent 
experiments. Background levels o f acétylation for the substrates, and the level o f 
acétylation of GST protein are all less than 70 dpm.
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Figure 15 Auto-acetylation of Flag-p300 FL
In this experiment, the amount o f Flag-p300 FL added to the standard 30 pi 
reaction was titrated (0.25 pg, 0.5 pg, 0.75 pg and 1 pg). The resulting changes 
in the auto-acetylation o f p300 were measured using a scintillation counter. 
Values plotted on the graph represent an average o f three independent 
experiments.
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The amount o f auto-acetylation appeared to be proportional to the concentration o f Flag- 
p300 FL when the total volume o f p300 in the reaction is less than 10 pi (representing a 
final concentration o f 20 ng/pl Flag-p300 FL in the reaction).
Adding more than 20 ng/pl Flag-p300 FL into the reaction causes further increases 
in the level of auto-acetylation, but the rate o f increase declined (perhaps due to higher salt 
concentration in the reaetion mix). A similar effect was obseiwed when varying the 
concentration o f Flag-p300 FL in the presence o f a constant amount o f core histones 
(Figure 16), and when vaiying the concentration o f Flag-p300 FL in the presence o f 
constant GST-pRb 1-376 (Figure 18). Varying the amount o f substrate protein acetylated 
by Flag-p300 FL gave a linear increase in the acétylation of histones (Figure 17) and GST- 
pRb 1-376 (Figure 19).
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Figure 16: The affect of titrating Flag-p300 FL on the acétylation of 2 pg core
histones
Core histones (2 pg) were added to each acétylation assay. Vaiying amounts o f
Flag-p300 FL were added to the reactions.
a) The figure shows the amount o f core histones in the acétylation assay 
visualised by coomassie staining.
b) The change in acétylation o f 2 pg of core histones by titration o f p300 (50 
ng, 100 ng, 250 ng, 500 ng, and 750 ng of Flag-p300 FL) is plotted. Values 
on the graph represent an average o f three independent experiments.
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Figure 17: Titration of the amount of core histones affects the level of in vitro
acétylation by Flag-p300 FL
Flag-p300 FL (0.5 pg) was added to each 30 pi acétylation assay. Varying 
amounts o f core histones were added to the reactions.
a) The figure shows the amount o f core histones in the acétylation assay 
visualised by coomassie staining.
b) The change in acétylation o f core histones (1 pg, 3 pg, 5 pg, and 10 pg o f 
core histones) facilitated by 0.5 pg o f Flag~p300 FL is plotted. Values 
represented on the graph an average of three independent experiments.
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Figure 18: The effect on the acétylation of GST-N-pRb by the titration of Flag-
p300 FL
GST-N-pRb 1-376 (4 pg) was added to each 30 pi acétylation assay. Varying
amounts o f Flag-p300 FL were added to the reactions.
a) The figure shows the amount of GST-N-pRb fusion protein in the 
acétylation assays visualised by coomassie staining. The asterix highlights 
the position o f GST N-pRb (67.4 KDa).
b) The change in acétylation of 4 pg of GST-N-pRb by titration of p300 (0.25 
pg, 0.5 pg and 1 pg o f Flag-p300 FL) is plotted. Values on the graph 
represent an average o f three independent experiments.
99
Figure 19
a)
b)
ug GST N-pRb
160^
105^
GST N-pRb (ug)
*  GST N-pRb 
1-376
2500
2000
^ 1500
-D 1 0 0 0  ..
500
0 1 2 3 4 5
100
Chapter 3
Figure 19: In vitro acétylation of GST-N-pRb by Flag-p300 FL is affected by the
titration of GST-N-pRb.
Flag-p300 FL (0.5 pg) was added to each 30 pi acétylation assay. Varying
amounts of GST-N-pRb were added to the reactions.
a) The figure shows the amount of GST-N-pRb in the acétylation assay 
visualised by coomassie staining. The asterix highlights the position o f 
GST-N-pRb (67.4 KDa).
b) The change in acétylation o f GST-N-pRb (1 pg, 2 pg and 4 pg o f GST-N- 
pRb) facilitated by 0.5 pg of Flag-p300 FL was plotted. Values on the graph 
represent an average o f tliree independent experiments.
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T h e  N - t e r m i n a l  d o m a in  o f  pRb i s  a c e t y l a t e d  in  HEK 293 c e l l s
HA-pRb 1-376 is acetylated in vivo
Many cancer cell lines do not express active pRb, but instead express truncated 
proteins resulting from frameshift mutations in Rb that lead to premature stop codons. I 
used the Dignam method of lysing cells in order to study the nuclear/cytoplasmic 
distributions o f Ha-pRb 1-376 in HEK 293 cells {Rb cells where pRb is functionally 
inactivated) and C33A cells (in which the Rb  is genetically inactivated), to study how N- 
terminal truncated pRb proteins might localise in tumours that have or do not have active 
endogenous pRb.
In order to explore whether the in vitro acétylation of pRb 1-376 reflect events that 
occur in cells, I used a pan-acetyl lysine antibody to assess acétylation o f the N-terminal 
domain of pRb in cells. The approach involved treating cells with agents that induce 
double-stranded DNA damage, in order to test whether DNA damage induces the 
acétylation of the N-teiminal domain in a similar way that has been shown for the C- 
teiminal domain [97]. The anti-acetyl lysine antibody has been previously characterised as 
specifically recognising acetyl-GST pRb 379-928 and HA-Rb FL [214]. Since this 
antibody can recognise a great number o f nuclear and cytoplasmic polypeptides (that 
contain acetylated K consensus sites found in histones), it was necessary to 
immunoprecipitate HA-pRb 1-376 to reduce the level o f other acetylated proteins.
Prior to haiwesting, cells were treated with TSA to prevent HD AC enzymes from 
reversing acétylation, thus aiding detection. HEK 293 cells were utilised because they have 
previously been shown to contain endogenous acetylated pRb. Immunoblots confirmed the 
presence of acetylated HA-pRb 1-376 (Figure 20, Lanes 3 to 10) that was specific (as no 
bands were detected in immunoprecipitates from non-transfected extracts,
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Figure 20: The N-terminal domain of pRb is acetylated in HEK 293 cells
HEK 293 cells were transfected with 2 pg pcDNA3 2HA-pRb 1-376 and 
iinmunoprecipitated with the anti-HAII antibody. Cells from all the samples 
(lanes 1 to 10) were haiwested 48 h post transfection.
a) Un-treated cell extracts were immunoblotted with anti-acetylated-lysine 
polyclonal antibody (Ac Lys) (top panel), anti-HA Y l l  polyclonal antibody 
(middle panel). Input (10 %) was immunoblotted with anti-HAII monoclonal 
antibody (bottom panel). pcDNA3 2HA-pRb 1-376 migrates to 47 KDa on an 
SDS-PAGE gel. Lane 1 is the mock control, and Lane 2 is transfected with 2 
pg o f empty pcDNA3 vector (as a transfection control). In Lane 3, extract was 
iinmunoprecipitated with goat anti-rabbit secondary antibody (used as the non- 
specifle antibody control). Lane 4 shows Ha-pRb 1-376 innnunoprecipitated by 
anti-HAII.
b) Cell extracts treated with etoposide, doxombicin and actinomycin D were
immunoblotted with anti-acetylated-lysine polyclonal antibody (Ac Lys) (top
panel), anti-HA Y l l  polyclonal antibody (middle panel). Input (10 %) was
immunoblotted with anti-HAII monoclonal antibody (bottom panel). In Lanes
5 to 10, cells were transfected with 2 pg pcDNA3 2HA-pRb 1-376. Prior to
harvesting, Lanes 5 and 6 were treated with 50 pM etoposide for 2 h and 16 h
respectively. Lanes 7 and 8 were treated with 2 pM  doxorubicin for 2 h and 16
h respectively. Lanes 9 and 10 were treated with 20 nM  actinomycin D for 2 h
105
and 16 h respectively.
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Figure 21 C
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Figure 21: The localization of pcDNA3 HA-N-Rb 1-376 in response to DNA damage
U 20S cells were transfected with either Ipg  or 3pg (B) o f pcDNA3 HA-N- 
pRb 1-376. Prior to immunostaining, cells were treated with DNA damaging 
agents. Part a) shows samples A to D, and part b) Shows samples E to H. All 
images were taken at 63 OX magnification and later computer manipulated to 
enlarge images for presentation. The white line at the bottom right corner of 
images stained with anti-HAII represents 10pm.
a) Cells in samples A and B were not treated prior to immunostaining. Cells in 
sample C were treated with 10 pM etoposide and incubated for 16 h prior to 
immunostaining. Cells in sample D were treated with 100 pM etoposide and 
incubated for 8 h prior to immunostaining.
b) Cells in sample E were treated with 20 iiM actinomycin D and incubated for 16 
h prior to immunostaining. Cells in sample F were exposed to 50 Jnf^ o f UVB 
light and incubated for 16 h prior to immunostaining. Cells in sample G were 
treated with 100 pM DFO and incubated for 24 h prior to immunostaining. 
Cells in sample H were incubated at 43 °C for 2 h to heat shock the cells, 
followed by 16 h incubation at 37 °C prior to immunostaining.
c) The table shows the number o f transfected cells scored per treatment and the 
percentage o f transfected cells (in each treatment A to H) that contain either 
only nuclear, only cytoplasmic or both nuclear and cytoplasmic staining. Five
110
fields of view (at X630 magnification) were scored for each treatment.
I l l
nor from extract derived from cells that were transfected with empty vector (Figure 20, 
Lanes 1 and 2). Protein G beads that were incubated with Goat anti-Rabbit secondary 
antibody failed to immunoprecipitate acetylated proteins or FIA-pRb 1-376) (Figure 20, 
Lane 3).
Cells that were treated with DNA damaging agents (dissolved in DMSO) prior to 
harvest showed an increased level o f acetylated HA-pRb 1-376 (Figure 20, Lanes 5 to 10). 
Cells were treated with DNA damaging agents that mimic the effects resulting from double 
stranded breaks in DNA. Cells were treated with etoposide (Figure 20, Lanes 5 and 6), 
with doxorubicin (Figure 20, Lanes 7 and 8), or with actinomycin D (Figure 20, Lanes 9 
and 10). Extract was m n on SDS-PAGE gels and blotted to visualise the levels o f HA-N- 
pRb 1-376 prior to carrying out the immunoprécipitation in order to ensure that each 
immunoprécipitation contained the same level of exogenous protein. Immunoprecipitated 
levels o f FIA-N-pRb 1-376 were observed to be approximately equal in all lanes by re- 
blotting the membranes with anti-HA antibody. Previous studies on DNA damage 
inducible acétylation o f K residues 873/874 in the C-teiminal domain o f pRb demonstrated 
that induction o f acétylation occurred between 6 h and 24 h post treatment with etoposide, 
but peaked by 16 h post treatment [97]. With that in mind, cells were harvested 2 h and 16 
h post treatment with the above-mentioned agents (to show a clear affect of the treatment). 
Any effect on the cells caused by the addition of DMSO (in the damaging agents) was 
mitigated by nomializing for volume o f DMSO in all the samples both 16 h and 2 h prior 
to harvesting the cells. All three DNA damaging agents induced acétylation of HA-N-pRb 
1-376 after 16 h incubation, but not after 2 h.
HA-N-pRb 1-376 localises to the nucleus in U 20S  cells
U 20S cells transfected HA-N-pRb 1-376 showed substantial nuclear localisation 
(Figure 21 a), samples A and B). Approximately 40 % of cells showed weak cytoplasmic
112
Figure 22
a HAII
HEK 293 C33A
M C  N C N C N C N
1051751t w
5 0 ^
. .
m
• HT»
1 2 3 4 5 6 7 8
*  HA-pRb 1-928
*  HA-N-pRb 1-376
113
Chapter 3
Figure 22: The localization of exogenous N-terminal domain pRb
HEK 293 (human embryonic kidney cells) and C33A cells (a cell line 
propagated by extracting tumour cells from a human cei'vical carcinoma) were 
transfected with either 2 pg o f HA-pRb 1-928 or 2 pg o f 2HA-pRb 1-376. 
Cells were incubated for 48h. Once harvested, the cells were lysed using the 
Dignam method to isolate nuclear and cytoplasmic protein fractions. The gel 
shows 100 pg o f both cytoplasmic and nuclear extract. Samples o f both FL- 
pRb and N-terminal domain pRb were run on SDS-PAGE gel, and 
immunoblotted with anti-HAII antibody.
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staining (Figure 21c). I decided to characterise the stained cells as entirely nuclear, entirely 
cytoplasmic or nuclear/cytoplasmic (Figure 21c). The percentage o f the total cells counted 
in samples that were nuclear, cytoplasmic or nuclear/cytoplasmic was calculated. The 
localization o f HA-N-pRb 1-376 was assessed in response to treatment with etoposide 
(Figure 21a, sample C and D), actinomycin D (Figure 21b, sample E), ultra violet light 
(UVB) (Figure 21b, sample F), desferrioxamine (DFO) (mimics hypoxia) (Figure 21 b, 
sample G), or heat shock (Figure 21 b, sample H). Etoposide activates mainly the 
ATM/Chlc2 arm o f the DNA damage response pathway by inhibiting DNA topoisomerase 
II, thereby inliibiting DNA synthesis, causing double stranded breaks in DNA. 
Actinomycin D creates DNA damage through inhibiting RNA polymerase III. Cells given 
these treatments displayed similar cellular morphologies. In these samples, most stained 
cells showed nuclear/cytoplasmic staining («70 % o f cells counted). The degree o f 
cytoplasmic staining was quite low, with approximately 80 % o f  total staining being 
retained in the nucleus. In short, double-stranded DNA damage promoted the cytoplasmic 
staining o f 20 % o f the HA-N-pRb 1-376 in 70 % o f cells counted.
U 20S  cells were treated with UVB light (Figure 21b, sample F), DFO (Figure 21b, 
sample G) and heat shock (Figure 21b, sample H). All three o f these treatments resulted in 
greater cytoplasmic staining levels o f HA-N-pRb 1-376 than treating cells with etoposide 
or actinomycin D. The UVB treatment resulted in the greatest level of cytoplasmic HA-N- 
pRb 1-376 (>50 % of staining appeared to be cytoplasmic in Figure 21b, sample F). DFO 
treated cells showed limited nuclear staining (Figure 21b, sample G). Although not as 
effective as UVB light or heat shock, DFO caused approximately 30-40 % o f the cells to 
exhibit cytoplasmic staining. Cells treated with heat shock (Figure 21b, sample H) all 
showed total nuclear/cytoplasmic localisation o f HA-N-pRb 1-376 in U 20S  cells. Again 
like UVB treatment greater than 50 % o f total staining was observed to be cytoplasmic.
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Cell type may influence the distribution of HA-N-pRb 1-376
HA-pRb 1-928 and HA-N-pRb 1-376 were transfected into both HEK 293 cells (Rb 
cells) and C33A cells (which express a truncated pRb that locates to the cytoplasm) 
(Figure 22). Cells were separated into cytoplasmic and nuclear fractions. Protein 
concentration of the extracts was measured by Bradford assay. Extract from both fractions 
was run on an SDS-PAGE gel, and proteins were immunoblotted with anti-HAII antibody. 
It was observed that in HEK 293 cells and C33A cells that HA-pRb 1-928 was extracted 
mainly in the nuclear fraction. In contrast, HA-N-pRb 1-376 was predominantly localized 
in nuclear fractions o f HEK 293 cells, but mostly in cytoplasmic fractions o f C33A cells 
(Figure 22).
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CHAPTER 3
DISCUSSION
T h e  N - t e r m i n a l  d o m a i n  o f  p R b  i s  a c e t y l a t e d  i n  v i t r o .
The acétylation o f the N-terminal domain o f pRb described here suggests an 
additional level o f  regulation o f pRb activity. Using limiting amounts o f p300 in the in 
vitro assay, it was found that both His-p300 1195-1673 and Flag-p300 1135-2414 do not 
efficiently acetylate GST-pRb fusion proteins. Flag-p300 FL was able to acetylate GST- 
pRb 379-928 and GST-pRb 1-376 approximately 8-fold less than it acetylates core 
hi stone s. Previous work has shown that Flag-p300 1135-2414 can acetylate pRb in vitro, 
but these reactions were carried out using high concentrations of Flag-p300 1135-2414 
[214]. There are many possibilities as to why FL p300 is more effective at acetylating pRb.
It is possible that the N-terminal and C-terminal trans-activation domains o f p300 
might help facilitate p300 auto-acetylation. His-p300 1195-1673 showed veiy little auto- 
acetylation comparative to Flag-p300 (1135-2414 and FL), despite being able to acetylate 
core histones effectively. Flag-p300 1135-2414 contains a ^raw^'-activation domain in its C- 
terminal domain (1673-2414), whilst Flag-p300 FL contains a further /ra«.?-activation 
region in its N-terminal domain (1-II95). The difficulty in using Flag-p300 FL purified 
from insect cells is the possibility o f contamination resulting from the immunoprécipitation 
o f other HAT enzymes. The extent o f such contamination could be assessed by comparing 
levels o f auto-acetylation from purified Flag-p300 FL with the levels of auto-acetylation 
observed using catalytically dead Flag-p300 FL.
Flag-p300 FL displays approximately 6-fold greater auto-acetylation than His-p300
1195-1673, and approximately 2-fold greater auto-acetylation than Flag-p300 1135-2414.
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However, this observation would be more significant if  the p300 enzymes were purified 
using ‘fast protein liquid chromatography’ (FPLC) to remove any possible contaminating 
HATs that could potentially be responsible for the observed auto-acetylation.
Recent studies suggest that hyper-acetylated p300 carries a higher basal catalytic 
activity than hypo-acetylated forms. Indeed, auto-acetylation o f a proteolytically sensitive 
loop region o f p300 (residues 1520 to 1560) greatly enhances p300 acetyl-transferase 
activity [237]. Perhaps the trans-ad\vaX\on domains in p300 aid interaction between p300 
proteins thereby increasing auto-acetylation. It may be possible that the other regions o f 
p300 have a stabilising effect on the overall tertiary structure of the p300 protein, and in 
that way augment its own auto-acetylation.
I f  this were the case why would the His-p300 1195-1673 acetylate core histones 
efficiently? Core histones are relatively small (less than 18KDa) compared with GST-pRb 
379-928 (97 KDa) and GST-pRb 1-376 (76KDa). At similar concentrations, the molar 
ratio o f core histones to GST-pRb 379-928 and GST-N-pRb 1-376 would be very high, and 
an individual core hi stone contains many more acetylated sites than pRb. Thus, there is a 
higher probability that the small histones (present in a greater molar ratio) might access the 
active site o f His-p300 1195-1673 easier than the bulky GST-pRb fusion proteins. 
Regardless, Flag-p300 FL is able to acetylate GST-pRb fusion proteins at quite low 
concentrations (20 ng/pl). GST-N-pRb 1-376 showed approximately half the acétylation o f 
GST-C-Rb 763-928 and GST-pRb 379-928.
Wliilst in vitro acétylation was demonstrated with p300, it is likely other proteins 
also influence in vivo acétylation. A recent report has shown that pRb is acetylated at 
residues 873/874 during differentiation. Further, both p300 and P/CAF were able to in 
vitro acetylate pRb at K residues 873/874, and in vivo acétylation during early 
differentiation required P/CAF [53]. It is therefore possible that other HAT enzymes like 
P/CAF could contribute to pRb acétylation, or help p300 target pRb for acétylation.
Cyclin D/Cdk4 and cyclin (A/E)/Cdk2 phosphorylate the N-teiminal domain o f
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pRb and several residues in the N-tenninal domain of pRb are phosphorylated during G l/S  
transition [146]. It will be necessary to use mass spectroscopy to identify the K residues 
acetylated in vitro by Flag~p300 FL. It will be interesting to study whether the acétylation 
o f the N-teiminal domain of pRb affects cyclin D/Cdk4 and cyclin (A/E)/Cdk2 mediated 
phosphorylation, in a similar fashion to the influence o f acétylation in the C-teiminal 
domain on phosphorylation by Cdks.
In summary, using an in vitro acétylation assay, I was able to show that the N- 
tenninal domain o f pRb can be acetylated by p300. In combination with the previously 
documented acétylation o f the C-terminal domain o f pRb, these results suggest that 
acétylation may regulate diverse aspects o f pRb tumour suppressor activity.
T h e  N - t e r m i n a l  d o m a i n  o f  p R b  is  a c e t y l a t e d  in  H E K  293 c e l l s
E2F-1 and p53 are both acetylated in response to DNA damage [75, 228], as is the 
C-terminal domain of pRb [97]. It is interesting that treating cells with etoposide, 
doxorubicin and actinomycin D induced acétylation o f the N-terminal domain o f pRb. 
DNA damage induced acétylation o f p53 is known to be dependent on Chlc2 [228] and 
preliminary work suggests that C-terminal domain pRb acétylation is also Chk2 dependent 
(Judith Soloway, personal communication). Both E2F-I and p53 are phosphorylated in 
response to DNA damage by Clik2 kinase [74, 228].
Interestingly, there are a number of potential Chk2 consensus phosphorylation sites
present in the N-terminal domain o f pRb (Figure 36, part e). Perhaps Chk2 is the upstream
kinase responsible for influencing the DNA damage induced acétylation o f pRb at both N-
terminal and C-terminal domains? If  that were the case, would phosphorylation have any
other consequences for pRb function (such as a change in localization)? Therefore the next
step would be to mutate potential Chk2 phosphorylation sites in the N-terminal domain to
see any affect acétylation. Mutating Chk2 phosphorylation sites ‘Ser residues to A sp’
(mimicking phosphorylated-Ser residues) or ‘Ser to A la’ (preventing phosphorylation)
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could be employed to ascertain if  Chk2 phosphoiylation is required for the induction o f 
acétylation.
A change in localization was observed for acetyl-pRb in U 20S cells in response to 
DNA damage [97]. It would be interesting to investigate whether DNA damage induced 
acétylation o f the N-tenninal domain o f pRb impacts on pRb localization in response to 
DNA damage. Perhaps the N-temiinal domain o f pRb is involved in regulation of the C- 
temiinal domain o f pRb. HA-pRb 1-376 localises predominantly to the cytoplasm in C33A 
cells, but conversely localises to the nucleus in HEK 293 cells (Figure 22).
It is possible therefore that the interaction between the N-terminal and the C- 
terrainal domains o f pRb requires the presence o f the pocket domain as a binding 
intermediary. However, there are limitations in drawing conclusions from this experiment. 
For example, there could be other genetic differences between HEK 293 and C33A cells 
that account for the different intra-cellular localization o f N-pRb. This could be resolved 
by repeating the experiment in and Rb'’' MEF cells. I will improve future experiments 
by immunoblotting for PCNA and GAPDH as positive controls. PCNA is an entirely 
nuclear protein [238]. Immunoblotting the cytoplasmic extract for PCNA will show the 
efficiency o f the nuclear extraction process used. GAPDH is an entirely cytoplasmic 
protein [239], which could be immunoblotted to determine the level of cytoplasmic 
contamination in the nuclear extract. Damaging U 20S cells using UV light, DFO or heat 
shock caused a change in the nuclear/cytoplasmic distribution o f HA-N-pRb 1-376 (Figure 
21b, samples F and G). Cells damaged with UV had less nuclear HA-N-pRb than cells 
damaged by treatment with etoposide or actinomycin D (compare Figure 21b, sample E 
with sample F). At the onset o f apoptosis, pRb is cleaved by caspases in the internal 
region, resulting in the production of two major protein fragments, p48 and p68 [136]. In 
cells treated with DNA damaging agents, caspase cleavage o f pRb proteins may result in 
the dissociation o f the N-terminal domain from the A domain o f the small pocket and in
the translocation o f  the p48 protein and the exogenous HA-pRb 1-376 to the cytoplasm.
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This may explain the observation that in C33A cells (containing genetically inactivated 
pRb), the HA-N-pRb 1-376 protein localizes mostly to the cytoplasm. HEK 293 cells and 
U 20S  cells (which express pRb) trap the HA-pRb 1-376 in the nucleus, and only during 
apoptosis does HA-N-pRb 1-376 escape (Figure 21b, samples F to H).
In summaiy, pRb is acetylated in vivo in response to DNA damage at both the N- 
terminal and C-tenninal domains. The N-tenninal domain derivative HA-N-pRb-1-376 
used here localized to the nucleus in U20S cells, but an altered nuclear/cytoplasmic 
staining occurred in response to UV treatment. In C33A cells, the majority o f HA-N-pRb- 
1-376 occurs in the cytoplasm, whereas in HEK 293 cells the majority o f HA-N-pRb 1-376 
is present in the nucleus.
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CHAPTER 4
INTRODUCTION: DNA DAMAGE RESPONSIVE ACETYLATION OF pRB 
REGULATES BINDING TO E2F-1.
G S T - C " P R b  763-928 i n t e r a c t s  w i t h  E2F-1 i n  v i t r o .
pRb has multiple roles in various cellular processes, including the repression o f 
E2F-1 dependent apoptosis [240]. Exogenous E2F-1 can cause quiescent cells to re-enter 
the cell cycle [91]. Despite this, other studies have shown that E2F-1 has the ability to 
induce apoptosis when expressed in the absence of proliferative signals [241-243]. The 
assertion that E2F-1 can induce apoptosis was bolstered by studies earned out on E2F-1 
knockout mice. E2F-F''' mice develop thymic hyperplasia, likely due to a lack o f 
thymocyte apoptosis during the development o f the mouse [244].
E2F-1 activation domain deletion mutants are still capable o f inducing
apoptosis [96]. Further, it was found that pRb mutants (which fail to repress trans- 
activation o f other E2F-1 genes) could still bind E2F-1. Other E2F proteins did not interact 
with the mutant pRb. Indeed, chimeric proteins made by substituting the marked 
box/marked box adjacent region of E2F-I (MB/MBA) with that o f E2F-4 failed to interact 
with mutant pRb [96]. This interaction was found to require an intact E2F-1 DNA binding 
domain and the MB/MBA region of E2F-1. This mutant pRb/E2F-l interaction was not 
pRb pocket dependent. The C-terminal domain of pRb residues (792-928) could still bind 
to E2F-I, and with equal affinity to wild-type pRb. These studies led to the possibility that 
post-translational modifications o f the C-temiinal domain o f pRb might regulate this C- 
pRb/E2F-l MB interaction.
Recent studies have shown that the C-pRb/E2F-l MB interaction is dependent on
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two sub-domains in the C-terminal domain of pRb and DP-1. The C-pRb core domain 
(residues 829-864) contributes to the majority of the binding energy, binding to E2F-1 with 
a Kd o f 5 pM. The C-pRb N-terminal domain (residues 786-800) also interacts with the 
E2F-1 MB segment increasing the affinity of C-pRb for E2F-1 MB by 36 fold 
(corresponding to a Kd o f 110 nM) [98].
The damage-induced acétylation o f pRb occurs in the C-terminal domain at 
residues K873/874, close to the C-pRb core sub-domain [97]. It was therefore 
hypothesised that acétylation at residues K873/874 might interfere with the C-pRb/E2F 
MB interaction, facilitating the release o f pRb and induction o f apoptosis. In addressing 
this question, GST-C-pRb 763-928 was mutated at K873/874. Mutant derivatives were 
engineered, one where residues K873/874 were substituted with R, and another for Q. 
Mutating K to Q has been shown to phenotypically mimic acétylation in histones [177], 
E2F-1 [75], and pRb [214]. Here I found that E2F-1 binds to the C-terminal domain o f pRb 
(amino acids 763-928). Furthermore, mutating K873/874 reduced binding to E2F-1. These 
results suggest that acétylation influences the binding affinity o f the C-terminal domain o f 
pRb for E2F-1.
T he ACETYLATION OF PRB AT RESIDUES K873/874 REDUCES THE E2F-1 INTERACTION IN 
CELLS.
The C-terminal domain o f pRb (residues 792 to 928 and 763 to 928) binds to E2F-1 
in vitro [96, 97], and interacts with the marked box region o f E2F-I[96]. The marked box 
region o f E2F-1 (Figure 7) influences the /raw.s'-activation function o f E2F-1 [240]. Cells 
transfected with marked box deletion mutants of E2F-1 show no difference in levels o f 
apoptosis over control cells, whereas over-expression o f wild-type E2F-I induces 
apoptosis [240].
pRb has anti-apoptotic functions (reviewed in [245]), which are likely mediated
through the binding o f the C-terminal domain o f  pRb with the marked box region o f E2F-1
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[96]. I have demonstrated that the binding o f E2F-1 to the C-pRb is prevented in vitro by 
mutating residues K873/874 o f pRb to Q residues (which mimic acétylation). 
Consequently, it was important to address whether the effect could be recapitulated in vivo, 
to test whether DNA damage responsive acétylation of pRb at residues 873/874 would 
affect the interaction between the C-pRb and E2F-1.
HEK 293 cells used in these experiments were transfomied nsing adenovirus, and 
therefore they express the E l A and E lB  oncoproteins [246]. E l A binds pRb small pocket 
region via its LXCXE m otif [41]. One o f the consequences of the pRb/El A interaction is 
the loss of binding between the small pocket o f pRb and the activation domain o f 
E2F-1 [40]. Therefore, HEK 293 cells were utilised to address whether the C-terminal 
domain o f pRb bound to E2F-1 in vivo, and whether mutating pRb residues 873/874 to Q 
residues affects this interaction. Wild-type pRb was also expressed in HEK 293 cells to 
address whether mutating residues 873/874 in context with the FL pRb protein affected the 
interaction with E2F-1.
A c é t y l a t i o n  a t  r e s i d u e s  K873/874 o f  p R b  i n c r e a s e s  t h e  i n t e r a c t i o n  b e t w e e n  
TH E C- AND N - t e r m i n a l  d o m a i n s  o f  p R b .
Residues K873/874 are acetylated in vivo during differentiation and in response to 
etoposide induced DNA damage [53, 97, 214]. In Chapter 3 o f this study the N-terminal 
domain of pRb was shown to be acetylated by Flag-p300 FL in vitro, and observed to be 
acetylated in HEK 293 cells in response to etoposide-induced DNA damage.
Despite a battery o f publications specifically on the N-terminal domain o f pRb 
(reviewed in [34]), not much is known about its main functions and how it interacts with 
the rest o f the protein. However, studies using the yeast two-hybrid system confirmed that 
the pRb could self-associate and that this association is mediated by interactions between 
the N-terminal and C-terminal domains o f the protein [135]. I wished to address whether
the N-terminal domain o f pRb is involved in regulation o f the C-terminal domain o f pRb,
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which might affect the localization o f pRb and perhaps also its binding affinity for E2F-1.
Here I present data that suggests post-translational modification of pRb regulates 
the binding o f the N-terminal domain to the C-terminal domain of pRb. Overall, the result 
is consistent with a role for the N-terminal domain o f pRb in the localization o f pRb during 
response to DNA damage thi'ough the interaction with the C-terminal domain o f pRb.
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CHAPTER 4
RESULTS
GST-C-pRb 763-928 i n t e r a c t s  w i t h  E2F-1 i n  v i t r o .
The C-terminal domain o f pRb binds to E2F-1
It was necessary to clarify that the C-terminal domain o f pRb could interact with 
E2F-I. GST-C-pRb 763-928 was used in a GST pull down assay. It was observed that 
GST-C-pRb 763-928 bound E2F-I in vitro, whereas GST protein failed to interact with 
^^S-methionine E2F-1 (Figure 23a). IVT ^^S-methionine labelled E2F-1 was used for the 
GST pull down (Figure 23b).
The GST-C-pRb 763-928 QQ mutant showed much reduced binding to E2F-1
A study using the pRb (378-928) QQ mutant derivative showed that the
exogenously expressed QQ mutant could arrest cells in G1 as efficiently as wild-type pRb
that had been acetylated by the addition o f exogenous p300 [214]. I wished to assess
whether pRb acétylation at residues K873/874 might alter the binding affinity o f pRb 763-
928 for E2F-I. Two mutant pRb 763-928 derivatives, GST-C-pRb 763-928 QQ and GST-
C-pRb 763-928 RR, were engineered to create a recombinant GST-C-pRb 763-928 that
mimics K residue acétylation (QQ mutant), and one that could not be acetylated (RR
mutant) (Figure 24a). The substitutions were selected based on their physical and chemical
similarities to K residues. R and Q residues were selected because they have a similar
physical mass (Da) and van der waals volume (A^) as K residues (Figure 24b). K, Q and R
residues are characteristically polar, but Q residues are neutral in charge mimicking
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acetylated K residues (Figure 25a, and 25b). Both Q and R make acceptable substitutions 
for K residues when they are solvent exposed (Figure 25 c) [247-249]. GST-C-pRb 763- 
928 mutants (Figure 26a) were combined with HEK 293 extracts containing E2F-1. It was 
a concern that mutating the pRb 763-928 at K residues 873/874 might have inactivated the 
mutant protein. In order to assess the integrity of the QQ and RR mutant proteins, each 
mutant was tested for binding with in vitro translated Mdm2 (Figure 26b), a known target 
for the C-terminal domain o f pRb [125]. Each GST-pRb derivative bound Mdni2 with 
equal efficiency (Figure 26b). HEK 293 cells were used as a source of endogenous E2F-1 
(Figure 26c). It was found that whilst the wild-type and RR mutant proteins efficiently 
bound E2F-1, the QQ mutant protein showed a significant loss of affinity. GST did not 
show affinity for E2F-1. Thus acétylation o f K873/874 may influence binding to E2F-1.
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Figure 23
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Figure 23: The C-terminal domain of pRb can bind E2F-1
^^S-Methionine labelled E2F-1 was incubated with 2 pg o f GST-C-pRb 763- 
928 or GST protein.
a) Binding of GST-pRb 763-928 to ^^S-Methionine labelled E2F-1 was 
assayed by autoradiography, and GST-pRb 763-928 was visualised by 
Coomassie staining.
b) IVT ^^S-Methionine labelled E2F-1 input levels (10 % of extract used in the 
binding assay) were also visualized by autoradiography.
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Figure 24
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Figure 24: A structural comparison between K, R, Q and acetyl-K residues
a) Comparison o f the chemical structures of K, R, Q and acetyl-K residues. 
The main chain is coloured black, with the variable side chains shown in 
red.
b) Table comparing the physical properties o f K, R, Q and acetyl-K residues.
131
Figure 25
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Figure 25: Comparison of the physical properties of K, R and Q
a) Venn diagram showing the relationship of the 20 naturally occurring 
amino acids.
K, R and Q are polar residues. K and R carry a positive charge whilst Q is 
neutral in charge. Q substitution is thought to mimic K  acétylation as both 
carry neutral charge.
b) A representation o f amino acids by Dayhoff mutation odds matrix
Highlighted in green are K, Q and R residues. Left and right o f the Y-axis 
indicate the degree o f polarity (non-polar and polar properties respectively). 
Above and below the X-axis indicates representative size o f amino acids 
(small to large respectively). R and Q are good candidates for substituting K 
residues due to their similar size and polarity.
c) Suggested amino acid substitutions for K  acétylation
The diagram depicts the possible amino acid substitutions for solvent
exposed amino acids ( > 3 0  square Angstroms exposed to the solvent).
Amino acids that are connected by a solid line can be substituted with 95 %
confidence [247], based on statistics from fifty five proteins. pRb residues
K873/874 are predicted to be exposed residues. Residues R and Q were
selected due to their similar physical properties to K residues. R was
selected for a residue that could not be acetylated. Q was selected as a
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mutant that phenotypically mimics K acétylation, presumably due to similar 
structure, size and charge of an acetyl-lysine.
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Figure 26
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Figure 26
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Figure 26: Mutating GST-C-pRb 763-928 residues K873/874 to Q inhibits binding
to E2F-1
a) Depicts the GST-C-Rb 763-928 (wild-type, QQ and RR mutant) recombinant 
constructs used in this experiment.
b) Binding o f GST-pRb 763-928, RR873/874 and QQ873/874 (1 pg) to E2F-1, 
Mdm2 and GST protein in HEK 293 cell extracts were assayed by 
immunoblotting with anti-E2F-l (KH95), anti-Mdm2 (SMP-14) and anti-GST 
(B14).
c) Input levels o f  endogenous E2F-1 and Mdm2 (10 % o f that used in pull downs) 
were visualised by immunoblotting.
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The ACETYLATION OF PRB AT RESIDUES K873/874 REDUCES THE E2F-1 INTERACTION IN 
CELLS.
M utating residues K873/874 to Q reduces the C-pRb/E2F-l interaction
HEK 293 cells were transiently transfected with constmcts encoding HA-pRb wild- 
type (Figure 27a, lane 1), HA-C-pRb RR and QQ mutant derivatives (figure 27a, lanes 2 
and 3), and HA-C-pRb wild-type (figure 27a, lanes 4 and 5). The cells were all co­
transfected with pCMV E2F-1. Co-immunoprecipitation experiments were carried out as 
described (page 143). Briefly, the HA-pRb wild-type and HA-C-pRb mutant proteins were 
immunoprecipitated using the anti-HA antibody and samples were analysed using 
electrophoresis followed by immunoblotting for E2F-1 and C-pRb (Figure 27a).
Although more HA-C-pRb QQ mutant protein inununoprecipitated than wild-type 
or RR mutants, the HA-C-pRb QQ mutant protein showed much reduced interaction with 
E2F-1. Less HA-C-pRb RR mutant protein immunoprecipitated from extracts than the HA- 
C-pRb wild-type or HA-C-pRb QQ mutant proteins, but significantly more E2F-1 
interacted with HA-C-pRb RR mutant protein than interacted with HA-C-pRb QQ mutant 
protein. The experiment contains a non-specific antibody control (Figure 27a, lane 5) and a 
non-transfection control (Figure 27a, lane 6).
Densitometric analysis was employed to compare the protein levels o f E2F-1 and 
HA-C-pRb 763-928 mutant derivatives immunoprecipitated (in Lanes 1 to 4) (Figure 27b). 
Relative amounts o f bound E2F-1 were adjusted by factoring in differences in 
immunoprecipitated HA-C-pRb 763-928. The HA-C-pRb QQ mutant derivative was only 
able to immunoprecipitate E2F-1 with 7 % efficiency o f the wt HA-C-pRb 763-928. In 
contrast, the HA-C-pRb RR mutant derivative could immunoprecipitate E2F-1 0.8 times 
less efficiency than the wild-type HA-C-pRb 763-928 (Figure 27b).
The pcDNA3 2HA-pRb (763 to 928) mutated derivatives expressed equally well in
HEK 293 cells (Figure 27c). pSG5L-HA-pRb (1-928) also expressed well in HEK 293
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cells. In order to check the accuracy o f the densitometric analysis, known amounts o f BSA 
protein were analysed using electrophoresis and coomassie blue staining (Figure 27d, left 
panel). Using densitometiy, the relative protein levels of the BSA bands were compared to 
the Ipg  band (lane 1). Calculations o f the amounts o f BSA loaded in lanes 2, 3 and 4 are 
shown (Figure 27d, right panel).
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Figure 27
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Figure 27: E2F-1 interacts with C-Rb
Extracts were prepared from HEK 293 cells transfected with the following 
expression vectors; 2 pg o f pcDNA3 HA-pRb 763-928 (wt, QQ, or RR) or 2 pg 
o f pSG5L-HA-pRb 1-928. All samples were transfected with pCMV-p-gal (0.5 
pg throughout).
a) Extracts were noraialized and immunoprecipitated (IP) with anti-HA antibody 
(Lanes 1-4 and 6) or with goat-anti-rabbit antibody as non-specific antibody 
(NAb) (Lanes 5), and after electrophoresis, immunoblotted with anti-E2F-l 
antibody (C20) (top panel) and anti-Rb C l5 antibody (bottom panel).
b) Quantification of the protein levels in a). Protein levels are compared to HA-C- 
pRb 763-928 wt (Lane 4), which is given the nominal value of 1. The levels o f 
both E2F-1 and HA-C-pRb mutant derivatives are shown. The levels o f bound 
E2F-1 are adjusted to take into account the different levels o f 
immunoprecipitated mutant HA-C-pRb 763-928 RR, QQ or wt.
c) Corresponding inputs showing 100 pg extract immunoblotted with anti-E2F- 
l(top panel) and anti-HA (bottom panel) antibodies.
d) Known amounts o f BSA (1, 1.5, 2 and 2.5 pg) were resolved on an SDS PAGE 
gel and visualized with coomassie staining (left panel). Densitometry was used 
to measure the relative concentrations of BSA (right panel).
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Mutating residues K873/874 to Q also reduces the FL-pRb/E2F-l interaction
A similar experiment was carried out comparing the binding efficiencies o f wild- 
type FL-pRb and FL-pRb mutant proteins to E2F-1. E l A bound pRb does not interact with 
the ^rrzMj'-activation domain o f E2F-1 as it might do in tumour cell lines that are not 
transformed with adenovirus (such as U 20S, T98G or MCF-7 cell lines) [40]. Therefore it 
was reasoned that transfecting FL-pRb mutants into HEK 293 cells would allow the study 
o f the pRb C-terminal domain and its interaction with E2F-1 in the context o f FL-pRb.
HEK 293 cells were transiently transfected with constructs encoding Ha-pRb wt 
(Figure 28a, lanes 1, 3 and 6), HA-pRb-QQ mutant derivative (Figure 28a, lanes 4 and 7), 
and HA-pRb RR mutant derivative (Figure 28a, lanes 5 and 8). All cells were co­
transfected with constructs encoding for E2F-1. FL-HA-pRb mutant derivatives were 
immunoprecipitated using the HA antibody and samples were analysed by electrophoresis 
followed by immunoblotting to detect immunoprecipitated HA-pRb mutant proteins and 
co-immunoprecipitated E2F-1 (Figure 28a). Lane 1 shows proteins immunoprecipitated 
using a non-specific antibody, and lane 2 shows proteins immunoprecipitated from the 
control extract. Significantly less E2F-1 immunoprecipitated with the FL HA-pRb QQ 
mutant in both un-treated cells (Figure 28a, Lane 4) and cells treated with etoposide 
(Figure 28a, Lane 7).
Densitometric analysis was employed to compare the protein levels o f E2F-1 and 
HA-pRb mutant derivatives immunoprecipitated (in Lanes 3 to 5, and Lanes 6 to 8) (Figure 
28b). Relative amounts of bound E2F-1 were adjusted by factoring in differences in 
immunoprecipitated HA-pRb. The HA-pRb QQ mutant derivative was only able to 
immunoprecipitate E2F-1 with 20 % o f the efficiency observed with the wt HA-pRb 
(Figure 28b). In cells, the HA- pRb RR mutant derivative could immunoprecipitate E2F-1 
with 11 % greater efficiency compared with the wt HA-pRb (Figure 28b). A more modest
reduction in E2F-1 immunoprécipitation was observed if  cells were treated with etoposide.
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The HA-pRb QQ mutant bound E2F-1 with efficiency about 60 % o f that compared to wt 
or RR HA-pRb mutant proteins.
Protein levels of E2F-1 immunoprecipitated with the FL FlA-pRb wt and RR 
mutant proteins were similar. As expected [229], levels o f E2F-1 immunoprecipitated with 
FL-pRb mutant proteins were higher in cells treated with etoposide (Figure 28c, Lanes 6 to 
8).
The FL-HA-pRb 1-928 constructs (pSG5-L HA-pRb wt, QQ, and RR) were 
expressed equally well in HEK 293 cells (Figure 28c). Etoposide treated HEK 293 cells 
expressed greater levels o f exogenous FL pRb mutant proteins than un-treated cells (Figure 
28c). Protein levels o f endogenous E2F-1 were consistent with that observed with DNA 
damage induced E2F-1 (Figure 28c) [229].
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Figure 28: E2F-1 interacts with HA-pRb 1-928
Extracts were prepared from mi-treated and etoposide treated HEK 293 ceils 
transfected with expression vectors encoding pSG5L-HA-pRb 1-928 (wt, QQ, 
or RR) (2 pg). All samples were transfected with pCMV-|3-gal (0.5 pg 
throughout),
a) Extracts were normalized and immunoprecipitated with anti-HA antibody 
(lanes 2 to 8), or with goat-anti-rabbit antibody as non-specific antibody (NAb) 
(lanes 1), and after electrophoresis, immunoblotted with anti-E2F-l antibody 
(C20) and anti-HAII antibody.
b) Quantification o f the protein levels in ‘a ’. Protein levels are compared to HA- 
pRb wt (Lane 4), which is given the nominal value o f 1. The levels o f both 
E2F-1 and HA-pRb mutant derivatives are shown. The levels of bound E2F-1 
are adjusted to take into account the amount of mutant HA-pRb wt, QQ or RR 
in the pull down.
c) Corresponding inputs showing 100 pg extract immunoblotted with anti-E2F-l 
KH95 antibody and anti-HA antibodies.
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Mutating FL-pRb residues 873/874 to Q alters sub cellular localization.
It was important to characterize the C-pRb mutant proteins intra-cellular 
localization. Using a specific antibody raised against acetylated K873/874 peptides 
(SK37), it was shown that acetylated pRb (at residues K873/874) underwent nuclear re­
localization in response to etoposide treatment in U 20S  cells [97]. The HA-C-pRb mutant 
constmcts (pcDNA 2HA-pRb 763-923 wild-type, QQ and RR) were therefore transfected 
into U 20S cells. Cells were immunostained using the HA antibody to detect the exogenous 
protein. The three HA-C-pRb proteins localized into the nucleus o f un-treated or etoposide 
treated U 20S cells (Figure 29a and 29b).
A characterization o f the intra-cellular localization o f FL-HA-pRb mutant 
derivative proteins was also investigated. The FL-HA-pRb mutant constructs (pSG5L-HA- 
pRb 1-928 wild-type, QQ and RR) were transfected into U 20S  cells. Cells were 
immunostained using the HA antibody to detect the exogenous protein. The wild-type and 
RR mutants both localized to the nucleus (Figure 30; top and bottom rows, respectively). 
The FL HA-pRb QQ mutant localised mainly to the cytoplasm with small amounts o f 
nuclear staining present (Figure 30; middle row).
DNA damage does not change the localization o f wt, QQ or RR mutant FL-Rb
A similar experiment was carried out using U 20S  cells treated with etoposide. 
Etoposide treatment had no obvious effect on the localization o f FL-HA-pRb mutant 
proteins (Figure 31), since localization was similar to that observed in Figure 30. The 
nuclear localization of endogenous pRb in U 20S cells with and without etoposide 
treatment.
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Figure 29: HA-C-pRb 763-928 (wt, QQ and RR mutants) localize to the nucleus of
both un treated and etoposide treated U 20S  cells
U 20S cells were transfected with 2 jag o f pcDNAB 2HA-Rb 763-928 wt or 
QQ or RR mutant DNA. After 48 h transfection, cells were immunostained 
using anti-HA antibody to detect the pRb mutant derivative proteins. All 
images are shown at 630 X magnification. Images were digitally manipulated 
for enlargement. A white bar at the bottom o f the images represents lOjam.
a) U 20S  cells un-treated and immunostained 48 h post-transfection.
b) U 20S cells treated with 50 jliM  etoposide for 8 h prior to immunostaining.
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The nuclear localization of endogenous pRb in U 20S  cells with and without etoposide 
treatment
As the exogenous C-pRb and FL-pRb mutant proteins (used in Figures 29-31) were 
over-expressed, it was reasoned that subtle changes in the intra-nuclear localization o f pRb 
would not be detected by staining for the exogenous protein. Therefore, U 20S  cells were 
stained with antibodies that detect endogenous pRb in both un-treated and etoposide 
treated cells (Figure 32). Cells were stained with IF8, or G3-245 (Figure 32a and 32b). 
Both pRb antibodies detected similar nuclear localization o f pRb whether the cells were 
etoposide treated or not. There was no obvious change in nuclear localization under DNA 
damage conditions.
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Figure 30: The localization of HA-pRb 1-928 (wt, QQ and RR) mutant proteins
U 20S cells were transfected with 2 pg o f pSG5L-HA-pRb wt or QQ or RR 
mutant DNA. After 48 h transfection, cells were immunostained using anti-HA 
antibody to detect the mutant derivative proteins. All pictures are shown at 
630X magnification. Images were digitally manipulated for enlargement. A 
white bar at the bottom of the images represents 10pm.
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Figure 31: The localization of HA-pRh 1-928 (wt, QQ and RR) mutant proteins in
response to etoposide treatment
U 20S cells were transfected with 2 pg of pSG5L-HA-pRb wt or QQ or RR 
mutant DNA. Cells were treated with 50 pM etoposide 40h post-transfection 
and immunostained 8h post-treatment. Cells were immunostained using anti- 
HA antibody to detect the mutant derivative proteins. All pictures are shown at 
63OX magnification. Images were digitally manipulated for enlargement. A 
white bar at the bottom of the images represents 10pm.
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Figure 32: The localization of endogenous pRb with and without etoposide
treatment
U 20S cells were treated without or with 50 pM etoposide 40h post­
transfection and immunostained 8h post treatment. Cells were immunostained 
using either anti-IFB antibody (raised against whole pRb) or G3-245 (which 
recognises an epitope between aa 322-344 o f pRb). All pictures are shown at 
63OX magnification. Images were digitally manipulated for enlargement. A 
white bar at the bottom o f the images represents 10pm.
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A c é t y l a t i o n  a t  r e s i d u e s  K873/874 o f  p R b  i n c r e a s e s  t h e  i n t e r a c t i o n  b e t w e e n
THE C  AND N -T E R M IN A L  DOMAINS O F P R B .
The N-pRb domain binds to the C-pRb in vitro
The regions in pRb used in this binding study are represented (Figure 33a). GST 
bound recombinant C-pRb 763-928 (wt, QQ and RR mutant protein) was used as bait for 
the nuclear extract containing N-pRb (Figure 33b). It was observed that the N-pRb bound 
to the C-pRb (Figure 33b, Lanes 3 and 4) but not to GST protein (Figure 33b, Lane 5). The 
middle panel shows the mutant protein levels o f pRb 763-928 bound to the GST beads 
(Figure 33b, Lanes 1 to 4). The protein level o f GST-pRb QQ mutant protein is 
approximately a fourth o f GST-pRb wt or GST-pRb RR protein levels, but it still binds to 
the N-pRb (Figure 33b, Lane 3). The C-pRb RR mutant protein was not observed to 
specifically bind the N-pRb protein (Figure 33b, Lane 2). As a positive control, pRb 763- 
928 wt was shown to interact with HA-pRb 1-928 (Figure 33b, Lane 1).
Densitometric analysis was employed to compare the protein levels o f HA-N-pRb 1-376 
and GST-C-pRb 763-928 mutant derivatives (Figure 33c). Relative amounts o f bound FIA- 
N-pRb 1-376 were adjusted by factoring in differences in levels o f GST-C-pRb 763-928 
mutant derivatives bound to GST Sepharose beads. The GST-C-pRb QQ mutant derivative 
was able to pull down HA-N-pRb approximately 4 times more efficiently than the wild- 
type GST-C-pRb 763-928. In contrast, the assay did not detect any interaction between 
GST-C-pRb RR mutant derivative and HA-N-pRb. Interestingly, wild-type GST-C-pRb 
was able to pull down FL HA-pRb 3.3 fold more efficiently than its interaction with HA- 
N-pRb.
The pcDNA3 2HA N-pRb was transfected into HER 293 cells, and nuclear extract 
harvested for use as a source o f N-pRb for in vitro pull down assays (Figure 33d).
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Figure 33: The N-terminal and C-terminal domains of pRb interact with each
other in vitro
a) The diagram in part ‘a ’ depicts the N-terminal domain and C-terminal domain 
constructs o f pRb used in the pull down assays.
b) Part ‘b ’ shows a GST in vitro pull down o f wild-type HA-pRb and HA-N-pRb 
1-376 (extracted from HEK 293 cells) by recombinant GST-C-pRb (763-928). 
Site directed mutagenesis was utilized to mutate GST-C-Rb residues 873/874 
from K to R or Q (acétylation mimic). Anti-HA antibody was used to detect 
wild-type HA-pRb and HA-N-pRb 1-376. Levels o f recombinant GST-C-pRb 
were assessed by immunoblotting using anti-C 15 antibody that detects a 
peptide at the C-terminal domain ofpRb.
c) Quantification o f  the protein levels in b). Protein levels are compared to GST- 
pRb 763-928 wt (Lane 4), which is given the nominal value o f 1. The levels o f 
both HA-N-pRb and GST-pRb mutant derivatives are shown. The levels o f 
bound HA-N-pRb are adjusted to take into account the amount o f mutant GST - 
pRb 763-928 wt, QQ or RR in the pull down.
d) HEK 293 cells were transfected with 2 pg o f pSG5L-HA pRb 1-928 or 2 pg o f 
pcDNA3-HA pRb 1-376. Nuclear and cytoplasmic extract (100 pg) was 
analysed by electrophoresis followed by immunoblotting using the anti-HA
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antibody. Extract from lanes 2 and 4 were used as sources of HA-pRb 1-928 
and HA-pRb 1-376 respectively in the GST in vitro pull down assay.
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DISCUSSION
GST-C-pRb 763-928 i n t e r a c t s  w i t h  E2F-I IN v i t r o .
The data presented here suggest that residues K873/874 maybe required for the C- 
terminal domain pRb/E2F-l interaction. The K to Q substitution at K873/874 o f the C- 
terminal domain in pRb appears to reduce the C-pRb/E2F-l interaction in vitro. The 
concordant K to R substitution at the same residues appears to retain E2F-I binding with 
almost equal level compared to the wild-type C-pRb. This result shows that acétylation o f 
C-pRb at K873/874 reduces the affinity o f C-pRb for E2F-1.
There are two main concerns in drawing eonclusions from these experiments. The 
in vitro assays do not preclude that the microenvironment in cells may be different. The 
second concern surrounds the validity o f  using K to Q substitution to infer the effects o f 
acétylation. However, the substitutions o f K to Q or R were chosen on the basis o f their 
similar physical properties (Figure 24 and 25) [247-249]. Other studies however have 
provided convincing results that K to Q substitution is a phenotypic mimic for acétylation 
[75, 177, 214]. In order to conflnn my results, it would be necessary to develop a method 
for separating in vitro acetylated C-pRb from the non-acetylated form. A recent publication 
suggests a way that acetylated protein forms can be isolated from lysate with a purity o f 
greater than 90 % [250]. Future work may use such techniques to obtain acetylated C-pRb 
for the in vitro binding assay studies.
There are a number o f possibilities as to why the C-pRb QQ mutant does not
interact with E2F-1. K873/874 o f C-pRb does not form part o f the consensus-binding site
for interaction with E2F-1. The two regions that were obseiwed to bind the marked box o f
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E2F-1 are residues 786-800 and residues 829-864 o f pRb [98]. It is possible therefore that 
acétylation o f K873/874 causes a confonnational change in the C-terminal domain o f pRb 
that affects one or both o f the C-pRb binding regions, preventing them from interacting 
with the E2F-1 marked box region.
Mutation o f K to Q changes the net charge o f residues 873/874 from +1 to neutral, 
which mimics the change in charge resulting from K acétylation. K and R residues are both 
basic amino acids whereas Q residues are more electronegative (Figure 24a). The pRb 763- 
928 QQ and RR mutants were still able to bind Mdm2 protein. This result suggests that the 
K to Q/R mutation does not simply ablate the binding ability o f the mutant proteins 
altogether, and also perhaps that another region o f C-pRb is involved in binding Mdm2. 
Crystallographic studies could be utilised to compare the ‘wild-type and Q Q ’ C-pRb 
proteins. In summary, E2F-1 binds to the C-terminal domain o f pRb 763-928, an 
interaction that is blocked by acétylation o f pRb residues K873/874.
T he ACETYLATION OF FRB AT RESIDUES K873/874 REDUCES THE E2F-1 INTERACTION IN 
CELLS.
Mutating residues 873/874 to Q reduces the C-pRb/E2F-l interaction
Using mammalian expression vectors encoding C-terminal domain pRb proteins 
(derived from GST C-pRb constmcts used in Figure 26), it has been demonstrated that the 
C-Rb QQ mutant protein binds weakly to E2F-1 in HEK 293 cells, pRb phosphorylation is 
the only post-translational modification reported to control the pRb/E2F-l interaction 
directly. Thus perhaps acetylating pRb in response to DNA damage releases the anti- 
apoptotic behaviour o f pRb by interfering with its interaction with E2F-1. Acétylation o f 
pRb at residues K873/874 is known to reduce pRb phosphorylation and facilitate cell cycle 
arrest [214].
HEK 293 cells are transformed with adenovirus, and express the E l A and E lB
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oncoproteins [246], which are likely to interfere with the pRb small pocket/E2F-I 
interaction. Therefore, the immunoprécipitations (in Figures 27 and 28) were likely to 
detect interactions between the C-terminal domain o f pRb and the marked box region o f 
E2F-1. Limited conclusions can be drawn from these data. Firstly endogenous E2F-1 
contains the ^ra^îs'-activation domain, so pRb that is not in complex with E l A could 
potentially produce false positives in vivo, by binding to E2F-1 using the small pocket 
region (domains A and B). Secondly, the endogenous pRb present may interact with the C- 
pRb mutant proteins. Indeed, pRb is known to bind to itself via N-terminal domain/C- 
terminal domain interactions [135].
Further study in this area might utilise gel shift assays to compare complex 
formation o f C-pRb w ild-type/E2F-l/D P-l with that of C-pRb QQ/E2F-1/DP-1. It might 
be expected that the C-pRb QQ mutant protein would cause less band shift complexes than 
the C-pRb wild-type protein, as the interaction between C-pRb QQ and E2F-1/DP-1 would 
be much weaker than that between wild-type C-pRb/E2F-l/D P-l.
The immunoprécipitation experiments in Figures 27 and 28 could be repeated using 
exogenously expressed E2F-1 (l-374)/D P-l instead o f relying on endogenous E2F-1/DP-1. 
This would prevent any HA-pRb pocket interactions with the rra/7.s'-activation domain o f 
endogenous E2F-1 because the two fonns o f  E2F-1 would resolve differently on an SDS- 
PAGE gel.
Mutating residues K873/874 to Q also inhibits the FL-pRb/E2F-l interaction
The immunoprécipitation o f E2F-1 with FL-pRb was meant to conflnn that pRb 
could bind E2F-1 using the small pocket interaction with the /ra/î.s'-activation domain o f 
E2F-1. Therefore, the expected result was that the FL-pRb QQ mutant would bind E2F-1 
as efficiently as FL-pRb wild-type derivative. It seems however that the FL-pRb QQ 
mutant binds E2F-1 less efficiently than the wild-type FL-pRb or FL-pRb RR mutants. 
This effect was mirrored in cells treated with etoposide.
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There maybe several reasons for this. Firstly, the E l A concentration in HEK 293 
cells could be significant enough to bind all exogenous FL pRb protein, thus preventing 
pRb small pocket interactions with E2F-1. Secondly, it is possible that mutating K residues 
873/874 to Q might alter the localization o f the FL-pRb QQ mutant protein but not alter 
the localization o f the C-pRb QQ mutant protein. Thirdly, it might be that basic residues 
(like K or R) are necessary for successful interaction between the C-terminal domain o f 
pRb and E2F-1 to occur. Perhaps neutralizing the charge on residues K873/874 by 
acétylation or Q substitution loosens the interaction between the C-terminal domain o f pRb 
and E2F-1.
Localization of the pRb exogenous proteins
The C-tenninal domain pRb mutant proteins all localized to the nucleus, even in 
cells treated with etoposide (Figure 29), as did the FL-pRb wild-type and RR mutant 
proteins. It is significant that the FL-pRb QQ protein localizes more to the cytoplasm than 
the nucleus. This result contradicts earlier data we published (Figure 4C [97]). However, 
subsequently we had cause to re-sequence this sample o f FL-pRb QQ mutant construct, 
which was confirmed to be contaminated with FL-pRb wt DNA. The sub cloning o f the FL- 
pRb QQ mutant construct was repeated, and all subsequent immunostaining experiments in 
U 20S  cells showed FL-pRb QQ mutant protein to localize more to the cytoplasm than the 
nucleus.
Using an anti-acetylated pRb antibody (SK37), we recently reported that DNA
damage responsive acetylated pRb localizes to the nucleus (showing only limited
cytoplasmic staining) [97]. This apparent contradiction between figure 1C of M arkham et
al 2006 [97] and Figures 30 and 31 o f this thesis should be further investigated. Presently
we have no definitive data indicating that treatment o f U 20S  cells with 10 pM  etoposide
induces acétylation o f residues 873/874 simultaneously. In figure 1C o f Markham et al
2006, U 20S  cells were treated with 10 pM etoposide for 8 h. It is possible that longer
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exposure to a greater concentration o f etoposide might induce further acétylation, altering 
acetylated pRb subcellular localization to a mainly cytoplasmic distribution.
The Rb protein contains two regions that confer nuclear localization (the A/B 
pocket, and the C terminal domain). The A/B pocket when fused to the pECE-p- 
galactosidase construct (pECE-p-gal-Rb-A/B) confers nuclear/cytoplasmic localization 
upon the heterologous protein [251]. The C-terminal domain o f pRb contains a bi-partite 
NTS that has been characterized as spanning residues 860-877 (Figurc 8) [252]. It is likely 
that mutating the K residues at 873/874 is enough to ablate nuclear localization conferred 
by the bi-partite NLS. The K residues in the NLS are central to its function, and even 
mutating adjacent residues to a Q is enough to cause pRb to localize to both the cytoplasm 
and the nucleus [253]. The FL-pRb mutated at K873/874 to Q is nuclear/cytoplasmic, but 
the corresponding C-pRb QQ mutant is nuclear. It is possible that the N-terminal domain 
o f pRb may interact with the C-terminal domain o f pRb in context with the FL protein to 
influence its intra-cellular localization.
In summary, the C-pRb protein binds to E2F-1 in HEK 293 cells, an interaction 
that is blocked by mutating residues K873/874 to Q. This interaction is independent o f 
endogenous pRb because HEK 293 cells express E l A that binds to the small pocket region 
o f pRb and prevents its association with the activation domain o f E2F-1 [105, 246]. 
Exogenously expressed FL-HA-pRb also binds E2F-1, and its binding was blocked when 
residues K873/874 o f pRb are mutated to Q. Although FL-pRb QQ mutant localizes 
mainly to the cytoplasm, this localization is unlikely to explain the loss o f binding to E2F- 
1 as the truncated C-pRb QQ mutant localizes to the nucleus, but also exhibits low binding 
to E2F-1.
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A c é t y l a t io n  a t  r e s id u e s  K873/874 o f  p R b  in c r e a s e s  t h e  in t e r a c t io n  b e t w e e n  
THE C  AND N - t e r m in a l  d o m a in s  o f  p R b .
The N-pRb binds to the C-pRb in vitro
The two-hybrid study by Sterner et al found that the N-terminal domain o f pRb 
interacts with the C-tenninal domain o f pRb in yeast [100]. It has been confirmed using in 
vitro pull down assays that the HA-N-pRb (derived from HEK 293 nuclear extract) does 
indeed interact with the GST-C-pRb. In vitro pull down assays utilizing C33A cells (in 
which Rb  is genetically inactivated) as the source o f exogenous HA-N-pRb were unable to 
detect an interaction between HA-N-pRb and GST-C-pRb. Lysing C33A cells to separate 
nuclear and cytoplasmic fractions later confinned that the exogenously expressed HA-N- 
pRb localized mostly to the cytoplasm, whereas in HEK 293 cells exogenously expressed 
HA-N-pRb localized mostly to the nucleus (Chapter 3, Figure 22).
One explanation is that HA-N-pRb interacts with endogenous nuclear wild-type 
pRb at the bridging region between the N-tenninal domain and the A domain (residues 
379-572), and that during the pull down, GST-C-pRb binds to the B domain (residues 646- 
772). In this hypothesis, the A/B pocket domain o f pRb might act as a protein scaffold to 
facilitate a binding surface for the exogenous HA-N-pRb and GST-C-pRb to interact. This 
hypothesis is supported by the obsei-vation that HA-pRb FL binds much more efficiently to 
GST-C-pRb than the HA-N-pRb does (Figure 33b, Lane 1). The affinity that the HA-N- 
pRb and GST-C-pRb wild-type proteins have for each other is quite modest compared to 
the affinity that the HA-tagged exogenous proteins have for the regions of pRb that they 
neighbour. Testing this hypothesis might require crystallographic analysis to assess the 
binding affinities o f  pRb N-terminal and C-terminal domains for the A/B pocket.
The mutant derivative GST-C-pRb QQ showed enlianced in vitro binding to HA-N-
pRb 1-376. In conti'ast, the GST-C-pRb RR mutant derivative showed greatly reduced in
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vitro binding affinity to HA-N-pRb 1-376. This is a new obsei*vation. One interpretation is 
that the acétylation o f residues K873/874 of GST-C-pRb promotes an increase in affinity 
between the N-terminal and C-temiinal domains. However, it is also possible that the 
acétylation of residues K873/874 might cause a change in the confonnation of the C- 
teiTninal domain o f pRb, thereby causing it to bind against the face o f the B domain o f the 
pRb small pocket. Thus a flip in conformation might bring the N-terminal and C-terminal 
domains close enough together to interact. Again, crystallographic analysis would be very 
useful in determining the effect o f acétylation on the binding properties o f the C-terminal 
domain.
It has been shown that residues K873/874 are acetylated in response to etoposide 
treatment in a number o f cell types [97]. Results presented here indicate that acétylation at 
residues K873/874 o f the C-pRb increases its in vitro affinity for the N-pRb. The next step 
would be to test the binding affinity o f N-pRb to C-pRb in vivo. It is possible that acetyl 
forms o f N-pRb also induce a conformational change at the N-terminal domain end o f pRb 
that promotes interaction between the C-terminal domain and the N-tenninal domain. The 
next step would be to identify the acetylated K residues in the N-pRb by mass 
spectroscopy. N-pRb acétylation mutants could then be engineered (K to Q), and these 
mutants could be tested in binding assays and crystallographic analysis to assess the 
combined effect o f acétylation o f both the N-terminal and C-terminal domains on their 
binding to each other and to the A/B small pocket region.
In summaiy, the N-teim inal domain o f pRb binds to the C-terminal domain o f pRb 
in vitro. The GST tagged C-pRb QQ mutant demonstrated 4-fbld greater binding to the N- 
terminal domain o f pRb comparative to C-pRb wild-type, indicating that acétylation o f 
pRb at residues 873/874 might induce greater binding between the N-teiminal and C- 
teiminal domains o f pRb.
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DISCUSSION
pRb is acetylated across multiple domains
There is now evidence that pRb is acetylated across four o f its five domains (only 
the spacer has not been studied (aa 572-646)). In vitro data can be summarized as follows: 
The Retinoblastoma N-tenninal (aa 1-376) and C-tenninal (aa 763-928) domains are 
efficiently acetylated by Flag-p300 FL (Figure 35a). The A domain derivative of pRb (aa 
379-572) does display acétylation in vitro by Flag-p300 FL, but it is barely detectable in 
gel based assays [214]. The B domain derivative of pRb (aa 646-792) does not show 
detectable in vitro acétylation (Figure 35-A) [214]. It is hypothesised that the A/B domains 
are more efficiently acetylated when they are interacting together [214]. A small 
polypeptide (aa 710 to 732) in the B domain (corresponding to exon 21) and which is 
conserved across species, can be acetylated at residue 713 [214].
Engineered GST-pRb derivatives spanning the C-terminal domain o f pRb show 
that there are two regions o f the C-terminal domain that are acetylated in vitro by Flag- 
p300 FL (residues 794-829 and residues 830-884) (Figure 35B(i)). However, mutating 
residues K873/874 to Q or R, completely ablates acétylation o f GST-C-pRb 763-928, 
suggesting that acétylation o f these residues is required for the acétylation o f other residues 
in GST-pRb 794-829 [97, 214] (Figure 35B (ii)).
A study by Nguyen et al [53] showed that GST-pRb 379-928 wild-type is 
acetylated in vitro by Flag-P/CAF, but the pRb derivative mutated at residues K873/874 
(GST-pRb 379-928 RR) is not acetylated by Flag-P/CAF. Further to this, Flag-p300 FL 
combined with Flag-P/CAF acetylates GST-pRb 379-928 wild-type more
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Figure: 34 The in vitro acétylation of GST pRb derivatives
Both Flag-p300 FL and Flag-P/CAF acetylate the Rb protein in vitro.
a) Top shows a schematic representation o f pRb 1-928. Below indicates which 
GST pRb domains are acetylated by Flag~p300. The derivatives are indicated 
by ticks or cross, indicating whether they are acetylated and their relative 
acétylation.
b) i) Shows GST pRb derivatives spanning the C-terminal domain o f pRb (aa 
763-928) that are acetylated by Flag-p300. Derivatives are indicated as 
acetylated or not as in a).
ii) Shows GST-pRb 763-928 wt, QQ and RR mutant derivatives (mutated at 
residues K873/874) that are acetylated by Flag-p300. Derivatives are indicated 
as acetylated or not as in a).
c) Shows GST pRb 379-928 wt, and RR mutant derivatives (mutated at residues 
873/874) that are acetylated by Flag-P/CAF.
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efficiently than either Flag-p300 FL or Flag-P/CAF could in isolation [53]. It is possible 
that p300 and P/CAF acetylate pRb more effectively in a complex. P/CAF is able to bind 
to pRb 379-928 [53], so perhaps P/CAF can recruit p300 to the pRb large pocket domain 
(residues 379-928).
Acétylation o f a K residue alters its physical properties by neutralizing the positive 
charge of the K  residue but maintaining its polar and steric properties (Chapter 4, Figure 
24 and 25). The B domain o f pRb is not highly acetylated [214]. This may be because six 
basic K residues in the B domain (K713, K720, K722, K729, K740 and K765) are required 
to hydrogen bond with acidic residues in the LXCXE peptide [41], an interaction that 
allows the LXCXE m otif containing proteins to bind the pRb small pocket. It is interesting 
that Flag-p300 FL can acetylate residues in the N-terminal domain o f pRb (Figure 36a and 
36b) and residues across the pRb large pocket [214], but P/CAF is only able to acetylate 
residues K873/874 [53].
There are thirty-one K residues across the N-terminal domain o f pRb (twenty three 
in the N sub-domain, and 8 in the R sub-domain) (Figure 36, parts a) and b)). Residue 136 
is the only point mutation observed from the thirty one K residues in the N-terminal 
domain in a patient suffering from unilateral retinoblastoma (Figure 36a and 36c) [254]. 
The only other significant mutations affecting the N-terminal domain are discrete internal 
mutations resulting in the deletion o f exons 4 and 8. Potential acétylation sites in these 
regions are highlighted (Figure 36d) [145]. Exons 4 and 8 encode protein sequence that is 
highly conserved among vertebrate species (bird, human, rodent, fish and amphibian) 
[111]. Also exon 8 contains S and T residues (position S250 and T252) that are 
phosphorylated by Cdks [146]. It may be therefore that acétylation o f the N-tenuinal 
domain will affect its phosphoiylation in a similar way to which acétylation at residues 
K873/874 reduce cyclin E/Cdk2 dependent phosphoiylation, thus promoting cell cycle 
arrest [214].
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Cdc25A 116 PALK ES H S D SLD H D 129
Cdc25C 209 SG LYBSPSM PEN LN 222
E2F1 357 PLLS E M G S LR A P VD 371
BRCA1 981 P P L F E IK S F V K T K C 994
p53 13 P LS O E T F S D LW K LL 26
C-Rb 804 817
C-Rb 888 901
C-Rb 899 O KliAEM TETRTRM O 912
N-Rb 75 88
N-Rb 172 lY L T Û P S S S IS T E I 185
N-Rb 180 193
N-Rb 340 D K T L Û T D S ID S F E T 353
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Figure 35: The N-terminal domain of pRb
a) Schematic o f the N-terminal domain o f pRb (residues 1-379). Directly above 
the schematic, mapped are regions encoded by each exon. Exons 4 (residues 
127-166) and exon 8 (238-286) are shaded in green because they have been 
found deleted in some human cancers. The vertical lines in red represent the 
position o f lysine residues aeross the N-terminal domain. Below the schematic, 
the three regions of the N-terminal domain that are highly conserved across 
species (residues 195-235, 270-289, and 317-343) are highlighted in blue. N- 
terminal domain point mutations found in human tumours are shown shaded in 
red. The locations o f known Cdk phosphorylation sites are shown as black 
circles labelled P, and the location o f possible Cdk sites are shown as white 
circles labelled P. The locations o f possible Chk2 phosphorylation sites are 
depicted as black and yellow circles labelled P.
b) The N-terminal domain o f pRb consists o f two protease/caspase resistant sub- 
domains labelled N (1-263 approximately 30KDa) and R (263-379 
approximately lOKDa). Secondary structural analysis predicts that the two 
domains are globular and connected by a hinge region.
c) There are thirty one potentially acetylated K residues in pRb 1-378. The 
potential acétylation sites in the N-terminal domain pRb protein sequence are 
highlighted in red. The K residue highlighted in green at aa position 136 is the
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only known point mutation that has been observed from a patient with 
unilateral retinoblastoma (K to X).
d) Discrete N-terminal domain internal mutations that are naturally occurring 
mutant alleles in human tumours were assessed for their proximity to potential 
acétylation sites (shown in red).
e) The Chk2 consensus phosphorylation sites in various transcription factors 
(from Cdc25A to p53). The C-pRb and N-pRb are predicted sites o f Chk2 
phosphorylation.
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Treating cells with etoposide Induces the acétylation of both K 873/874 and the N- 
terminal domain of pRb
The N-terminal domain o f pRb was acetylated in HEK 293 cells, and treating cells 
with etoposide induced greater levels o f acétylation. A similar result is observed when 
comparing N-terminal domain acétylation with damage-inducible acétylation o f residues 
K873/874 o f pRb. Etoposide-inducible acétylation is so far detectable in six cell types 
(HEK 293, NIH 3T3, WI38, HCT15, AT fibroblasts, and F9 cells) [97]. Levels o f  pRb 
acétylation at residues K873/874 are increased upon treating WI38 cells and HEK 293 
cells with TSA. Etoposide is known to activate the ATM damage response pathway [255], 
but curiously preliminary data suggest that ATM is not a requirement for damage- 
inducible pRb acétylation because it is detectable in AT cells (Darran O ’Connor, personal 
communication).
Chan et al 2001 [214] studied the regulation o f  pRb acétylation during cell cycle 
progression. Immunoprecipitated endogenous pRb was immunoblotted with anti-acetylated 
K antisera. In T98G cells, which express wild-type pRb, cell cycle progression was 
monitored after semm-stimulating starved cells. Under these conditions, cells entered S- 
phase at 16-20 h when assayed by flow cytometry, suggesting that acetylated pRb 
accumulated at the G 1/S phase transition.
Increased G1 anest is obseiwed in SA 0S2 cells by exogenously expressing pRb 
379-928 QQ mutant derivative, thereby mimicking the acétylation o f pRb [214]. This 
observed increase in G1 arrest might result from the affect o f acétylation at residues 
K873/874 on Cyclin A/E docking [256]. Cell cycle progression proceeds up until cyclin 
D/Cdk 4/6 phosphorylation o f pRb. Acétylation at K residues 873/874 prevents Cyclin A/E 
from docking to the C-terminal domain o f pRb [214], thereby preventing cells from 
entering the S-phase [256]. Cell cycle arrest also occurs prior to cells undergoing 
differentiation [53], entering senescence [257] or prior to apoptosis (reviewed by [245].
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p300 and P/CAF may form a HAT complex to facilitate pRb acétylation
Acétylation o f pRb at residues K873/874 is inducible in U937 cells under 
conditions o f serum starvation [214]. This suggested that acétylation o f pRb might be 
involved in regulating differentiation. A study by Nguyen et al 2004 [53] provided 
evidence that pRb undergoes acétylation upon cellular differentiation, including skeletal 
myogenesis. In addition to p300, P/CAF can mediate pRb acétylation as pRb interacts 
directly with the acetyl-transferase domain o f P/CAF in vitro and can associate with 
P/CAF in differentiated cells. Significantly, by using a C-terminal domain acétylation- 
impaired mutant o f pRb, they revealed that acétylation does not affect pRb-dependent 
growth arrest or the repression o f  E2F transcriptional activity. Instead, acétylation is 
required for pRb-mediated terminal cell cycle exit and the induction o f late myogenic gene 
expression. It would be interesting to detennine whether the N-tenninal domain o f pRb is 
required for pRb-mediated differentiation, and assess whether the N-terminal domain 
undergoes acétylation during differentiation.
E2F-1 ^roKx-activates apoptotic genes, and genes required for G l/S-phase through 
two separate domains
The Rb protein plays an essential role in cell sui’vival by regulating the activity o f
multiple apoptotic mediators (reviewed by [245]). pRb inhibits apoptosis by binding to the
E2F-1 transcription factor, thereby preventing rrans'-activation o f apoptotic genes by E2F-
1 [240]. It was first proposed by Hsieh et al [240] that pRb may inliibit E2F-1 induced
apoptosis by mechanisms other than steric suppression o f the E2F-1 frnrzs-activation
domain (E2F-I 374-437). Over-expression o f E2F-1 (in which the ?raw5'-activation domain
has been deleted) can still induce E2F-1 dependent apoptosis [96, 240]. E2F-1 (132) is a
point deletion mutant, defective for DNA binding. In reporter assays, this mutant failed to
activate transcription and also failed to induce E2F-1-dependent apoptosis in SAOS2 cells
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[240].
A significant increase in DNA-binding activity can be achieved when an E2F 
family member heterodimerizes with a DP family member. An increase in the DNA 
binding capacity of E2F-1 is accompanied by a dramatic increase in apoptosis (in cells 
over-expressing E2F-1/DP-1 or a cyclin A-binding-defective mutant o f  E2F-1 (E2FA24)) 
[258-260]. This stimulation o f DNA-binding activity is reflected in the increase in E2F- 
dependent transcription when E2F-1 is co-transfected with DP-1 [261, 262]. Those 
particular studies were canded out around the same time as the discovery that E2F-1 over­
expression induces apoptosis independently and concun'ently with p53-dependent 
apoptosis [241-243].
pRb has two binding domains for E2F-1
Dick et al [96] created a mutant Rb (RbAE2F-G) that had lost pocket/E2F binding 
but retained binding to viral oncoproteins such as E l A or HPV E7. Using RbAE2F-G, they 
discovered that pRb contained two E2F-1 binding domains. Using binding assays they 
isolated a new E2F-1 binding domain to the C-terminal domain o f pRb. Using gel shift 
assays, they showed that RbAE2F-G caused a shift in E2F-1/DP-1 complex. In contrast to 
wild-type pRb, RbAE2F-G failed to cause a shift in the E2F-4/DP-1 complex. What is of 
greater interest was their finding that increasing concentrations o f RbAE2F-G reduced the 
binding affinity o f E2F-I/DP-1 for the DNA probe (where as the wild-type protein did 
not). This led to the suggestion that pRb (through its C-teiininal domain) might inhibit 
E2F-1 ^ra/î5-activation at pro-apoptotic promoters [96].
The interaction between RbAE2F-G and E2F-1 may prevent E2F-1/DP-1 from
binding DNA. This affect is rrai75-activation domain independent, and may explain why
E2F-1 1-374 still causes E2F-1-dependent apoptosis, despite lacking a //"n^j'-activation
domain. Thus, there are two E2F-1 binding domains (the A/B small pocket, and the C-
tenninal domain) interacting with two different regions o f E2F-1 (the /rai?5-activation
184
domain and the marked box domain (MB)). Does pRb inhibit promoters at S-phase genes 
and simultaneously allow E2F-1 to ?ra/?5'-activate apoptotic promoters? What are the 
upstream signals that detennine whether pRb inliibits E2F-1 apoptosis or releases 
inhibition?
The previous model suggested that pRb interacted with the /ra«5-activation domain 
o f E2F-1 and prevented any o f the transcription machinery from accessing E2F-1, thereby 
preventing expression. Repression was released through sequential phosphorylation o f the 
C-terminal domain by cyclin D/Cdk 4/6 which facilitated phosphoiylation of the B domain 
by cyclin (E/A)/Cdk2. This model seemed reasonable until the unexpected finding that the 
C-terminal domain o f pRb (residues 792-928) can interact with the marked box region 
(MB) o f E2F-1 [96].
Recent structural studies have shed light on how the two E2F-1 binding domains in 
pRb cooperate to repress E2F-1 activation, and why this repression is lifted by
phosphorylation o f the C-terminal domain of pRb. It was discovered that the C-pRb/E2F-l 
interaction was dependent on E2F-I heterodimerizing with its DP-1 partner [96, 98]. There 
are two segments o f C-pRb involved in the interaction with E2F-1 MB domain. The C-pRb 
domain (residues 829-864) contributes the majority o f the binding energy, binding to 
E2F-1 with a Kd o f 5 pM. The C-pRb domain (residues 786-800) also interacts with 
E2F-1 MB segment, increasing the affinity of C-pRb for E2F-1 MB by 36 fold 
(corresponding to a Kd o f 110 uM).
This led to a revised model. In its active state, pRb binds E2F-1 MB using both C- 
pRbcorc C-pRb" '^^™ domains, and also pRb binds E2F-1 P'-ar?.^-activation domain via the 
small pocket. Cyclin D/Cdk4/6 first phosphorylates S788 and S795 o f the C-pRb" '^^™ 
domain. This ablates the binding between C-pRb"‘°™ domain and E2F-1 MB domain. 
Further phosphoiylation by cyclin D/Cdk4/6 allows access of cyclin E/A/Cdk2 to its 
docking site on C-pRb, and further phosphorylation o f T821 and T826 by cyclin E/A/Cdk2
allows the release o f E2F-1 [98]. Etoposide induced DNA damage responsive acétylation
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of residues 873/874 will prevent cyclin E/A docking to the C-pRb‘^ '^ ’^‘^ , and thus aiTest cells 
in G l/S  phase.
Assuming no DNA damage, cyclin E/Cdk2 phosphorylates E2F-1, which 
stimulates transcription o f cyclin E. This positive feedback loop sends the cell into S-phase 
[191]. This model is not the whole story as there are many more phosphoiylation events 
during G l/S  phase and S-phase. There are a total o f sixteen Cdk phosphorylation sites 
across pRb that are phosphorylated during G l/S  phase transition and S-phase (Chapter 1, 
Figure 8) (reviewed by [104]).
The effect of damage responsive acétylation on pRb, E2F-1 and p53
It is clear that acétylation at residues K873/874 o f pRb can do more than just 
induce cell cycle arrest. Excitingly, the C-pRb 763-928 QQ mutant showed much reduced 
binding to E2F-1 both in vitro and in vivo. In contrast the C-pRb QQ mutant could still 
bind Mdm2, consistent with earlier reports suggesting that acétylation at K873/874 
increased its affinity for Mdm2 [214]. Further to this, FL-pRb QQ mutant derivatives 
failed to efficiently bind E2F-1 in HEK 293 cells. Due to being transformed with 
adenovims, HEK 293 cells over-express E l A. The reason for using HEK 293 cells was to 
allow a situation in which exogenous FL-pRb did not bind the ^ran.y-activation domain o f 
E2F-1 efficiently. Thus any remaining binding would be attributable to the C-terminal 
domain of pRb and its interaction with E2F-1 MB. FL-pRb wild-type and FL-pRb RR 
mutant derivatives both bound E2F-1, but the FL-pRb QQ mutant did not. Therefore, it is 
suggested that damage-responsive acétylation at residues K873/874 o f pRb prevents its 
association with the MB of E2F-1, thereby allowing ?raw5-activation at apoptotic 
promoters.
It is likely that most o f the pRb in the cell is not acetylated in response to DNA
damage. Using an antibody specific for acetyl-K at residues 873/874, acetylated pRb
^raw.s'locates from a diffuse nuclear staining (seen in un-treated cells) to punctate nuclear
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speckles (in etoposide ti^eated cells) [97]. However, staining with an endogenous pRb 
antibody showed no obvious difference in pRb intra-cellular location (Chapter 4, Figure 
32). Indeed other reports confnin that pan-pRb antibodies do not detect trans\oc?it\on o f 
pRb resulting from post-translational modification, and that specific antibodies are 
required (designed against specific modifications) in order to track changes in nuclear 
location [106, 107]. In a similar mamier, not all E2F-1 is phosphorylated in response to 
etoposide induced DNA damage. Using a phospho-specific antibody against phospho- 
S364, a change in the intra-cellular location o f Chk2 phosphoiylated B2F-1 was observed 
[229]. E2F-1 phosphorylated by Chk2 /‘ram locates from a diffuse nuclear staining (seen in 
un-treated cells) to punctate nuclear speckles (in etoposide treated cells), in a similar 
fashion to acetylated pRb staining in U 20S cells.
Presently, two other reports have described the DNA damage induced acétylation 
o f the cell cycle transcription factors E2F-1 and p53 [75, 228]. These studies both report 
that treating cells with doxorubicin (for E2F-1) and IR (for p53) results in the induction o f 
acétylation. Studies on E2F-1 demonstrate that residues 117, 121, and 125 are acetylated in 
vivo in response to doxorabicin treatment. This induction o f acétylation occurs between 8 
and 16h post treatment (induction o f pRb acétylation by etoposide occurs between 4 and 
24h post treatment [97]. TUNEL assays show that K to Q triple mutant derivatives o f E2F- 
1 (at residues 117, 121, and 125) cause an increase in apoptosis in un-treated cells to a 
similar degree that E2F-1 wild-type causes when cells are treated with doxorubicin. E2F-1 
is stabilized by DNA damage induced Chk2 phosphorylation o f S364 [229] in parallel with 
DNA damage induced acétylation (at residues 117, 121, and 125).
A similar study on DNA damage inducible Chkl/2  phosphorylation of p53 more
closely studied the link between Chk phosphorylation and DNA damage inducible
acétylation [228]. p53 is phosphorylated hy Chkl and Chk2 S/T protein kinases at its N-
terminal and C-terminal domains. Most o f the Chk phosphorylation sites characterized so
far map to the N-terminal domain o f p53 and are thought to contribute to the DNA damage
187
induced stabilization o f p53. This recent study characterized six Chkl/Chk2 sites in the C- 
terminal domain of p53. Chk-mediated phosphorylation o f three sites (S366, S378, and 
T387) is induced by double-stranded breaks in DNA. Chkl specifically phosphoiylates 
T387, whilst Chk2 phosphorylates S366. Chkl and Chk2 both phosphorylate S378.
Importantly, Chkl and Chk2 have roles in regulating p53 acétylation. Using siRNA 
to knockdown C hkl/2, it is observed that levels o f C-terminal p53 phosphoiylation and 
acétylation of K382 is reduced [228]. This leads to a reduced activation o f the p21 and Bax 
genes in response to DNA damage. Reduced Chk kinase levels resulted in,a reduction of 
DNA damage responsive p53 acétylation, and a corresponding diop in apoptosis was 
observed. Acétylation o f p53 augments its affinity for DNA, thereby stimulating the trans- 
activation o f p53 target genes [206, 263].
This study progressed further to characterize the affects o f DNA damage induced 
C hkl/2 phosphorylation on p53. S/T to D mutants were engineered to mimic 
phosphorylation o f S366 and T387. These mutants interact more efficiently with p300, and 
showed higher levels o f K373 and K382 acétylation in vivo. The p53 S366D and T387D 
mutant derivatives hound more strongly to the p21 promoter and AIPI promoters in ChIP 
assays. Phoshorylation by Chkl/Chk2 o f S366 and T387 facilitates an increase in K373 
and K382 acétylation and a coiTesponding increase in binding to p21 and AIPI promoters, 
thus facilitating apoptosis [228].
The ATM/Chk2 pathway may activate DNA damage responsive acétylation of pRb
In response to DNA damage, E2F-1 and p53 are phosphorylated by Chlc2, thereby 
leading to increases in their levels o f acétylation.
Perhaps DNA damage inducible acétylation o f pRb (at residues K873/874) is also 
controlled by Chk2 phophoiylation. In this regard, preliminary results are encouraging. 
Recent work in our group has shown that the C-terminal domain o f pRb is phosphorylated 
by Chk2 kinase in vitro. Further to this, expressing a Chk2 dominant negative construct in 
NIH3T3 cells ablates etoposide-induced acétylation (personal communication, Judith 
Soloway). There are several Chk2 consensus phosphorylation sites in the C-terminal o f 
pRb (Figure 36e). The S residues are fairly near to residues K873/874 and may serve to 
directly recmit p300/P/CAF complex to pRh/E2F-I.
In HEK 293 cells, the N-terminal domain o f pRb is also acetylated in response to 
DNA damage (Chapter 3, Figure 20). Close inspection o f the N-terminal domain pRb 
protein sequence revealed the presence o f four potential Chk2 consensus phosphorylation 
sites (Figure 36e). There are 6 potential acétylation sites neighbouring theses Clik2 
consensus phosphorylation sites (Figure 36a), three o f which are encoded for by exon 4 
(KVD, KKYD and KLER), and one by exon 8 (KEPYK) (Figure 36d). Exon 4 and exon 8 
o f pRb have been found deleted in tumour-derived samples and both regions are highly 
conserved across species [111].
The reports on E2F-1 and p53 damage responsive acétylation suggest that it is
Chk2 phosphorylation that causes a change in intra-cellular location of pRb/E2F in
response to DNA damage. Both acetylated pRb and Chk2 phosphorylated E2F-1 are shown
to translocate to distinct nuclear speckles [74, 97]. If  Chk2 phosphorylation is confirmed as
the upstream activator o f pRb acétylation, it could be that pRb translocates to these nuclear
speckles during damage in response to its phosphoiylation by Chk2. Perhaps Chk
phosphorylation may trigger E2F-1 and pRb to translocate during DNA damage. Also,
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they may translocate whilst still in complex,
E2F-1 is primarily stabilized by ATM kinase. In response to DNA damage, 
activated ATM phosphorylates E2F-1 at S31 [73]. Degradation of E2F-1 was shown to be 
dependent on S31 binding to SCF/p45® '^^  ^ thereby mediating E2F-1 proteosomal 
degradation [264]. Upon ATM dependent E2F-1 stabilization, E2F-1 and E2F-2 can 
further activate ATM. Over-expressing E2F-1 and E2F-2 induce the phosphorylation o f 
ATM [265]. Thus ATM activity is induced by E2F stabilization and can phosphorylate 
more Chk2 kinase.
Further to this, E2F-1 up regulates Chk2 kinase independently o f ATM. In this 
way, a continued DNA damage response might cause a gradual increase in nuclear levels 
o f E2F-1. This would lead to greater up-regulation o f Chlc2 increased ATM kinase activity 
[265]. This led to the hypothesis that at basal levels o f E2F-1, its activity is blocked by 
pRb and is thus inactive, but upon mitogenic stimulation, E2F-1 induces G l/S  phase 
transition. Wlien E2F-1 levels are stabilized in response to DNA damage by ATM and 
Chk2, E2F-1 levels exceeded a threshold beyond which leads to E2F-1 dependent 
apoptosis [56].
Nuclear translocation of pRb/E2F-l through Chk2 phosphorylation
It seems logical that phosphorylation by ATM and Chk2 might stabilize E2F-1
gradually, and that when the pRb/E2F-l complex is sufficiently phosphorylated by Chk2,
translocdition to damage responsive promoters might occur. Once localized to apoptotic
promoters, p300-P/CAF might be recruited to phospho-E2F-l/pRb and hi stone H4,
resulting in their acétylation. Acétylation o f the C-pRb then blocks C-pRb/E2F interaction,
allowing the MB domain o f E2F-1 to positively influence transcription. In the case o f pRb
there is good reason to suggest that Chk2 phophorylation might be involved in nuclear
translocdiûon. During the G l/S  phase transition, sequential phosphorylation o f C-pRb by
cyclin D/Cdk4/6 and cyclin E/A/Cdk2 dissociates pRb from E2F-1. Chk2 phosphorylation
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of pRb/E2F-l complex may facilitate the nuclear p^<7/75location o f the whole complex, 
rather than just pRb.
pRb contains two NLS, in the ‘A/B pocket’ and the ‘C-terminal domain bi-partite 
N LS’ (Chapter 1, Figure 8). The C-terminal domain of pRb contains the bi-partite NLS 
which spans residues 869-877 [252]. It is possible that Chk2 phosphorylation o f the C- 
tenninal domain (residues S895 and S906) might impact on the pRbC-terminal domain 
NLS. The K residues at 873/874 form a vital part of the bi-partite NLS (indeed it is bi­
partite because it has two basic K patches that are required for its function) [253]. It was 
shown that mutating residues K873/874 o f FL-pRb to Q caused widespread 
nuclear/cytoplasmic staining among populations of cells (Chapter 4 Figure 30 and 31). 
Mutating the C-pRb residues K873/874 to Q had no effect on the nuclear localization 
regardless o f whether cells were treated with etoposide or not (Chapter 4 Figure 29A and 
29B). The FL-pRb-QQ mutant protein may leave the nucleus due to a lack o f Chk2 
phosphorylation. However, no translocation event was ohseiwed with HA-C-pRb QQ 
mutant indicating that the influence o f the A/B domain and the N-terminal domain o f pRb 
can impact upon the intra-cellular localization o f pRb.
This localization change o f pRb/E2F in response to DNA damage might occur
through a change in affinity o f pRb for Lamins A/C and Lap2a. Both these proteins bind
pRb and are components o f nuclear inteimediate filament complexes [266]. Lamin A/C
might play a role in mediating the foimation o f the pRb foci because pRb is dispersed
throughout the nucleus and fails to associate with E2F foci in their absence [267]. Recent
studies find that nuclear anchorage o f pRb also requires LA P2a [268],
Lamin A/C and LA P2a tether hypophosphorylated pRb to the nucleus. During S
phase, pRb distributes to hundreds o f small foci throughout the nucleus, which indicates
that progressive phosphoiylation o f  pRb results in dissociation from these matrix-
associated sites of function. In response to intra-S phase DNA damage and activation o f
protein phosphatase 2A, hypophosphorylated pRb resumes a focal staining pattern that is
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reminiscent of perinucleolar foci, and inhibits origins of DNA replication and prevents 
endoreduplication [269].
Maybe during DNA damage, a proportion of pRb is required to inliibit E2F-1 at S- 
phase promoters and promoters of genes involved in endoreduplication. If DNA damaging 
signals persist, cells would perhaps require activating E2F-1-dependent and p53-dependent 
apoptosis. How might pRb remain bound to S-phase promoters whilst at the same time be 
released from apoptotic promoters? Specific signals might be sent to pRb at damage 
responsive promoters that cause the release o f pRb and the ^r<3m-activation o f apoptotic 
genes, or alternatively signals might be sent to pRb causing it to re-localize to damage 
responsive promoters to displace repressive pl07/E2F-4 complexes with activating 
pRb/E2F-l complexes.
Activating pRb/E2F-l complexes swap places with repressing p l07/E2F-4 complexes 
at apoptotic promoters in response to DNA damage
Earlier, a study by Pediconi was cited concerning E2F-1 acétylation being linked to 
increased apoptosis [75]. As part o f this study, ChIP assays were utilized to assess 
E2F/pocket protein complex promoter occupancy in un-treated and doxombicin treated 
cells. This study indicates that under normal cell culture conditions, pl07/E2F-4 
complexes occupy and repress p73, whereas pRb/E2F-l complexes occupy TK  and DHFR  
promoters. Under doxorubicin treatment, the pRb/E2F-l complex and the pl07/E2F-4 
complex swap promoters leading to acétylation o f H4 a tp73  promoter and deacetylation of 
H4 at TK and DHFR  promoters [75]. W hat this study doesn’t address is how pRb/E2F 
complexes are able to translocate from one area o f the nucleus to another. If  Chk2 
phosphorylation o f  pRb alters binding to Lamins or LA P2a, what proteins might 
chaperone pRb/E2F-l complex to apoptotic promoters?
It is interesting that the N-terminal domain of pRb binds more efficiently to the
GST-C-pRb QQ mutant derivative in GST pulldown assays. Perhaps DNA damage
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responsive acétylation o f pRb might induce conformational change in pRb tertiary 
structure, resulting in binding between the N-terminal and C-tenninal domains. For 
instance, in response to DNA damage induced acétylation (maybe at apoptotic promoters), 
the N-teiminal domain o f pRb might bind to the C-terminal domain o f pRb resulting in the 
loss o f E2F-1 binding. The N-terminal domain is the largest domain in pRb, and it might 
be involved in detennining what proteins can bind the C-terminal domain during DNA 
damage. The N-terminal domain o f pRb might influence post-translational modification 
(for instance phosphorylation and de-phosphoiylation), stability, and steady-state levels, as 
well as other auto-regulatoiy mechanisms o f the pRb protein [140].
A model for how ATM/Chk2 pathway activates E2F-l-dependent apoptosis and p53- 
dependent apoptosis in response to DNA damage
Recent studies combined with work presented here on pRb acétylation have helped 
form a model o f how ATM/Chk2 pathways facilitate E2F-1 and p53-dependent apoptosis. 
Routine cell cycle progression is shown (Figure 37). In response to mitogenic signalling, 
cyclin D/Cdk4/6 phosphorylates RbC"^ *^ ™, causing it to dissociate from E2F-1/DP-I. 
Subsequent phosphoiylation o f the pRb B domain by cyclin E/Cdk2 leads to the release o f 
E2F-1, and promotes the activation o f E2F target genes [98].
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Figure 36: Proposed model for pRb repression of E2F genes that control G l/S  and S- 
phase
The diagram depicts the small pocket region o f pRb (residues 379-792) 
bound to the /rrzM^-activation domain o f E2F-I and the C-terminal domain o f 
pRb (792-928) bound to the marked box domain o f E2F-1 and DP-1. Two 
regions o f the C-tenninal domain o f pRb are involved in binding E2F-1 marked 
box (MB) (RbC"°"" (residues 829-864) and RbC"'"™ (residues 786-800)). Initial 
phosphorylation o f pRb by cyclin D/Cdk4/6 blocks the RbC"'*^™ interaction with 
E2F-1 MB. The activation o f cyclin E/Cdk2 and further phosphorylation of the 
pRb small pocket blocks the RbC‘^ ’^^‘^ interaction with the MB and also the small 
pocket interaction with E2F-1 TD. The RbC“ ' ‘^ region binds back onto the small 
pocket leaving E2F-1 to activate G l-S  phase and S-phase genes. Hyper- 
phosphorylated pRb is de-phosphorylated by PPl in response to etoposide 
treatment (see part B).
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In response to etoposide induced DNA damage, PPl de-phosphoiylates pRb 
(Figure 38) [107]. Double stranded breaks in DNA are bound by the TIP60 HAT enzyme, 
which forms initial DNA repair complexes. Upon DNA damage, TIP60 rapidly acetylates 
ATM kinase, thereby activating it [72]. ATM kinase targets Chk2 kinase. Phosphorylation 
o f Chk2 results in its activation, from where it targets a number of transcription factors 
including p53, E2F-1 and potentially pRb (Figure 38)[228, 229].
p53 and E2F-1 are targeted by ATM kinase (Reviewed in [270] [265]. In the case 
o f E2F-1, ATM stabilizes the protein by preventing the binding o f SCF/p45 thereby 
preventing E2F-1 proteosomal degradation [264]. Further damage responsive 
phosphorylation of p53 and E2F-1 by Chk2 mediates a variety o f effects. Chk2 
phosphorylation induces p53 acétylation, which results in increased DNA binding and 
thereby up regulating ?ra/7^-activation o f cell cycle arrest genes (such as p27) and apoptotic 
genes (such as Bax). p53 acétylation also interferes with p53 ubiquitination, hence 
increasing its stability [228]. p53 mediates cell cycle aiTest through ?ra/7.5-activation o fp21 
and subsequent drop in pRb phosphorylation.
Chk2 phosphorylation o f the pRb/E2F complexes may occur gradually, as 
stabilised E2F-1 up regulates Chk2 kinase expression, and ATM activation [265]. When 
E2F-1 protein is stabilized over a certain threshold level, phospho-pRb/E2F complex may 
translocditQ to apoptotic promoters such as p73 and Apaf-1 (Figure 39) [75]. They would 
thereby displace the pl07/E2F4 repressor complexes (which then r^rzM/ylocate to promoters 
o f S-phase genes to repress the cell cycle) (Chapter 1, Figure 6). The Chk2 phosphorylated 
‘pRb/E2F complex’ would promote the recimitment o f the p300/P/CAF HAT complex. 
This complex would form scaffolds to facilitate transcription at apoptotic promoters. 
p300/P/CAF acetylates histone tails (such as histone H4) allowing the local unwinding o f 
chromatin. p300/P/CAF then acetylates pRb (causing it to dissociate with E2F-1).
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Figure: 37: Proposed model for stabilization of E2F-1 and pRb through 
phosphorylation by ATM/Chk2 and the recruitment of P/CAF/p300 
complexes
The ATM/Chk2 pathway controls the damage responsive acétylation o f 
pRb, E2F-1 and p53. ATM kinase, which phosphoiylates and activates Chlc2 
kinase, phosphoiylates E2F-1 at S31. In turn, Chk2 kinase phosphorylates 
E2F-1 at residue 364, thus contributing to its increased stability. The diagram 
depicts a model in which DNA inducible acétylation is dependent on Chk2 
activation. Clik2 may phosphorylate pRb at is N-terminal domain, where 
several Chk2 kinase consensus phosphorylation sites occur (Figure 36e). It is 
suggested that Chk2 phosphorylation may recm it p300/P/C AF to pRb and 
E2F-1 to facilitate acétylation.
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Figure: 38: Proposed model to explain pRb/E2F-l translocation from S-phase 
promoters to apoptotic promoters
The phosphorylation model depicted in Figure 39 involves the 
recruitment o f p300/P/CAF complexes that acetylate pRb and E2F-1. 
Acétylation o f pRb at residues K873/874 and in the N-teiminal domain may 
cause a change in confoi*mation to block the binding o f the C-terminal domain 
of pRb with the MB domain o f E2F-1. The acétylation o f residues K873/874 
promotes binding o f  the N-tenninal domain, which may alter the intra-cellular 
localization o f pRb. Acétylation o f E2F-1 in its DNA binding domain may 
serve to increase its affinity for DNA binding, thus promoting the trans- 
activation of genes involved with apoptosis.
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E2F-1 is also acetylated thereby facilitating its DNA binding and stimulating transcription 
(Figure 39) [88].
Future prospectives
In the future, it would be useful to engineer other HAT enzymes into baculovirus in 
order to assess whether other HAT enzymes can acetylate pRb. Perhaps combining HAT 
enzymes in acétylation assays could shed light on potential transcription factor HAT 
complexes. For instance, it would be useful to study whether P/CAF can acetylate the N- 
tenninal domain o f pRb (both on its own and with p300), and to address whether 
p300/P/CAF complexes can from in response to DNA damage. It is likely that the in vitro 
acétylation o f the A/B pocket would require an intact A/B interface. It would be interesting 
to study further the observations by Chan that K713 in the B pocket is acetylated in vitro 
[214]. Perhaps acétylation o f K713 might disrupt binding o f LXCXE proteins (such as 
HD AC enzymes and cyclin D).
The key steps in the study o f N-terminal domain pRb acétylation include analysing 
the acetylated N-tenuinal domain pRb using mass spectroscopy to define which residues 
Flag-p300 FL acetylates. This data eould be used to create mutant N-terminal domain pRb 
derivatives that mimic acétylation (K to Q) or prevent acétylation (K to R). Next, the link 
between Chk phosphorylation and acétylation could be studied. Utilizing in vitro kinase 
assays, potential Chk2 kinase consensus phosphoiylation sites could be studied. Site- 
directed-mutagenesis could be used to assess which consensus sites are phosphorylated by 
Clik2 in vitro.
GST pulldown experiments showed that HA-N-pRb bound to GST-C-pRb QQ
mutant derivative with approximately 4 fold greater binding affinity than to GST-C-pRb
wt. Once the sites o f acétylation have been mapped, it would be interesting to test N-
terminal domain acétylation mimics for binding to the C-terminal domain o f pRb. Perhaps
the acétylation o f the N-terminal domain of pRb will further increase the binding between
201
the two-pRb derivatives. Cdk enzymes phosphorylate pRb at residues 250 and 252 of the 
N-terminal domain. Perhaps acétylation might interfere with phosphorylation at these sites, 
and help facilitate G1 arrest. This can be assessed using N-pRb (K to Q) mutants.
In cells, it is necessary to test whether N-terminal domain acétylation is under the 
control o f Chk2 phosphorylation. Using HCT15 cells (which do not express Chk2), 
dominant negative Chk2 mutant DNA could be exogenously expressed, and the levels o f 
acétylation o f HA-N-pRb 1-376 with or without damage could be compared with HCT15 
cells expressing wild-type Chk2 protein. Also in cells, siRNA approaches could be utilized 
to study whether P/CAF is required for damage responsive acétylation o f pRb. Already 
preliminary siRNA experiments in our group have concluded that p300 is required for 
acétylation at residues K873/874 (Darran O ’Comior, personal communication). It is 
expected that P/CAF might complex with p300 to acetylate pRb.
The affect that pRb acétylation has on apoptosis should be investigated using the 
TUNEL assay. Rb " cells could be transiently transfected with pRh acétylation mutant 
constructs (K to Q) to compare levels of apoptosis with cells which are transfected with 
pRh acétylation dead mutant constructs (K to R). Protein levels o f p73 and Apafl could be 
assessed in cells transfected with acetylated pRb mutants. Using Rb" ' cells, the ability o f 
pRb acétylation mutants to activate p73  reporter constructs could be studied under DNA 
damage conditions. Using FACS analysis, E2F-1 dependent apoptosis could be measured 
comparing cells transfected with wild-type pRb verses those transfected with acétylation 
mutants. The binding properties o f pRb acétylation mutants could be further studied using 
gel shift assays, to assess their effect on E2F-1 binding to DNA.
In cells, the effect of Chk2 phosphorylation on pRb acétylation at residues 
K873/874 could be studied using 2D electrophoresis. Mutant derivatives o f pRb in which 
potential Chk2 sites are either mutated to A or D (preventing or mimicking 
phosphorylation) could be transfected into cells and pRb acétylation at residues K873/874 
measured using the acetyl-pRb SK37 antibody.
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In cells transfected with dominant negative Chk2, the intra-cellular location o f 
acetyl-pRb and phospho-E2F-l could be assessed in the presence or absence o f DNA 
damage in order to confirm whether Chk2 phosphorylation affects pRb/E2F location. In 
this regard, the binding o f Lamin A/C and LA P2a proteins to acetyl-pRb mutants could be 
assessed in the presence and absence of DNA damage. In future it would be interesting to 
study the mechanisms behind pRb/E2F nuclear /rara-location.
In conclusion, acétylation o f pRb at residues K873/874 affects the binding o f pRb 
with E2F-1 under DNA damage conditions. Future work should seek to assess the affect o f 
the N-tenninal domain o f pRb (and its acétylation) on the interaction with E2F-1. In this 
regard crystallographic studies may well be required to further elucidate the precise nature 
o f  interactions between the C-terminal domain and the N-terminal domain of pRb. 
Understanding the mechanisms hy which post-translational modification o f pRb controls 
its anti-apoptotic function may lead to the identification o f possible dmg targets (such as 
HD AC inliibitors [271]) that utilize the cells apoptotic mechanisms to target tumour cells 
for death, leaving non-transformed cells unharmed.
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